A common genetic variation in the 3uuntranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis

DOI: 10.1182/blood.v88.10.3698.bloodjournal88103698
Blood, 1996, 88, 3698-3703.

#	Paper	IF	Citations
2298	Headaches in patients with brain tumors: a study of 111 patients. **1993**, 43, 1678-83		336
2297	Thromboembolic risks and complications in nephrotic children. **1997**, 23, 271-80		68
2296	Activated protein C resistance: What have we learned now that the dust has settled?. **1997**, 29, 469-72		6
2295	The inherited basis of venous thrombosis. **1997**, 29, 341-7		21
2294	Inherited hypercoagulable states. **1997**, 2, 313-20		20
2293	Inherited thrombophilias. **1997**, 90, 375-8		5
2292	Congenital thrombophilia. **1997**, 11, 431-45		27
2291	The pill and thrombosis: epidemiological considerations. **1997**, 11, 565-85		6
2290	Increased prevalence of a polymorphism in the gene coding for human prothrombin in patients with coronary heart disease. *Thrombosis Research*, **1997**, 87, 521-6	8.2	51
2289	Factor V Leiden: detection in whole blood by ASA PCR using an additional mismatch in antepenultimate position. *Thrombosis Research*, **1997**, 88, 59-66	8.2	27
2288	An improved method for the detection of the G20210A transition in the prothrombin gene. *Thrombosis Research*, **1997**, 88, 441-3	8.2	9
2287	[New causes of inherited thrombophilia]. **1997**, 18 Suppl 6, 626s-635s		6
2286	A Common Prothrombin Variant (20210 G to A) Increases the Risk of Myocardial Infarction in Young Women. *Blood*, **1997**, 90, 1747-1750	2.2	297
2285	Familial thrombophilia: genetic risk factors and management. **1997**, 242, 9-15		35
2284	Factor V Leiden and other coagulation factor mutations affecting thrombotic risk. **1997**, 43, 1678-1683		120
2283	A prothrombin gene mutation is significantly associated with venous thrombosis. **1997**, 17, 2875-9		68
2282	The A20210 Allele of the Prothrombin Gene Is Not Frequently Associated With the Factor V Arg 506 to Gln Mutation in Thrombophilic Families. *Blood*, **1997**, 90, 1711-1711	2.2	21

2281	The Transition G to A at Position 20210 in the 3?-Untranslated Region of the Prothrombin Gene Is Not Associated With Cerebral Ischemia. *Blood*, **1997**, 90, 3806-3806	2.2	44
2280	Thrombophilia: an expanding group of genetic defects that predispose to thrombosis. **1997**, 3, 303-9		3
2279	The impact of pharmacogenetics on the future of healthcare. **1997**, 8, 692-5		17
2278	The prothrombin gene G20210A variant: prevalence in a U.K. anticoagulant clinic population. **1997**, 98, 353-5		167
2277	Risk of venous thromboembolism associated with a G to A transition at position 20210 in the 3'-untranslated region of the prothrombin gene. **1997**, 98, 907-9		151
2276	A hitherto unknown splice site defect in the protein S gene (PROS1): the mutation results in allelic exclusion and causes type I and type III protein S deficiency. **1997**, 99, 298-300		6
2275	The venous thrombosis risk factor 20210 A allele of the prothrombin gene is not a major risk factor for arterial thrombotic disease. **1997**, 99, 304-7		85
2274	The Laboratory of Hypercoagulability: A Review of Present-Day Techniques. **1998**, 5, 269-276		1
2273	Practical strategies for hormone replacement therapy and risk of venous thromboembolism. **1998**, 105, 376-9		4
2272	A mutation in the prothrombin gene contributing to venous thrombosis during pregnancy. **1998**, 105, 923-5		12
2271	Do inherited prothrombotic factors have a role in myocardial infarction with normal coronary arteriogram?. **1998**, 244, 543-544		16
2270	Luteinizing hormone-releasing hormone analogue: leuprorelin acetate for the prevention of menstrual bleeding in premenopausal women undergoing stem cell transplantation. **1998**, 21, 821-3		30
2269	Genetic susceptibility to pregnancy-related venous thromboembolism: roles of factor V Leiden, prothrombin G20210A, and methylenetetrahydrofolate reductase C677T mutations. **1998**, 179, 1324-8		155
2268	Novel inherited risk factors for venous thrombosis. **1998**, 132, 444-5		1
2267	Prevalence of the prothrombin 20210 G-to-A variant in blacks: infants, patients with venous thrombosis, patients with myocardial infarction, and control subjects. **1998**, 132, 452-5		60
2266	Thrombophilia: disorders predisposing to venous thromboembolism. **1998**, 11, 525-40		9
2265	Heparin and low-molecular-weight heparin in the treatment of venous thromboembolism. **1998**, 11, 621-37		11
2264	Acute myocardial infarction with large bilateral intracoronary thrombi in a young patient with the prothrombin 20210 G-->A mutation. **1998**, 44, 427-30		1

2263	Thrombophilia: a mechanism of disease in women with adverse pregnancy outcome and thrombotic lesions in the placenta. **1998**, 7, 277-86		109
2262	Prothrombin gene 20210 G-A mutation in the Turkish population. **1998**, 58, 249		61
2261	Prothrombin mutant, factor V Leiden, and thermolabile variant of methylenetetrahydrofolate reductase among patients with sickle cell disease in Brazil. **1998**, 59, 46-50		50
2260	Prothrombin gene 20210 G-A mutation in Turkish patients with thrombosis. **1998**, 59, 179-80		25
2259	Increased rate of factor V Leiden mutation in patients with cerebral venous thrombosis. **1998**, 245, 149-52		33
2258	Cerebral venous sinus thrombosis in infancy and childhood: role of genetic and acquired risk factors of thrombophilia. **1998**, 157, 555-60		70
2257	The transition G to A at position 20210 in the 3'-untranslated region of the prothrombin gene is not associated with migrainous infarction. **1998**, 18, 229-30		5
2256	Risk of recurrent venous thromboembolism in patients with the factor V Leiden (FVR506Q) mutation: effect of warfarin and prediction by precipitating factors. East Anglian Thrombophilia Study Group. **1998**, 100, 764-8		33
2255	Budd-Chiari syndrome, portal vein and mesenteric vein thrombosis in a patient homozygous for factor V Leiden mutation treated by TIPS and thrombolysis. **1998**, 102, 929-31		41
2254	Additional genetic risk factors for venous thromboembolism in carriers of the factor V Leiden mutation. **1998**, 103, 871-6		52
2253	Factor V Arg306-->Thr (factor V Cambridge) and factor V Arg306-->Gly mutations in venous thrombotic disease. **1998**, 103, 888-90		14
2252	Prothrombin antigen levels in symptomatic and asymptomatic carriers of the 20210A prothrombin variant. **1998**, 103, 1045-50		44
2251	Additional genetic risk factors for venous thromboembolism in carriers of the factor V leiden mutation. **1998**, 102, 871-876		1
2250	Factor V Arg306- Thr (factor V Cambridge) and factor V Arg 306 mutations in venous thrombotic disease. **1998**, 102, 888-890		
2249	Factor II 20210 G-->A polymorphism associated to factor V Leiden: a report of two thrombophilic families. *Thrombosis Research*, **1998**, 89, 249-52	8.2	5
2248	The factor V Leiden mutation increases the risk of venous thrombosis in patients with inflammatory bowel disease. **1998**, 115, 830-4		105
2247	An unknown genetic defect increases venous thrombosis risk, through interaction with protein C deficiency. **1998**, 63, 569-76		32
2246	Inherited thrombophilia due to factor V Leiden mutation*. *Molecular Diagnosis and Therapy*, **1998**, 3, 55-62		6

2245	Update on genetic risk factors for thrombosis and atherosclerotic vascular disease. **1998**, 12, 1193-209, vi	12
2244	An unexpected product from polymerase chain reaction-mediated site-directed mutagenesis due to misalignment of the mismatched primer. *Molecular Diagnosis and Therapy*, **1998**, 3, 157-161	
2243	Venous thromboembolic events in pediatric patients. Diagnosis and management. **1998**, 12, 1283-312, vii	28
2242	Laboratory evaluation of hypercoagulable states. **1998**, 12, 1141-66, v	37
2241	Prevalence of the G20210A polymorphism in the 3'-untranslated region of the prothrombin gene in different human populations. **1998**, 100, 9-12	72
2240	Increased risk for venous thrombosis in carriers of the prothrombin G-->A20210 gene variant. **1998**, 129, 89-93	162
2239	Plasma levels of activated protein C in healthy subjects and patients with previous venous thromboembolism: relationships with plasma homocysteine levels. **1998**, 18, 1371-5	29
2238	Review. **1998**, 22, 472-483	1
2237	Genetic polymorphisms and risk of coronary artery disease. **1998**, 24, 245-50	26
2236	Laboratory investigation of hypercoagulability. **1998**, 24, 111-26	16
2235	Venous thrombosis--the interaction of genes and environment. **1998**, 338, 1840-1	47
2234	Pulmonary embolism. **1998**, 339, 1555; author reply 1557	
2233	Laboratory diagnosis of hereditary thrombophilia. **1998**, 24, 309-20	23
2232	Screening test for thrombophilic patients: which tests, for which patient, by whom, when, and why?. **1998**, 24, 321-7	27
2231	Hereditary thrombophilia and venous thromboembolism. **1998**, 158, 1369-73	48
2230	High risk of cerebral-vein thrombosis in carriers of a prothrombin-gene mutation and in users of oral contraceptives. **1998**, 338, 1793-7	564
2229	Frequency of the 20210 G-->A mutation in the 3'-untranslated region of the prothrombin gene in 35 cases of cerebral venous thrombosis. **1998**, 29, 1398-400	62
2228	Interaction of coagulation defects and cardiovascular risk factors: increased risk of myocardial infarction associated with factor V Leiden or prothrombin 20210A. **1998**, 97, 1037-41	253

2227	Anti-prothrombin antibodies and their relation with thrombosis and lupus anticoagulant. **1998**, 7 Suppl 2, S32-6		40
2226	Genetics and pulmonary medicine. 4. Pulmonary embolism. **1998**, 53, 698-702		6
2225	Spontaneous internal carotid artery dissection with isolated vagus nerve deficit. **1998**, 51, 317-8		6
2224	Kongre□f□□Laboratoriumsmedizin 1998. **1998**, 22, 637-684		
2223	Polymorphisms of coagulation factor genes--a review. **1998**, 36, 897-906		4
2222	Screening for factor V Leiden and a prothrombin gene polymorphism in patients with Glanzmann's thrombasthenia. **1998**, 101, 593-4		4
2221	Clinical studies and thrombin generation in patients homozygous or heterozygous for the G20210A mutation in the prothrombin gene. **1998**, 18, 1287-91		127
2220	Antithrombotic therapy for venous thromboembolic disease. **1998**, 114, 561S-578S		170
2219	Risk of stroke in young women and two prothrombotic mutations: factor V Leiden and prothrombin gene variant (G20210A). **1998**, 29, 577-80		163
2218	Current concepts of coagulation and fibrinolysis. **1998**, 33, 133-68		9
2217	The prothrombin gene G20210A variant in an unselected thromboembolic population. A Belgian prospective clinical study. **1998**, 53, 344-8		4
2216	The results of diagnostic studies for thrombophilia in a large group of patients with a personal or family history of thrombosis. **1998**, 110, 673-82		7
2215	Antithrombotic therapy in children. **1998**, 114, 748S-769S		73
2214	Simultaneous polymerase chain reaction restriction fragment length polymorphism identification of the factor V Leiden allele and the prothrombin 20210A mutation. **1998**, 7, 180-3		7
2213	Prothrombin gene G20210-->A transition is a risk factor for cerebral venous thrombosis. **1998**, 29, 1765-9		133
2212	Venous thrombosis in older people: prevalence of the factor V gene mutation Q506. **1998**, 46, 1545-9		15
2211	Geographic Distribution of the 20210 G to A Prothrombin Variant. *Thrombosis and Haemostasis*, **1998**, 79, 706-708	7	598
2210	Multiplex ASA PCR for a Simultaneous Determination of Factor V Leiden Gene, G -> A 20210 Prothrombin Gene and C -> T677 MTHFR Gene Mutations. *Thrombosis and Haemostasis*, **1998**, 79, 1054-1055	7	54

2209	Detection of the 20210 A/G Variation in the Prothrombin Gene by Denaturing Gradient Gel Electrophoresis (DGGE). *Thrombosis and Haemostasis*, **1998**, 79, 1055-1056	7	4
2208	Superficial Vein Thrombosis of Lower Limbs: Influence of Factor V Leiden, Factor II G20210A and Overweight. *Thrombosis and Haemostasis*, **1998**, 80, 239-241	7	54
2207	Prevalence of FVR506Q and Prothrombin 20210A Mutations in the Navarrese Population. *Thrombosis and Haemostasis*, **1998**, 80, 522-523	7	32
2206	Factor V Leiden and Prothrombin Gene G 20210 A Variant in Children with Ischemic Stroke. *Thrombosis and Haemostasis*, **1998**, 80, 763-766	7	128
2205	Prothrombin 20210A Variant and Age at Thrombosis. *Thrombosis and Haemostasis*, **1998**, 79, 444-455	7	5
2204	The Methylenetetrahydrofolate Reductase TT677 Genotype Is Associated with Venous Thrombosis Independently of the Coexistence of the FV Leiden and the Prothrombin. *Thrombosis and Haemostasis*, **1998**, 79, 907-911	7	131
2203	Prevalence of 20210 A Allele of the Prothrombin Gene in Venous Thromboembolism Patients. *Thrombosis and Haemostasis*, **1998**, 80, 49-51	7	108
2202	Coincidence of factor V Leiden mutation and a mutation in the prothrombin gene at position 20210 in a patient with puerperal cerebral venous thrombosis. **1998**, 29, 1739-40		17
2201	Prothrombin 20210A Polymorphism and Third Generation Oral Contraceptives A Case Report of Coeliac Axis Thrombosis and Splenic Infarction. *Thrombosis and Haemostasis*, **1998**, 79, 1214-1215	7	6
2200	The Value of Free Enterprise. **1998**, 44, 1366-1367		
2199	Thrombotic Risks: A Clarification. **1998**, 44, 1580-1580		6
2198	The Mutation G20210->A in the Prothrombin Gene Is a Strong Risk Factor for Pulmonary Embolism. **1998**, 44, 1365-1366		9
2197	A mnemonic for thrombophilia screening tests. **1998**, 168, 582-582		
2196	Reliable Genotyping of the G-20210-A Mutation of Coagulation Factor II (Prothrombin). **1998**, 44, 349-351		41
2195	Homozygous G20210A Prothrombin Gene Mutation without Thromboembolic Events: A Case Report. *Thrombosis and Haemostasis*, **1998**, 80, 1028-1029	7	16
2194	The Prothrombin Gene 3?-Untranslated Region Mutation Is Frequently Associated With Factor V Leiden in Thrombophilic Patients and Shows Ethnic-Specific Variation in Allele Frequency. *Blood*, **1998**, 91, 1092-1093	2.2	25
2193	Rapid Simultaneous Screening of Factor V Leiden and G20210A Prothrombin Variant by Multiplex Polymerase Chain Reaction on Whole Blood. *Blood*, **1998**, 91, 2208-2209	2.2	45
2192	Prothrombin G20210A Mutant Genotype Is a Risk Factor for Cerebrovascular Ischemic Disease in Young Patients. *Blood*, **1998**, 91, 3562-3565	2.2	201

2191	Factor V Cambridge: A New Mutation (Arg306->Thr) Associated With Resistance to Activated Protein C. *Blood*, **1998**, 91, 1140-1144	2.2	234
2190	A Common Genetic Polymorphism (46 C to T Substitution) in the 5?-Untranslated Region of the Coagulation Factor XII Gene Is Associated With Low Translation Efficiency and Decrease in Plasma Factor XII Level. *Blood*, **1998**, 91, 2010-2014	2.2	169
2189	The Prothrombin 20210 A Allele Is Frequently Coinherited in Young Carriers of the Factor V Arg 506 to Gln Mutation With Venous Thrombophilia. *Blood*, **1998**, 91, 2209-2210	2.2	45
2188	The A20210 Allele of the Prothrombin Gene Is Frequently Associated With the Factor V Arg 506 to Gln Mutation But Not With Protein S Deficiency in Thrombophilic Families. *Blood*, **1998**, 91, 2210-2211	2.2	45
2187	The Prothrombin G20210A Mutation and Factor V Leiden Mutation in Patients With Cerebrovascular Disease. *Blood*, **1998**, 92, 704-705	2.2	17
2186	A Single Genetic Origin for the Common Prothrombotic G20210A Polymorphism in the Prothrombin Gene. *Blood*, **1998**, 92, 1119-1124	2.2	162
2185	An Association Between the Common Hereditary Hemochromatosis Mutation and the Factor V Leiden Allele in a Population With Thrombosis. *Blood*, **1998**, 92, 1461-1462	2.2	21
2184	The 20210A Allele of the Prothrombin Gene Is Frequent in Young Women With Unexplained Spinal Cord Infarction. *Blood*, **1998**, 92, 1840-1841	2.2	13
2183	The Val34Leu Polymorphism in the A Subunit of Coagulation Factor XIII Contributes to the Large Normal Range in Activity and Demonstrates That the Activation Peptide Plays a Role in Catalytic Activity. *Blood*, **1998**, 92, 2766-2770	2.2	105
2182	An Even Easier Method for One-Step Detection of Both FV Leiden and FII G20210A Transition. *Blood*, **1998**, 92, 3478-3479	2.2	11
2181	A Three-generation Family Presenting Five Cases of Homozygosity for the 20210 G to A Prothrombin Variant. *Thrombosis and Haemostasis*, **1998**, 80, 859-860	7	12
2180	Superior Sagittal Sinus Thrombosis in a Patient Heterozygous for the Novel 20210 A Allele of the Prothrombin Gene. *Thrombosis and Haemostasis*, **1998**, 79, 235-235	7	11
2179	Homozygous G20210A Transition in the Prothrombin Gene Associated with Severe Venous Thrombotic Disease: Two Cases in a French Family. *Thrombosis and Haemostasis*, **1998**, 80, 1027-1028	7	24
2178	Prevalence of FXIII V34L in Populations with Different Cardiovascular Risk. *Thrombosis and Haemostasis*, **1998**, 80, 523-524	7	40
2177	Prevalence of the 677C to T Mutation in the Methylenetetrahydrofolate Reductase Gene in Italian Patients with Venous Thrombotic Disease. *Thrombosis and Haemostasis*, **1998**, 79, 686-687	7	16
2176	Risk Factors Associated with Postpartum Ovarian Vein Thrombosis. *Thrombosis and Haemostasis*, **1999**, 82, 1015-1019	7	64
2175	Prevalence of Prothrombin G20210A, Factor V G1691A (Leiden), and Methylenetetrahydrofolate Reductase (MTHFR) C677T in Seven Different Populations Determined by Multiplex Allele-specific PCR. *Thrombosis and Haemostasis*, **1999**, 81, 733-738	7	97
2174	The 536C->T Transition in the Human Tissue Factor Pathway Inhibitor (TFPI) Gene Is Statistically Associated with a Higher Risk for Venous Thrombosis. *Thrombosis and Haemostasis*, **1999**, 82, 1-5	7	21

2173	Hereditary Homozygous Heparin Cofactor II Deficiency and the Risk of Developing Venous Thrombosis. *Thrombosis and Haemostasis*, **1999**, 82, 1011-1014	7	28
2172	Coexistence of Factor V Leiden and Factor II A20210 Mutations and Recurrent Venous Thromboembolism. *Thrombosis and Haemostasis*, **1999**, 82, 1583-1587	7	110
2171	Prothrombotic Genetic Risk Factors and the Occurrence of Gestational Hypertension with or without Proteinuria. *Thrombosis and Haemostasis*, **1999**, 81, 349-352	7	66
2170	Prothrombin Gene Mutation (G20210A) in Healthy Centenarians. *Thrombosis and Haemostasis*, **1999**, 81, 990-991	7	5
2169	The Relationship of Mutations in the MTHFR, Prothrombin, and PAI-1 Genes to Plasma Levels of Homocysteine, Prothrombin, and PAI-1 in Children and Adults. *Thrombosis and Haemostasis*, **1999**, 81, 739-744	7	117
2168	Allelic Discrimination of Factor V Leiden Using a 5Nuclease Assay. *Thrombosis and Haemostasis*, **1999**, 82, 1294-1296	7	35
2167	The Risk of Recurrent Venous Thromboembolism in Carriers and Non-carriers of the G1691A Allele in the Coagulation Factor V Gene and the G20210A Allele in the Prothrombin Gene. *Thrombosis and Haemostasis*, **1999**, 81, 684-689	7	184
2166	High-speed prothrombin G-->A 20210 and methylenetetrahydrofolate reductase C-->T 677 mutation detection using real-time fluorescence PCR and melting curves. **1999**, 27, 234-6, 238		33
2165	Double Fluorescent-amplification Refractory Mutation Detection (dF-ARMS) of the Factor V Leiden and Prothrombin Mutations. *Thrombosis and Haemostasis*, **1999**, 81, 76-80	7	12
2164	Genetic Risk Factors for Superficial Vein Thrombosis. *Thrombosis and Haemostasis*, **1999**, 82, 1215-1217	7	106
2163	Risk Factors for Venous Thrombotic Disease. *Thrombosis and Haemostasis*, **1999**, 82, 610-619	7	282
2162	The Prevalence of the Prothrombin 20210 G ->A Mutation Is not Increased in Angiographically Confirmed Coronary Artery Disease. *Thrombosis and Haemostasis*, **1999**, 81, 161-162	7	12
2161	The Risk of Early Recurrent Venous Thromboembolism after Oral Anticoagulant Therapy in Patients with the G20210A Transition in the Prothrombin Gene. *Thrombosis and Haemostasis*, **1999**, 81, 14-17	7	114
2160	The Factor II G20210A and Factor V G1691A Gene Transitions and Coronary Heart Disease. *Thrombosis and Haemostasis*, **1999**, 81, 208-213	7	44
2159	Multiplex PCR for One-step Determination of the G20210A Variation and the Factor V Leiden Mutation by Denaturing Gradient Gel Electrophoresis (DGGE). *Thrombosis and Haemostasis*, **1999**, 81, 313-314	7	4
2158	Zusammenhang zwischen AB0-Blutgruppe und Thromboseneigung. Was ist gesichert?. **1999**, 26, 14-19		
2157	The Factor V Gene A4070G Mutation and the Risk of Venous Thrombosis. *Thrombosis and Haemostasis*, **1999**, 81, 193-197	7	101
2156	Factor XIII Val34Leu Is a Genetic Factor Involved in the Aetiology of Venous Thrombosis. *Thrombosis and Haemostasis*, **1999**, 81, 676-679	7	115

2155	Inherited Thrombophilia and Pregnancy Loss. *Thrombosis and Haemostasis*, **1999**, 82, 634-640	7	52
2154	Simultaneous Genotyping for Factor V Leiden and Prothrombin G20210A Variant by a Multiplex PCR-SSCP Assay on Whole Blood. *Thrombosis and Haemostasis*, **1999**, 81, 162-163	7	5
2153	Genetic Modulation of Plasma Protein S Levels by Two Frequent Dimorphisms in the PROS1 Gene. *Thrombosis and Haemostasis*, **1999**, 82, 1088-1092	7	25
2152	Factor V Leiden, Prothrombin 20210 G -> A and the MTHFR C677T Mutations in Childhood Stroke. *Thrombosis and Haemostasis*, **1999**, 81, 690-694	7	99
2151	Recurrent Deep Vein Thrombosis and Two Coagulation Factor Gene Mutations: Quo Vadis?. *Thrombosis and Haemostasis*, **1999**, 82, 1564-1566	7	24
2150	Budd-Chiari Syndrome in a Patient Heterozygous for both Factor V Leiden and the G20210A Mutation on the Prothrombin Gene. *Thrombosis and Haemostasis*, **1999**, 82, 1366-1367	7	10
2149	The Prothrombin 20210A Allele and Its Association with Myocardial Infarction. *Thrombosis and Haemostasis*, **1999**, 81, 861-864	7	36
2148	Activated Protein C Resistance (FV:Q506) and Pregnancy. *Thrombosis and Haemostasis*, **1999**, 81, 532-537	7	193
2147	Absence of the Prothrombin Gene Variant in Koreans. *Thrombosis and Haemostasis*, **1999**, 81, 990-990	7	9
2146	The Influence of Developmental Haemostasis on the Laboratory Diagnosis and Management of Haemostatic Disorders During Infancy and Childhood. **1999**, 19, 39-70		35
2145	Prevalence of the Prothrombin Gene 20210A Mutation in Thrombophilic and Healthy Algerian Subjects. *Thrombosis and Haemostasis*, **1999**, 82, 1554-1555	7	14
2144	The Risk of Fetal Loss in Family Members of Probands with Factor V Leiden Mutation. *Thrombosis and Haemostasis*, **1999**, 82, 1237-1239	7	44
2143	Synergistic Effects of Prothrombotic Polymorphisms and Atherogenic Factors on the Risk of Myocardial Infarction in Young Males. *Blood*, **1999**, 93, 2186-2190	2.2	77
2142	Automated Detection of the Factor V Leiden Mutation Using the LCx Microparticle Enzyme Immunoassay. **1999**, 45, 41-46		8
2141	Rapid Detection of Prothrombotic Mutations of Prothrombin (G20210A), FactorV (G1691A), and Methylenetetrahydrofolate Reductase (C677T) by Real-Time Fluorescence PCR with the LightCycler. **1999**, 45, 694-696		89
2140	A Whole Blood, Multiplex PCR Detection Method for Factor V Leiden and the Prothrombin G20210A Variant. *Thrombosis and Haemostasis*, **1999**, 81, 464-465	7	10
2139	Factor-V Leiden: a risk factor for cerebral palsy. **1999**, 41, 781-5		15
2138	Prothrombotic Genetic Risk Factors in Young Survivors of Myocardial Infarction. *Blood*, **1999**, 94, 46-51	2.2	205

2137	Venous Thromboembolic Disease and the Prothrombin, Methylene Tetrahydrofolate Reductase and Factor V Genes. *Thrombosis and Haemostasis*, **1999**, 81, 506-510	7	88
2136	Cerebral Vein Thrombosis not Related to Use of Oral Contraceptives in a 7-year-old Child Carrier of the Prothrombin 20210A Allele. *Thrombosis and Haemostasis*, **1999**, 81, 991-992	7	2
2135	Thrombophilic Polymorphisms Are Common in Women with Fetal Loss without Apparent Cause. *Thrombosis and Haemostasis*, **1999**, 82, 6-9	7	198
2134	Anticoagulant prophylaxis and therapy in patients with cancer. **2000**, 50, 149-58		3
2133	The VITA Project: Prothrombin G20210A Mutation and Venous Thromboembolism in the General Population. *Thrombosis and Haemostasis*, **1999**, 82, 1395-1398	7	37
2132	Prospective Evaluation of the Thrombotic Risk in Children With Acute Lymphoblastic Leukemia Carrying the MTHFR TT 677 Genotype, the Prothrombin G20210A Variant, and Further Prothrombotic Risk Factors. *Blood*, **1999**, 93, 1595-1599	2.2	172
2131	Extensive Venous and Arterial Thrombosis Associated With an Inhibitor to Activated Protein C. *Blood*, **1999**, 94, 895-901	2.2	32
2130	Gene-Gene and Gene-Environment Interactions Determine Risk of Thrombosis in Families With Inherited Antithrombin Deficiency. *Blood*, **1999**, 94, 2590-2594	2.2	115
2129	Association of a Common Polymorphism in the Factor XIII Gene With Venous Thrombosis. *Blood*, **1999**, 93, 906-908	2.2	191
2128	Hormonal Therapy After Stem Cell Transplantation and the Risk of Veno-occlusive Disease. *Blood*, **1999**, 93, 3154-3154	2.2	9
2127	Lipoprotein (a) and Genetic Polymorphisms of Clotting Factor V, Prothrombin, and Methylenetetrahydrofolate Reductase Are Risk Factors of Spontaneous Ischemic Stroke in Childhood. *Blood*, **1999**, 94, 3678-3682	2.2	294
2126	Inhibition of Activated Protein C Anticoagulant Activity by Prothrombin. *Blood*, **1999**, 94, 3839-3846	2.2	61
2125	Double-Homozygosity for Factor V Leiden and the Prothrombin Gene G20210A Variant in a Young Patient With Idiopathic Venous Thrombosis. *Blood*, **1999**, 94, 1828-1829	2.2	10
2124	Normal Thrombin Generation. *Blood*, **1999**, 94, 2169-2178	2.2	314
2123	Coinheritance of the HR2 Haplotype in the Factor V Gene Confers an Increased Risk of Venous Thromboembolism to Carriers of Factor V R506Q (Factor V Leiden). *Blood*, **1999**, 94, 3062-3066	2.2	103
2122	Renal allograft thrombosis: can thrombophilia explain the inexplicable?. **1999**, 14, 2297-303		24
2121	Hematology: Molecular Testing for the Factor V-Leiden Mutation in the Clinical Laboratory. *Laboratory Medicine*, **1999**, 30, 681-683	1.6	
2120	Hypercoagulable state and graft rejection--is there a link?. **1999**, 14, 2293-6		5

2119	Heritable thrombophilia and hypofibrinolysis. Possible causes of retinal vein occlusion. **1999**, 117, 43-9	79
2118	Identification of a genetic risk factor for idiopathic dilated cardiomyopathy. Involvement of a polymorphism in the endothelin receptor type A gene. CARDIGENE group. **1999**, 20, 1587-91	40
2117	Treatment of hereditary and acquired thrombophilic disorders. **1999**, 25, 387-406	55
2116	Factor V leiden and factor II G20210A mutations in patients with recurrent abortion. **1999**, 14, 2448-50	66
2115	Activated protein C resistance and thrombosis: molecular mechanisms of hypercoagulable state due to FVR506Q mutation. **1999**, 25, 273-89	51
2114	Venous thromboembolism. **1999**, 159, 1-14	408
2113	Chiasmal apoplexy, an unusual complication of cerebral glioblastoma. **1999**, 13 (Pt 2), 268-9	2
2112	Retinal vein occlusion, the contraceptive pill and the prothrombin 20210A allele. **1999**, 13 (Pt 2), 269	1
2111	Perinatal aspects of inherited thrombophilia. **1999**, 25, 481-5	12
2110	Screening for the G to A Transition at Position 20210 in the 3'-Untranslated Region (UTR) of the Prothrombin Gene. **1999**, 31, 269-74	
2109	Prothrombin G20210A gene mutation, heparin cofactor II defects, primary (essential) thrombocythemia, and thrombohemorrhagic manifestations. **1999**, 25, 375-86	8
2108	Multiplex PCR for Detection of the Prothrombin 3'-UTR (G20210A) Polymorphism and the Factor V Leiden Mutation. **1999**, 31, 287-9	1
2107	Genetic risk factors in acute coronary disease. **1999**, 29, 212-8	7
2106	Warfarin-induced skin necrosis in a patient with a mutation of the prothrombin gene. **1999**, 340, 735	10
2105	Procoagulant mutations and venous thrombosis in Beh□et's disease. **1999**, 38, 1298-9	42
2104	Prothrombin G20210A gene mutation and further prothrombotic risk factors in childhood thrombophilia. **1999**, 19, 2568-72	135
2103	Familial association of hypoplasminogenemia and heterozygous factor V deficiency. **1999**, 5, 277-81	1
2102	Low incidence of venous thrombosis in homozygous patients with NT 20210 G to a prothrombin polymorphism. **1999**, 5, 205-7	5

2101	Single and combined prothrombotic factors in patients with idiopathic venous thromboembolism: prevalence and risk assessment. **1999**, 19, 511-8	216
2100	Coexistence of two prothrombotic mutations, factor V 1691 G-A and prothrombin gene 20210 G-A, and the risk of cerebral infarct in pediatric patients. **1999**, 16, 565-6	8
2099	Inherited prothrombotic conditions and premature ischemic stroke: sex difference in the association with factor V Leiden. **1999**, 19, 1751-6	100
2098	Prothrombinmutation 20210 G->A, Prothrombinspiegel und Faktor V Leiden-Mutation bei ven□□en und arteriellen Gef□□Verschl□□sen.. **1999**, 23, 351-356	1
2097	Mesenteric infarction due to combined protein C deficiency and prothrombin 20210 defects. **1999**, 75, 742-3	6
2096	Central retinal vein thrombosis associated with prothrombin 20210G/A gene variant. **1999**, 5, 190-1	
2095	Management of pulmonary thrombo-embolism using catheter manipulation: a report of four cases and review of the literature. **1999**, 75, 737-41	8
2094	Fatal phenytoin hypersensitivity syndrome. **1999**, 75, 734-6	10
2093	The G20210A polymorphism in the 3'-untranslated region of the prothrombin gene in Mexican mestizo patients with primary antiphospholipid syndrome. **1999**, 5, 158-60	14
2092	Coagulation factors II, V, VII, and X, prothrombin gene 20210G-->A transition, and factor V Leiden in coronary artery disease: high factor V clotting activity is an independent risk factor for myocardial infarction. **1999**, 19, 1020-5	84
2091	Complex association of protein C gene promoter polymorphism with circulating protein C levels and thrombotic risk. **1999**, 19, 1573-6	55
2090	Asymptomatic homozygous nt 20210 G to A prothrombin polymorphism in two blood donors belonging to two different kindreds. **1999**, 5, 48-51	15
2089	Factor V1691 G-A, prothrombin 20210 G-A, and methylenetetrahydrofolate reductase 677 C-T variants in Turkish children with cerebral infarct. **1999**, 14, 749-51	62
2088	Homozygous prothrombin gene mutation and ischemic cerebrovascular disease: a case report. **1999**, 102, 101-3	17
2087	Plasma glutathione peroxidase deficiency and platelet insensitivity to nitric oxide in children with familial stroke. **1999**, 19, 2017-23	66
2086	Hypertensive encephalopathy in a patient with retroperitoneal fibrosis. **1999**, 75, 730-1	3
2085	Increased resistance to activated protein C and factor V Leiden in recurrent abortions. Review of other hypercoagulability factors. **1999**, 4, 135-144	9
2084	Study of the prothrombin gene 20201 GA variant in FV:Q506 carriers in relationship to the presence or absence of juvenile venous thromboembolism. **1999**, 19, 276-80	47

2083	Interaction between the G20210A mutation of the prothrombin gene and oral contraceptive use in deep vein thrombosis. **1999**, 19, 700-3	149
2082	Risk of venous thromboembolism and clinical manifestations in carriers of antithrombin, protein C, protein S deficiency, or activated protein C resistance: a multicenter collaborative family study. **1999**, 19, 1026-33	117
2081	Hormone replacement therapy and venous thromboembolism. **1999**, 2, 224-31	2
2080	Clinical manifestations in thrombotic children with factor V Leiden mutation. **1999**, 16, 233-7	22
2079	High-grade glioma mimicking acute viral encephalitis--three case reports. **1999**, 75, 727-30	15
2078	Increased lipoprotein(a) is an important risk factor for venous thromboembolism in childhood. **1999** , 100, 743-8	193
2077	Inherited thrombophilia genes in minorities. **1999**, 3, 371-3	6
2076	Paget-Schroetter syndrome associated with FV:Q506 and prothrombin 20210A--a case report. **1999** , 50, 689-92	14
2075	Hemostasis and Thrombosis Protocols. **1999**,	6
2074	Cardiovascular disease and combined oral contraceptives: reviewing the evidence and balancing the risks. **1999**, 5, 721-35	61
2073	The effect of carbamazepine and sodium valproate on the blood and serum values of children from a third-world environment. **1999**, 14, 751-3	5
2072	Visceral leishmaniasis masquerading as tuberculosis in a patient with AIDS. **1999**, 75, 732-4	4
2071	Thrombophilia: a feature of importance in retinal vein thrombosis?. **1999**, 77, 619-21	15
2070	Factor V Leiden and prothrombin 20210 A mutations in patients with central and branch retinal vein occlusion. **1999**, 77, 622-4	33
2069	Factor V Leiden: should all women be screened prior to commencing the contraceptive pill?. **1999**, 13, 8-13	22
2068	A prospective coagulation study including resistance to activated protein C and mutations in factors V and II in venous leg ulcers. **1999**, 141, 259-63	15
2067	The 20210 G-->A mutation in the 3'-untranslated region of the prothrombin gene and the risk for arterial thrombotic disease. **1999**, 104, 50-4	80
2066	Pseudohomozygosity for activated protein C resistance is a risk factor for venous thrombosis. **1999**, 106, 232-6	9

2065	Contribution of the glycoprotein Ia 807TT, methylene tetrahydrofolate reductase 677TT and prothrombin 20210GA genotypes to prothrombotic risk among factor V 1691GA (Leiden) carriers. **1999**, 106, 237-9	12
2064	Prevalence of mild hyperhomocysteinaemia and association with thrombophilic genotypes (factor V Leiden and prothrombin G20210A) in Italian patients with venous thromboembolic disease. **1999**, 106, 564-8	44
2063	Influence of three potential genetic risk factors for thrombosis in 43 families carrying the factor V Arg 506 to Gln mutation. **1999**, 106, 889-97	9
2062	Factor V Leiden and the common haemochromatosis mutation HFE C282Y: is there an association in familial venous thromboembolic disease?. **1999**, 107, 210-2	9
2061	A chronic hypercoagulable state in patients with beta-thalassaemia major is already present in childhood. **1999**, 107, 739-46	83
2060	Inherited protein C deficiency, protein S deficiency and hyperhomocysteinaemia in a patient with hereditary spherocytosis. **1999**, 21, 211-4	
2059	The investigation and management of inherited thrombophilia. **1999**, 21, 77-92	27
2058	Development of an internal restriction control in the PCR detection of the prothrombin 20210A mutation. **1999**, 21, 281-3	3
2057	Do inherited prothrombotic factors have a role in myocardial infarction with normal coronary arteriogram?. **1999**, 245, 554-555	
2056	The role of inherited thrombophilia in venous thromboembolism associated with pregnancy. **1999**, 106, 756-66	43
2055	A second mutation in the methylenetetrahydrofolate reductase gene and the risk of venous thrombotic disease. **1999**, 105, 556-559	41
2054	Born to clot: the European burden. **1999**, 105, 564-566	96
2053	Clinical and analytical relevance of the combination of prothrombin 20210A/A and factor V Leiden: results from a large family. **1999**, 105, 560-563	25
2052	Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment. **1999**, 22, 168-70	498
2051	The prothrombin gene variant G20210A but not factor V leiden may be associated with veno-occlusive disease following BMT. **1999**, 24, 693-4	17
2050	Genetic determinants of heritable venous thrombosis: genotyping methods for factor V(Leiden)A1691G, methylenetetrahydrofolate reductase C677T, prothrombin G20210A mutation, and algorithms for venous thrombosis investigations. **1999**, 32, 223-8	13
2049	Prothrombin 20210G/A mutation in two patients with mesenteric ischemia. **1999**, 44, 1910-3	13
2048	Genetic thrombophilia in patients with retinal vascular occlusion. **1999**, 23, 155-60	28

2047	Prothrombin and the prothrombin 20210 G to A polymorphism: their relationship with hypercoagulability and thrombosis. **1999**, 13, 205-10	23
2046	Interaction of the protein C/protein S anticoagulant system, the endothelium and pregnancy. **1999**, 13, 127-46	25
2045	Analysis of three genetic polymorphisms as risk factors for thrombosis. **1999**, 29, 174-5	
2044	Elsberg syndrome due to infarction of the conus medullaris associated with a prothrombin mutation. **1999**, 246, 507-8	6
2043	Duration and intensity of anticoagulation among patients with genetic predispositions to venous thrombosis. **1999**, 1, 88-90	4
2042	Preeclampsia and genetic risk factors for thrombosis: a case-control study. **1999**, 181, 975-80	121
2041	POSTOPERATIVE THROMBOTIC COMPLICATIONS. **1999**, 17, 895-922	7
2040	Human genetic diseases of proteolysis. **1999**, 13, 87-98	30
2039	Prevalence of factor V Leiden, prothrombin G20210A, and MTHFR C677T mutations in a Greek population of blood donors. **1999**, 61, 265-7	46
2038	Feasibility of restriction enzyme protocols for the molecular diagnosis of abnormal hemoglobins in Turkish population. **1999**, 62, 198	2
2037	Fatal pulmonary fibrosis after a low cumulated dose of bleomycin: role of alpha1-antitrypsin deficiency?. **1999**, 62, 198-9	1
2036	Mesenteric vein thrombosis secondary to combined protein C deficiency and double heterozygosity for factor V Leiden and prothrombin G20210A. **1999**, 62, 199-200	5
2035	Salvage therapy and long-term remission with danazol and cyclosporine in refractory Evan's syndrome. **1999**, 62, 200	1
2034	Prothrombotic risk factors in childhood stroke and venous thrombosis. **1999**, 158 Suppl 3, S117-21	59
2033	Factor V G1691A and prothrombin G20210A in childhood spontaneous venous thrombosis--evidence of an age-dependent thrombotic onset in carriers of factor V G1691A and prothrombin G20210A mutation. **1999**, 158 Suppl 3, S105-8	41
2032	Clinical relevance of genetic risk factors for thrombosis in paediatric oncology patients with central venous catheters. **1999**, 158 Suppl 3, S143-6	73
2031	Multicentre evaluation of combined prothrombotic defects associated with thrombophilia in childhood. Childhood Thrombophilia Study Group. **1999**, 158 Suppl 3, S97-104	91
2030	Role of genetic prothrombotic risk factors in childhood caval vein thrombosis. **1999**, 158 Suppl 3, S109-12	28

2029	Goals and objectives for molecular pathology education in residency programs. The Association for Molecular Pathology Training and Education Committee. **1999**, 1, 5-15		16
2028	Increased frequency of genetic thrombophilia in women with complications of pregnancy. **1999**, 340, 9-13		913
2027	The risk of recurrent deep venous thrombosis among heterozygous carriers of both factor V Leiden and the G20210A prothrombin mutation. **1999**, 341, 801-6		407
2026	[Exploration of hemostasis disorders in children (excluding the neonatal period)]. **1999**, 6, 1086-91		1
2025	Analysis of prothrombotic and vascular risk factors in patients with nonarteritic anterior ischemic optic neuropathy. **1999**, 106, 739-42		155
2024	Small for gestational age infant in association with maternal prothrombin gene variant (nt 20210A). **1999**, 83, 143-4		11
2023	[Resistance to activated protein C and portal vein thrombosis: two new cases and review of the literature]. **1999**, 20, 602-6		1
2022	Deep-vein thrombosis. **1999**, 353, 479-85		196
2021	Thrombosis in pregnancy: maternal and fetal issues. **1999**, 353, 1258-65		506
2020	Venous thrombosis: a multicausal disease. **1999**, 353, 1167-73		1195
2019	Prothrombin G20210A mutation in a child with spinal cord infarction. **1999**, 134, 777-9		19
2018	Factor V Leiden and other hypercoagulable state mutations are not associated with osteonecrosis during or after treatment for pediatric malignancy. **1999**, 134, 310-4		15
2017	The G20210A mutation of the prothrombin gene in patients with previous first episodes of deep-vein thrombosis: prevalence and association with factor V G1691A, methylenetetrahydrofolate reductase C677T and plasma prothrombin levels. *Thrombosis Research*, **1999**, 93, 1-8	8.2	106
2016	Two multiplex PCR-based DNA assays for the thrombosis risk factors prothrombin G20210A and coagulation factor V G1691A polymorphisms. *Thrombosis Research*, **1999**, 93, 265-9	8.2	12
2015	Treatment of hyperhomocysteinemia with folic acid and vitamins B12 and B6 attenuates thrombin generation. *Thrombosis Research*, **1999**, 95, 281-8	8.2	41
2014	Multiplex analysis of mutations in four genes using fluorescence scanning technology. *Thrombosis Research*, **1999**, 96, 57-64	8.2	13
2013	The prothrombin gene G20210A mutation and the platelet glycoprotein IIIa polymorphism PlA2 in patients with central retinal vein occlusion. *Thrombosis Research*, **1999**, 96, 323-7	8.2	20
2012	Two additional homozygous patients for the 20210 prothrombin polymorphism with no venous thrombosis. *Thrombosis Research*, **1999**, 96, 415-7	8.2	14

2011	Thrombosis, factor V Leiden, and inflammatory bowel disease. **1999**, 116, 778-9	0
2010	Reply. **1999**, 116, 779	0
2009	Frequent factor II G20210A mutation in idiopathic portal vein thrombosis. **1999**, 116, 144-8	85
2008	The prothrombin G20210A mutation: a new high-prevalence congenital risk factor for thrombosis. **1999**, 116, 213-5	12
2007	Development of a simple multiplex polymerase chain reaction for the simultaneous detection of factor V Leiden and prothrombin 20210A mutations. *Molecular Diagnosis and Therapy*, **1999**, 4, 247-50	11
2006	A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. **1999**, 340, 901-7	876
2005	G20210A mutation in prothrombin gene and risk of myocardial infarction, stroke, and venous thrombosis in a large cohort of US men. **1999**, 99, 999-1004	225
2004	Prothrombin gene variant (G20210A) in a patient with cerebral venous sinus thrombosis. **1999**, 101, 53-5	6
2003	Hypercoagulable state mutation analysis in white patients with early first-trimester recurrent pregnancy loss. **1999**, 71, 1048-53	133
2002	Thrombophilia-associated pregnancy wastage. **1999**, 72, 765-74	99
2001	The molecular genetics of familial venous thrombosis. **1999**, 12, 479-503	13
2000	Idiopathic central retinal vein occlusion in a thrombophilic patient with the heterozygous 20210 G/A prothrombin genotype. **1999**, 128, 247-8	14
1999	Prevention and Treatment of Thrombo-embolic Disease in Gynaecological Surgery. **1999**, 21, 1087-1094	
1998	Prethrombotic disorders in children with arterial ischemic stroke and sinovenous thrombosis. **1999**, 56, 967-71	96
1997	Pr□vention et traitement de la thromboembolie en chirurgie gyn□cologique. **1999**, 21, 1095-1102	
1996	Broadsheet number 53: Activated protein C resistance: diagnosis and clinical management. **1999**, 31, 365-71	
1995	Venous thrombosis: prevalence and interaction of risk factors. **1999**, 29 Suppl S1, 1-9	16
1994	Clinical aspects and laboratory problems in hereditary thrombophilia. **1999**, 29, 76-99	1

1993	Mutaci□ñ 20210G/A del gen de la protrombina en un paciente con trombosis venosa profunda y embolia pulmonar sin otros factores de riesgo tromb□Ëico. **1999**, 35, 567-570		1
1992	Factor V Leiden: death and DNA. **1999**, 111, 302-3		
1991	A novel clotting assay for quantitation of plasma prothrombin (factor II) using Echis multisquamatus venom. **1999**, 112, 705-11		7
1990	The plasminogen activator inhibitor-1 gene, hypofibrinolysis, and osteonecrosis. **1999**, 133-46		102
1989	Deep vein thrombosis and pulmonary embolism: a single disease entity with different risk factors?. **2000**, 118, 1234-6		20
1988	Prothrombin Gene Mutation Uncommon in Pulmonary Embolism. **2000**, 93, 1073-1077		3
1987	Hereditary thrombophilia in cerebral venous thrombosis. **2000**, 10, 161-2		18
1986	Prothrombin G20210A mutation: is it associated with pre-eclampsia?. **2000**, 50, 254-7		32
1985	Thrombotic risk factors in pulmonary hypertension. **2000**, 15, 395-9		228
1984	Application of the TaqMan-PCR for Genotyping of the Prothrombi G20210A Mutation and of the Thermolabile Methylenetetrahydrofolate Reductase Mutation. *Thrombosis and Haemostasis*, **2000**, 84, 144-145	7	17
1983	Prothrombotic Risk Factors in Children with Acute Lymphoblastic Leukemia Treated with Delayed E. coli Asparaginase (COALL-92 and 97 Protocols). *Thrombosis and Haemostasis*, **2000**, 83, 840-843	7	65
1982	Recurrent Venous Thrombosis and Markers of Inflammation. *Thrombosis and Haemostasis*, **2000**, 83, 536-539	7	110
1981	Thrombophilia, polymorphisms, and vascular disease. **2000**, 53, 300-6		25
1980	Genetic heterogeneity in hereditary thrombophilia. **2000**, 30 Suppl 2, 1-10		6
1979	The HR2 Haplotype of Factor V: Effects on Factor V Levels, Normalized Activated Protein C Sensitivity Ratios and the Risk of Venous Thrombosis. *Thrombosis and Haemostasis*, **2000**, 83, 577-582	7	71
1978	Gestational Outcome in Thrombophilic Women with Recurrent Pregnancy Loss Treated by Enoxaparin. *Thrombosis and Haemostasis*, **2000**, 83, 693-697	7	255
1977	Effects on Coagulation of Levonorgestrel- and Desogestrel-containing Low Dose Oral Contraceptives: a Cross-over Study. *Thrombosis and Haemostasis*, **2000**, 84, 4-8	7	147
1976	Venous Thrombotic Risk in Family Members of Unselected Individuals with Factor V Leiden. *Thrombosis and Haemostasis*, **2000**, 83, 817-821	7	68

1975	Inherited Thrombophilia as a Risk Factor for the Development of Ischemic Stroke in Young Adults. *Thrombosis and Haemostasis*, **2000**, 83, 229-233	7	96
1974	Diagnostic testing for coagulopathies in patients with ischemic stroke. **2000**, 31, 3067-78		120
1973	Transient focal neurological deficits during pregnancy in carriers of inherited thrombophilia. **2000**, 31, 892-5		12
1972	Factor V Leiden and antiphospholipid antibodies are significant risk factors for ischemic stroke in children. **2000**, 31, 1283-8		262
1971	Cerebral venous thrombosis and the G20210A mutation of factor II. **2000**, 31, 543-4		5
1970	Comparison of thrombotic risk between 85 homozygotes and 481 heterozygotes carriers of the factor V Leiden mutation: retrospective analysis from the Procare Study. **2000**, 11, 511-8		20
1969	Fatal pulmonary artery thrombosis in a patient with Beh□et's disease, activated protein C resistance and hyperhomocystinemia. **2000**, 11, 421-3		3
1968	Screening for abnormalities of the protein C anticoagulant pathway using the ProC Global assay. Results of a European multicenter evaluation. **2000**, 11, 447-54		23
1967	Prevalence of the prothrombin G20210A mutation in the Irish populations: use of a novel polymerase chain reaction approach. **2000**, 11, 669-72		4
1966	Long-term treatment for venous thromboembolism. **2000**, 7, 302-8		7
1965	Prevalence of factor V Leiden and the G20210A prothrombin-gene mutation in inflammatory bowel disease. **2000**, 11, 499-503		29
1964	Angiotensin-converting enzyme DD genotype, angiotensin type 1 receptor CC genotype, and hyperhomocysteinemia increase first-trimester fetal-loss susceptibility. **2000**, 11, 657-62		50
1963	Two families with combined homozygous/heterozygous factor V Leiden mutation and heterozygous G20210A factor II variant. **2000**, 11, 783-4		1
1962	Systemic disorders associated with retinal vascular occlusion. **2000**, 11, 462-7		68
1961	The A20210 allele in the prothrombin gene enhances the risk of venous thrombosis in carriers of inherited protein S deficiency. **2000**, 11, 321-6		4
1960	DNA technology for the detection of common genetic variants that predispose to thrombophilia. **2000**, 11, 683-700		11
1959	Severe Preeclampsia and High Frequency of Genetic Thrombophilic Mutations. **2000**, 96, 45-49		2
1958	Clinical and laboratory expression of associated thrombophilic conditions (homozygous/heterozygous factor V Leiden mutation and heterozygous prothrombin variant 20210A) in an Italian family. **2000**, 11, 379-84		4

1957	The impact of the search for thrombophilia risk factors among antiphospholipid syndrome patients with thrombosis. **2000**, 11, 679-82	18
1956	Causes of venous thrombosis in fifty Chinese patients. **2000**, 63, 74-8	27
1955	Fluorescence-based single-strand conformation polymorphism analysis of mutations by capillary electrophoresis. **2000**, 21, 375-9	17
1954	Incidence of thrombophilia in patients with Gaucher disease. **2000**, 95, 429-31	10
1953	Fibrinogen bellingham: a gamma-chain R275C substitution and a beta-promoter polymorphism in a thrombotic member of an asymptomatic family. **2000**, 64, 242-50	21
1952	Prevalence of the G1691A mutation in the factor V gene (factor V Leiden) and the G20210A prothrombin gene mutation in the Thai population. **2000**, 65, 119-22	49
1951	The 4G/5G polymorphism of the type 1 plasminogen activator inhibitor gene and thrombosis in patients with antiphospholipid syndrome. **2000**, 43, 2349-58	61
1950	Inherited coagulation disorders in cirrhotic patients with portal vein thrombosis. **2000**, 31, 345-8	210
1949	Cause of portal or hepatic venous thrombosis in adults: the role of multiple concurrent factors. **2000**, 31, 587-91	461
1948	Evaluation of the Roche diagnostics LightCycler-Factor V Leiden Mutation Detection Kit and the LightCycler-Prothrombin Mutation Detection Kit. **2000**, 33, 213-6	22
1947	'Blood doping' with recombinant erythropoietin (rhEPO) and assessment of functional iron deficiency in healthy volunteers. **2000**, 108, 883-4	5
1946	Deletions of the p53 gene in multiple myeloma. **2000**, 108, 886	3
1945	The G1691 --> A mutation of factor V, but not the G20210 --> A mutation of factor II or the C677 --> T mutation of methylenetetrahydrofolate reductase genes, is associated with venous thrombosis in patients with lupus anticoagulants. **2000**, 108, 865-70	35
1944	The multigenic basis for venous thrombosis. **2000**, 109, 508-11	5
1943	Prevalence of factor V Leiden and prothrombin G20210A mutations in unselected patients with venous thromboembolism. **2000**, 110, 125-9	45
1942	Prevalence of methylenetetrahydrofolate reductase C677T and its association with arterial and venous thrombosis in the Chinese population. **2000**, 109, 870-4	51
1941	Influence of the -675 4G/5G dimorphism of the plasminogen activator inhibitor 1 promoter on thrombotic risk in patients with factor V Leiden. **2000**, 110, 135-8	13
1940	Factor V Leiden: the venous thrombotic risk in thrombophilic families. **2000**, 110, 939-45	33

1939	Screening for thrombophilic risk factors among 25 German patients with cerebral venous thrombosis. **2000**, 102, 31-6	23
1938	High prevalence of the prothrombin gene mutation in women with intrauterine growth retardation, abruptio placentae and second trimester loss. **2000**, 79, 963-967	10
1937	PAI-1 promoter 4G/5G genotype as an additional risk factor for venous thrombosis in subjects with genetic thrombophilic defects. **2000**, 111, 122-128	4
1936	Identification of mutations in 15 Hungarian families with hereditary protein C deficiency. **2000**, 111, 129-135	
1935	Abdominal venous thrombosis in neonates and infants: role of prothrombotic risk factors a multicentre case control study. **2000**, 111, 534-539	2
1934	A comparison of polymorphism in the 3?-untranslated region of the prothrombin gene between Chinese and Caucasians in Australia. **2000**, 111, 1253-1255	
1933	The risk of venous thromboembolism in family members with mutations in the genes of factor V or prothrombin or both. **2000**, 111, 1223-1229	
1932	Poor reversal of low molecular weight heparin by protamine. **2000**, 108, 884-5	35
1931	Isochromosome 12p in mediastinal centroblastic lymphoma. **2000**, 108, 885-6	3
1930	Reply to Drach et al. **2000**, 108, 887-887	1
1929	Pregnancy and the impact of inherited thrombophilias. **2000**, 40, 118-21	3
1928	Prothrombin 20210 G-->A, MTHFR C677T mutations in women with venous thromboembolism associated with pregnancy. **2000**, 107, 565-9	64
1927	Inherited risk factors for venous thromboembolism: implications for clinical practice. **2000**, 2, 1-14	0
1926	Prevalence of Factor V Leiden in three ethnic groups of patients with deep vein thrombosis in the Western Cape province of South Africa. **2000**, 65, 78-9	2
1925	A homozygosity state for 20210A prothrombin variant in a young woman as cause of a deep venous thrombosis during pregnancy. **2000**, 65, 80-1	5
1924	Prothrombotic disorders and ischemic stroke in children. **2000**, 7, 301-8	60
1923	Genetic factors associated with thrombosis in pregnancy in a United States population. **2000**, 183, 1271-7	48
1922	Update in internal medicine. **2000**, 31, 329-52	

1921	Inflammatory bowel diseases are not associated with major hereditary conditions predisposing to thrombosis. **2000**, 45, 1465-9		69
1920	[47-year-old patient with resistant pulmonary embolism in congenital hemodynamic disorder]. **2000**, 41, 61-5		
1919	The molecular mechanisms of inherited thrombophilia. **2000**, 89, 575-86		11
1918	Recent portal or mesenteric venous thrombosis: increased recognition and frequent recanalization on anticoagulant therapy. **2000**, 32, 466-70		394
1917	Guidelines on diagnosis and management of acute pulmonary embolism. Task Force on Pulmonary Embolism, European Society of Cardiology. **2000**, 21, 1301-36		421
1916	Prevalence of prothrombin 20210A allele and methylenetetrahydrofolate reductase C677T genetic mutations in the Chinese population. **2000**, 79, 239-42		16
1915	Rapid simultaneous screening of whole blood for factor V leiden and for G20210G-A prothrombin variant by multiplex polymerase chain reaction withHindIII. **2000**, 34, 418-419		
1914	Prothrombotic genetic risk factors in chronic daily headache. **2000**, 1, S183-S185		
1913	Translational pathophysiology: a novel molecular mechanism of human disease. *Blood*, **2000**, 95, 3280-3288	2.2	178
1912	High levels of factor IX increase the risk of venous thrombosis. *Blood*, **2000**, 95, 3678-3682	2.2	309
1911	Identification and characterization of a thrombomodulin gene mutation coding for an elongated protein with reduced expression in a kindred with myocardial infarction. *Blood*, **2000**, 95, 569-576	2.2	43
1910	Role of hemostatic gene polymorphisms in venous and arterial thrombotic disease. *Blood*, **2000**, 95, 1517-1532	2.2	426
1909	Risk for subsequent venous thromboembolic complications in carriers of the prothrombin or the factor V gene mutation with a first episode of deep-vein thrombosis. *Blood*, **2000**, 96, 3329-3333	2.2	112
1908	Congenital relapsing fever (Borrelia hermsii). *Blood*, **2000**, 96, 3333-3333	2.2	2
1907	Fibrinogen Ale s: a homozygous case of dysfibrinogenemia (Asp330 ->Val) characterized by a defective fibrin polymerization site . *Blood*, **2000**, 96, 3473-3479	2.2	17
1906	Fibrinogen Thr312Ala polymorphism and venous thromboembolism. *Blood*, **2000**, 96, 1177-1179	2.2	102
1905	Familial thrombophilia associated with fibrinogen Paris V: Dusart syndrome. *Blood*, **2000**, 96, 1191-1193	2.2	23
1904	Combinations of 4 mutations (FV R506Q, FV H1299R, FV Y1702C, PT 20210G/A) affecting the prothrombinase complex in a thrombophilic family. *Blood*, **2000**, 96, 1443-1448	2.2	50

1903	Val34Leu polymorphism of plasma factor XIII: biochemistry and epidemiology in familial thrombophilia. *Blood*, **2000**, 96, 2479-2486	2.2	116
1902	Hyperprothrombinemia may result in acquired activated protein C resistance. *Blood*, **2000**, 96, 3295-3296	2.2	26
1901	Linkage analysis demonstrates that the prothrombin G20210A mutation jointly influences plasma prothrombin levels and risk of thrombosis. *Blood*, **2000**, 95, 2780-2785	2.2	102
1900	Increased lipoprotein (a) levels as an independent risk factor for venous thromboembolism. *Blood*, **2000**, 96, 3364-3368	2.2	141
1899	Genistein: A Potent Natural Antiandrogen. **2000**, 46, 887-888		20
1898	Lack of Association of the Prothrombin Gene Variant G20210A with Myocardial Infarction in Caucasian Males. *Thrombosis and Haemostasis*, **2000**, 83, 796-797	7	6
1897	High Plasma Concentration of Factor VIIIc Is a Major Risk Factor for Venous Thromboembolism. *Thrombosis and Haemostasis*, **2000**, 83, 5-9	7	379
1896	Management of venous and cardiovascular thrombosis: enoxaparin. **2000**, 61, 628-36		5
1895	Fibrinogen Caracas V, an Abnormal Fibrinogen with an Aα532 Ser->Cys Substitution Associated with Thrombosis. *Thrombosis and Haemostasis*, **2000**, 84, 263-270	7	33
1894	Venous Thromboembolism and Associated High Plasma Factor VIII Levels:Linked to Cytomegalovirus Infection?. *Thrombosis and Haemostasis*, **2000**, 83, 510-511	7	28
1893	Thrombophilic Mutations in Iran. *Thrombosis and Haemostasis*, **2000**, 83, 351-352	7	15
1892	Factor II G20210A and Factor V G1691A Gene Mutations and Peripheral Arterial Occlusive Disease. *Thrombosis and Haemostasis*, **2000**, 83, 20-22	7	25
1891	Massive Skin Necrosis Associated to the Prothrombin Gene G20210A Mutation. *Thrombosis and Haemostasis*, **2000**, 83, 966-967	7	1
1890	Branch retinal vein occlusion associated with the 20210 G-to-A prothrombin variant. **2000**, 10, 177-9		3
1889	Homozygosity for the Protein S Heerlen Allele Is Associated with Type I PS Deficiency in a Thrombophilic Pedigree with Multiple Risk Factors. *Thrombosis and Haemostasis*, **2000**, 83, 102-106	7	19
1888	The Factor V R2 Allele: Risk of Venous Thromboembolism, Factor V Levels and Resistance to Activated Protein C. *Thrombosis and Haemostasis*, **2000**, 83, 204-208	7	56
1887	Causes of thrombophilia yet to be discovered: a personal view. **2000**, 30 Suppl 2, 26-33		
1886	Aspects of the clinical management of hereditary thrombophilia: a personal perspective. **2000**, 30 Suppl 2, 11-5		

1885	Automated, Simultaneous Detection of the Factor V Leiden and Prothrombin (G20210A) Variants Using Multiplex PCR and a Line Probe Assay. *Thrombosis and Haemostasis*, **2000**, 83, 354-355	7	8
1884	High Levels of Factor VIII and Venous Thrombosis. *Thrombosis and Haemostasis*, **2000**, 83, 1-2	7	76
1883	Demonstration of an Association between Chlamydia pneumoniae Infection and Venous Thromboembolic Disease. *Thrombosis and Haemostasis*, **2000**, 83, 887-891	7	25
1882	Factor V Leiden and Prothrombin G 20210A Variant Are Risk Factors for Venous Thromboembolism in the Argentinean Population. *Thrombosis and Haemostasis*, **2000**, 83, 509-510	7	6
1881	WHITHER THROMBOPROPHYLAXIS AFTER TOTAL HIP REPLACEMENT?. **2000**, 82-B, 469-472		4
1880	Thromboembolic events during chemotherapy for germ cell cancer: a cohort study and review of the literature. **2000**, 18, 2169-78		179
1879	Genotyping of Factor V G1691A (Leiden) without the Use of PCR by Invasive Cleavage of Oligonucleotide Probes. **2000**, 46, 1051-1056		43
1878	A High Factor II/Factor X Functional Ratio Is Not a Useful Predictor of the FII G20210A Gene Mutation in Thromboembolic Patients Undergoing Oral Anticoagulant Treatment. **2000**, 46, 886-887		
1877	Rapid Single-Tube Genotyping of the Factor V Leiden and Prothrombin Mutations by Real-Time PCR Using Dual-Color Detection. **2000**, 46, 1191-1195		26
1876	Comparison of the Risk of Pulmonary Embolism and Deep Vein Thrombosis in the Presence of Factor V Leiden or Prothrombin G20210A. *Thrombosis and Haemostasis*, **2000**, 83, 352-354	7	14
1875	G20210A Prothrombin Gene Polymorphism and Extent of Coronary Disease. *Thrombosis and Haemostasis*, **2000**, 84, 142-143	7	6
1874	Prothrombin Activation Is Increased among Asymptomatic Carriers of the Prothrombin G20210A and Factor V Arg506Gln Mutations. *Thrombosis and Haemostasis*, **2000**, 84, 396-400	7	20
1873	Thrombotic Complications in PNH. **2000**, 101-112		3
1872	Coagulation Factor II Activity Determination Is Not Useful as a Screening Tool for the G20210A Prothrombin Gene Allele. *Thrombosis and Haemostasis*, **2000**, 84, 141-142	7	7
1871	Management of patients with hereditary hypercoagulable disorders. **2000**, 51, 169-85		89
1870	Factor V leiden and prothrombin G20210A mutations, but not methylenetetrahydrofolate reductase C677T, are associated with recurrent miscarriages. **2000**, 15, 458-62		134
1869	Molecular Pathology Protocols. **2000**,		
1868	The significance or nonsignificance of the G to A 20210 prothrombin polymorphism. **2000**, 6, 239-40		3

1867	Inclusion of the hepatic locus control region, an intron, and untranslated region increases and stabilizes hepatic factor IX gene expression in vivo but not in vitro. **2000**, 1, 522-32	212
1866	The impact of the factor V Leiden mutation on pregnancy. **2000**, 6, 301-6	24
1865	Die Renaissance der Einzelfaktoren: Zeigen hohe Spiegel ein h□heres Risiko f□r ven□se Thromboembolien an?. The Renaissance of Clotting Factors □Do High Levels Indicate a Higher Risk for Venous Thromboembolism?. **2000**, 24, 139-145	
1864	Inflammatory bowel disease promotes venous thrombosis earlier in life. **2000**, 35, 619-23	101
1863	Thrombophilia in pregnancy. **2000**, 53, 573-80	69
1862	Combined genetic defect (homogeneity for factor V Leiden and heterogeneity for prothrombin G20210A allele), in a young patient, with recurrent deep vein thrombosis and serious postphlebitic syndrome--a case report. **2000**, 51, 325-9	2
1861	Familial thrombophilia and retinal vein occlusion. **2000**, 14 (Pt 1), 13-7	23
1860	Association of the prothrombin G20210A mutation with factor V Leiden in a midwestern American population. **2000**, 114, 272-5	10
1859	Inherited thrombophilic risk factors and venous thromboembolism: distinct role in peripheral deep venous thrombosis and pulmonary embolism. **2000**, 118, 1405-11	71
1858	Higher risk of venous thrombosis during early use of oral contraceptives in women with inherited clotting defects. **2000**, 160, 49-52	147
1857	Safety of withholding heparin in pregnant women with a history of venous thromboembolism. Recurrence of Clot in This Pregnancy Study Group. **2000**, 343, 1439-44	336
1856	Mutations in coagulation factors in women with unexplained late fetal loss. **2000**, 343, 1015-8	259
1855	Interaction between hyperhomocysteinemia and inherited thrombophilic factors in venous thromboembolism. **2000**, 26, 305-11	34
1854	Molecular diagnosis of hereditary thrombotic disorders. **2001**, 49, 413-26	
1853	Venous thromboembolism: risk factors and prophylaxis. **2000**, 21, 493-501	2
1852	Thrombophilia and adverse pregnancy outcome. **2000**, 18, 369-77	13
1851	Hereditary and acquired thrombophilia. **2000**, 21, 483-91	1
1850	Congenital Hemorrhagic Disorders: New Insights into the Pathophysiology and Treatment of Hemophilia. **2000**, 241-265	19

1849	Homocysteine and venous thrombosis: outline of a vitamin intervention trial. **2000**, 26, 297-304	16
1848	Genetics and ischaemic stroke. **2000**, 123 (Pt 9), 1784-812	289
1847	Prothrombin and factor V mutations in women with a history of thrombosis during pregnancy and the puerperium. **2000**, 342, 374-80	414
1846	Evaluation of the prothrombin gene polymorphism in patients with advanced retinopathy of prematurity. **2000**, 4, 75-7	2
1845	Acute myocardial infarction associated with the prothrombin G20210A mutation. **2000**, 6, 111-2	
1844	Congenital and acquired thrombotic risk factors in women using oral contraceptives: clinical aspects. **2000**, 6, 162-8	5
1843	Combined heterozygous plasminogen deficiency and factor V Leiden defect in the same kindred. **2000**, 6, 36-40	9
1842	G to A 20210 prothrombin polymorphism and venous thrombosis: simple association or causal relationship?. **2000**, 6, 135-8	4
1841	Review and management of patients with the prothrombin G20210A polymorphism. **2000**, 6, 94-9	5
1840	Portal vein thrombosis associated to prothrombin G20210A mutation and protein C deficiency. **2000**, 6, 179-80	3
1839	A system for specific, high-throughput genotyping by allele-specific primer extension on microarrays. **2000**, 10, 1031-42	258
1838	Multiple arterial thromboembolisms in a patient with the 20210 A prothrombin gene mutation. **2000**, 135, 721-2	3
1837	Recurrent miscarriage syndrome due to blood coagulation protein/platelet defects: prevalence, treatment and outcome results. DRW Metroplex Recurrent Miscarriage Syndrome Cooperative Group. **2000**, 6, 115-25	54
1836	Neue Aspekte in der Diagnostik und Klinik hereditä er Thrombophilien. New Aspects in the Diagnostics and Clinical Picture of Hereditary Thrombophilia. **2000**, 24, 298-301	
1835	Genetic determinants of hemostasis phenotypes in Spanish families. **2000**, 101, 1546-51	214
1834	Prevalence of genetic mutations that predispose to thrombophilia in a Greek Cypriot population. **2000**, 6, 104-7	28
1833	High plasma levels of factor VIII and the risk of recurrent venous thromboembolism. **2000**, 343, 457-62	596
1832	Peri-operative management of patients with coagulation disorders. **2000**, 85, 446-55	53

1831	Prevalence of the C677T methylenetetra- hydrofolate reductase mutation in Thai patients with deep vein thrombosis. **2000**, 103, 191-6		20
1830	Protective effect of a thrombin receptor (protease-activated receptor 1) gene polymorphism toward venous thromboembolism. **2000**, 20, 585-92		48
1829	Thrombophilia testing: what do we think the tests mean and what should we do with the results?. **2000**, 53, 167-70		8
1828	Polymorphisms in the 5' regulatory region of the tissue factor gene and the risk of myocardial infarction and venous thromboembolism: the ECTIM and PATHROS studies. Etude Cas-T moins de l'Infarctus du Myocarde. Paris Thrombosis case-control Study. **2000**, 20, 892-8		94
1827	Prothrombin gene 20210 G-->A and Factor V Arg 506 to Gln mutation in a patient with Buerger's disease--a case report. **2000**, 51, 421-3		6
1826	Anticoagulant proteins in childhood venous and arterial thrombosis: a review. **2000**, 26, 540-60		28
1825	Genetic risk factors for venous thrombosis. **2000**, 71, 51-61		14
1824	[G20210A transition in the prothrombin gene and venous thromboembolic disease]. **2000**, 21, 911-4		
1823	Lack of prothrombin gene mutation in young stroke patients. **2000**, 9, 229-231		1
1822	Genetic polymorphisms associated with thrombotic disorders in the Japanese population. **2000**, 14, 155-164		8
1821	Genetic susceptibility to thrombosis and its relationship to physiological risk factors: the GAIT study. Genetic Analysis of Idiopathic Thrombophilia. **2000**, 67, 1452-9		245
1820	[Mesenteric vein and inferior vena cava thrombosis: disseminated intravascular coagulation and/or G 20210 A mutation of the prothrombin gene?]. **2000**, 19, 42-6		4
1819	Severe preeclampsia and high frequency of genetic thrombophilic mutations. **2000**, 96, 45-9		109
1818	Detection of methylenetetrahydrofolate reductase (MTHFR) C677T and prothrombin G20210A mutations: second restriction site for digestion control of PCR products. **2000**, 301, 219-23		3
1817	Sudden infant death syndrome, childhood thrombosis, and presence of genetic risk factors for thrombosis. *Thrombosis Research*, **2000**, 98, 233-9	8.2	5
1816	Prothrombin G20210A, factor V Leiden, and factor XIII Val34Leu: common mutations of blood coagulation factors and deep vein thrombosis in Austria. *Thrombosis Research*, **2000**, 99, 35-9	8.2	47
1815	The role of the t-PA I/D and PAI-1 4G/5G polymorphisms in African-American adults with a diagnosis of myocardial infarction or venous thromboembolism. *Thrombosis Research*, **2000**, 99, 223-30	8.2	61
1814	The allele frequency of mutations in four genes that confer enhanced susceptibility to venous thromboembolism in an unselected group of New York State newborns. *Thrombosis Research*, **2000**, 99, 317-24	8.2	35

1813	Protein C and protein S deficiencies are the most important risk factors associated with thrombosis in Chinese venous thrombophilic patients in Taiwan. *Thrombosis Research*, **2000**, 99, 447-52	8.2	67
1812	Prothrombin activity and concentration in healthy subjects with and without the prothrombin G20210A mutation. *Thrombosis Research*, **2000**, 99, 549-56	8.2	17
1811	Prothrombotic risk factors in children with spontaneous venous thrombosis and their asymptomatic parents: a family study. *Thrombosis Research*, **2000**, 99, 531-7	8.2	47
1810	The role of prothrombotic mutations in patients with Buerger's disease. *Thrombosis Research*, **2000**, 100, 143-7	8.2	38
1809	Prevalence of three prothrombotic polymorphisms. Factor V G1691A, factor II G20210A and methylenetetrahydrofolate reductase (MTHFR) C 677T in Argentina. On behalf of the Grupo Cooperativo Argentino de Hemostasia y Trombosis. *Thrombosis Research*, **2000**, 100, 127-31	8.2	14
1808	Effect of plasminogen activator inhibitor-1 4G/5G polymorphism in Turkish deep vein thrombotic patients with and without FV1691 G-A. *Thrombosis Research*, **2000**, 97, 227-30	8.2	42
1807	The prothrombin nt20210 A allele as a risk factor for venous thromboembolism: detection of heterozygous and homozygous carriers by alternative methods. *Thrombosis Research*, **2000**, 97, 359-63	8.2	4
1806	Common C677T polymorphism in the methylenetetrahydrofolate reductase gene increases the risk for deep vein thrombosis in patients with predisposition of thrombophilia. *Thrombosis Research*, **2000**, 98, 1-8	8.2	27
1805	Blood coagulation. **2000**, 355, 1627-32		520
1804	High levels of coagulation factor XI as a risk factor for venous thrombosis. **2000**, 342, 696-701		503
1803	Analytical evaluation of primer engineered multiplex polymerase chain reaction-restriction fragment length polymorphism for detection of factor V Leiden and prothrombin G20210A. **2000**, 2, 153-7		29
1802	The factor V Leiden mutation: a possible contributor to the hepatic artery thrombosis encountered after liver transplantation in a child. **2000**, 35, 607-9		10
1801	The caput medusae of hypercoagulability. **2000**, 31, 396-405		13
1800	Fatal pulmonary embolism: A study of genetic and acquired factors. *Molecular Diagnosis and Therapy*, **2000**, 5, 53-58		
1799	Factor V (His 1299 Arg) in young Turkish patients with cerebral infarct. **2000**, 30, 118-22		3
1798	Functional effects of the ABO locus polymorphism on plasma levels of von Willebrand factor, factor VIII, and activated partial thromboplastin time. **2000**, 20, 2024-8		146
1797	Thrombin generation in children with acute lymphoblastic leukemia: effect of leukemia immunophenotypic subgroups. **2000**, 17, 667-72		30
1796	Symptomatic ischemic stroke in full-term neonates : role of acquired and genetic prothrombotic risk factors. **2000**, 31, 2437-41		283

1795	Prothrombin G20210A polymorphism and thrombophilia. **2000**, 75, 595-604	38
1794	[Hereditary thrombophilia in venous thromboembolic disease]. **2000**, 200, 77-83	0
1793	Efficient recovery of DNA from peripheral blood for diagnostic analysis with a vacuum manifold. *Molecular Diagnosis and Therapy*, **2000**, 5, 151-154	
1792	Recurrent miscarriage syndrome and infertility caused by blood coagulation protein or platelet defects. **2000**, 14, 1117-31	22
1791	Primary habitual abortions are associated with high frequency of factor V Leiden mutation. **2000**, 74, 987-91	74
1790	Budd-Chiari syndrome: combination of genetic defects and the use of oral contraceptives leading to hypercoagulability. **2000**, 33, 509-12	28
1789	Prevalence of factor V Leiden and prothrombin variant G20210A in patients age . **2000**, 36, 717-22	58
1788	Factor V Leiden and prothrombin gene mutation in inflammatory bowel disease in a Mediterranean area. **2001**, 33, 559-62	19
1787	Genetic susceptibility to venous thrombosis. **2001**, 344, 1222-31	642
1786	Family history as a risk factor for early onset myocardial infarction in young women. **2001**, 156, 201-7	51
1785	Increased fibrin monomer plasma concentration in stable coronary artery disease in patients without oral anticoagulation. **2001**, 157, 417-22	3
1784	Cerebral vein thrombosis and prothrombin gene (G20210A) mutation. **2001**, 103, 191-3	8
1783	Factor V Leiden and G20210A prothrombin mutations are risk factors for very early recurrent miscarriage. **2001**, 108, 1251-1254	44
1782	G20210A mutation in the prothrombin gene and the risk of recurrent venous thromboembolism. **2001**, 37, 215-8	73
1781	American College of Medical Genetics consensus statement on factor V Leiden mutation testing. **2001**, 3, 139-48	141
1780	[Clinical manifestations and prevalence of hypercoagulable states in patients with venous thromboembolic disease]. **2001**, 116, 201-5	0
1779	Prothrombotic inherited abnormalities other than factor v leiden mutation do not play a role in venous thrombosis in inflammatory bowel disease. **2001**, 96, 1448-1454	9
1778	Oral contraceptives and the risk of venous thrombosis. **2001**, 344, 1527-35	429

1777	Factors V leiden and II 20210A in patients with symptomatic pulmonary embolism and deep vein thrombosis. **2001**, 110, 12-5		23
1776	Increased efficiency of mRNA 3' end formation: a new genetic mechanism contributing to hereditary thrombophilia. **2001**, 28, 389-92		221
1775	The mechanisms of thrombotic risk induced by hormone replacement therapy. **2001**, 40, 17-38		33
1774	Genetic aspects of venous thrombosis. **2001**, 95, 189-92		7
1773	Oral contraceptives, thrombosis and haemostasis. **2001**, 95, 193-7		27
1772	Hypercoagulable thrombophilic defects and hyperhomocysteinemia in patients with recurrent pregnancy loss. **2001**, 45, 65-71		76
1771	Thrombophilic gene mutations and recurrent spontaneous abortion: prothrombin mutation increases the risk in the first trimester. **2001**, 46, 124-31		106
1770	Basilar artery thrombosis in a child heterozygous for factor V Leiden mutation. **2001**, 24, 69-71		18
1769	[Post-varicella thrombosis and factor V Leiden mutation]. **2001**, 8, 961-4		1
1768	[Neonatal renal vein thrombosis in a heterozygous carrier of both factor V Leiden and prothrombin mutations]. **2001**, 8, 1222-5		5
1767	Air travel-related deep venous thrombosis. Chicago views. **2001**, 9, 150-3; discussion 153-6		2
1766	Automated detection of the G20210A prothrombin mutation using the LCx microparticle enzyme immunoassay. **2001**, 314, 249-54		3
1765	Postnatal screening for thrombophilia in women with severe pregnancy complications. **2001**, 97, 753-9		62
1764	Pathologic features of the placenta in women with severe pregnancy complications and thrombophilia. **2001**, 98, 1041-4		70
1763	Unexplored territories in the nonsurgical patient: a look at pregnancy. **2001**, 38, 39-48		3
1762	ProC global: an automated screening test for factor V Leiden and prothrombin mutation 20210 G to A detection. *Thrombosis Research*, **2001**, 101, 215-6	8.2	6
1761	Coexistence of thrombophilic gene polymorphisms among 559 unrelated consecutive patients with a history of thrombosis. *Thrombosis Research*, **2001**, 101, 317-9	8.2	2
1760	Common mutations at the homocysteine metabolism pathway and pediatric stroke. *Thrombosis Research*, **2001**, 102, 115-20	8.2	75

1759	Long-term use of oral contraceptive therapy in women with the prothrombin 20210 G-A polymorphism without thrombotic complications: a study of 13 women (12 heterozygotes and 1 homozygote). *Thrombosis Research*, **2001**, 102, 205-10	8.2	9
1758	Prothrombin 20210A-associated thrombosis may need concurrency of another prothrombotic factor. *Thrombosis Research*, **2001**, 102, 381-3	8.2	0
1757	Interaction of fibrinolysis and prothrombotic risk factors in neonates, infants and children with and without thromboembolism and underlying cardiac disease. a prospective study. *Thrombosis Research*, **2001**, 103, 93-101	8.2	21
1756	Thrombotic events revisited in children with acute lymphoblastic leukemia: impact of concomitant Escherichia coli asparaginase/prednisone administration. *Thrombosis Research*, **2001**, 103, 165-72	8.2	92
1755	Homozygous 20210G/A prothrombin gene mutation associated with bilateral iliac vein thrombosis: a case report. *Thrombosis Research*, **2001**, 104, 293-6	8.2	7
1754	Major and potential prothrombotic genotypes in a cohort of patients with venous thromboembolism. *Thrombosis Research*, **2001**, 104, 317-24	8.2	29
1753	Incidence of venous thromboembolism in hospitalized patients vs community residents. **2001**, 76, 1102-10		245
1752	Management of venous thromboembolic disease in the chronically critically ill patient. **2001**, 22, 105-22		3
1751	Mutation detection using fluorescent hybridization probes and melting curve analysis. **2001**, 1, 92-101		94
1750	La trombofilia venosa:Una enfermedad de etiolog□a multifactorial. **2001**, 8, 2817-2822		
1749	Simultaneous allele-specific amplification: A strategy using modified primer-template mismatches for SNP detection[mdash]Application to prothrombin 20210A (factor II) and factor V Leiden (1691A) gene mutations. *Molecular Diagnosis and Therapy*, **2001**, 6, 201-209		4
1748	Factor V Leiden mutation screened by PCR and detected with lanthanide-labeled probes. **2001**, 5, 291-7		5
1747	Genetic variation in coagulation and fibrinolytic proteins and their relation with acute myocardial infarction: a systematic review. **2001**, 104, 3063-8		164
1746	Factor V Leiden, prothrombin gene G20210A variant, and methylenetetrahydrofolate reductase C677T genotype in young adults with ischemic stroke. **2001**, 7, 346-50		48
1745	Oral contraceptives and the risk of myocardial infarction. **2001**, 345, 1787-93		295
1744	Moderne molekularbiologische Thrombophiliediagnostik: Die Genotypisierung der Faktor-V-Leiden- und der Prothrombin-G20210A-Mutation mit dem LightCycler□*Hamostaseologie*, **2001**, 21, 37-43	1.9	
1743	Thrombophilias and pre-eclampsia. **2001**, 305-324		
1742	Retinal vein occlusion and factor V Leiden and prothrombin 20210 G:A mutations. **2001**, 11, 351-5		15

1741	TROMBOFILIAS HEREDITARIAS. **2001**, 34, 248		1
1740	The generation of narrative interpretations in laboratory medicine: a description of service-specific sign-out rounds. **2001**, 116 Suppl, S133-40		4
1739	Changes in haemostasis after laparoscopic surgery in gynaecology: contribution of the thrombin generation test. **2001**, 31, 32-41		1
1738	Factor X Levels, Polymorphisms in the Promoter Region of Factor X, and the Risk of Venous Thrombosis. *Thrombosis and Haemostasis*, **2001**, 85, 1011-1017	7	55
1737	Symptomatic Onset of Severe Hemophilia A in Childhood is Dependent on the Presence of Prothrombotic Risk Factors. *Thrombosis and Haemostasis*, **2001**, 85, 218-200	7	114
1736	Adrenal apoplexy: an inconspicuous cause of hypotension in the intensive care patient. **2001**, 175, 384-5		2
1735	Risk of recurrent venous thrombosis in children with combined prothrombotic risk factors. *Blood*, **2001**, 97, 858-62	2.2	242
1734	Multiplexed Mutagenically Separated PCR: Simultaneous Single-Tube Detection of the Factor V R506Q (G1691A), the Prothrombin G20210A, and the Methylenetetrahydrofolate Reductase A223V (C677T) Variants. **2001**, 47, 333-335		26
1733	Prevalence of Molecular Risk Factors FV Leiden, FV HR2, FII 20210G>A and MTHFR 677C>T in Different Populations and Ethnic Groups of Germany, Costa Rica and India. **2001**, 1, 33-39		14
1732	Pathophysiology of venous thromboembolism. **2001**, 62, 765-72		2
1731	Foetal Growth Restriction in Children with Prothrombotic Risk Factors. *Thrombosis and Haemostasis* , **2001**, 86, 1012-2001	7	42
1730	Characterization and Structural Impact of Five Novel PROS1 Mutations in Eleven Protein S-deficient Families. *Thrombosis and Haemostasis*, **2001**, 86, 1392-1399	7	13
1729	Thromboembolism in Newborns, Infants and Children. *Thrombosis and Haemostasis*, **2001**, 86, 464-474	7	79
1728	The Prothrombin G20210A Mutation Is a Risk Factor for Sudden Hearing Loss in Young Patients. *Thrombosis and Haemostasis*, **2001**, 86, 1118-1119	7	18
1727	Polymorphisms in the Prothrombin Gene and their Association with Plasma Prothrombin Levels. *Thrombosis and Haemostasis*, **2001**, 85, 1066-1070	7	44
1726	Combined Effect of Factor V Leiden and Prothrombin 20210A on the Risk of Venous Thromboembolism. *Thrombosis and Haemostasis*, **2001**, 86, 809-816	7	278
1725	Prevalence of Factor V Leiden and Prothrombin 20210A Mutations in Indigenous Australians. *Thrombosis and Haemostasis*, **2001**, 86, 1592-1593	7	14
1724	Phenotypic APC Resistance in Carriers of the A20210 Prothrombin Mutation Is Associated with an Increased Risk of Venous Thrombosis. *Thrombosis and Haemostasis*, **2001**, 86, 804-808	7	19

1723	Thrombophilia, Thrombosis and Pregnancy. *Thrombosis and Haemostasis*, **2001**, 86, 104-111	7	70
1722	Invited review: Pharmacogenetics of estrogen replacement therapy. **2001**, 91, 2776-84		35
1721	Coexistence of factor V G1691A and factor II G20210A gene mutations in a thrombotic family is associated with recurrence and early onset of venous thrombosis. **2001**, 31, 99-105		7
1720	Genetic Screening of Candidate Genes for a Prothrombotic Interaction with Type I Protein C Deficiency in a Large Kindred. *Thrombosis and Haemostasis*, **2001**, 85, 82-87	7	20
1719	Factor V Leiden and Factor V R2 Allele: High-throughput Analysis and Association with Venous Thromboembolism. *Thrombosis and Haemostasis*, **2001**, 86, 1188-1192	7	23
1718	Conventional Fibrinolytic Assays for the Evaluation of Patients with Venous Thrombosis: Don Bother. *Thrombosis and Haemostasis*, **2001**, 85, 377-378	7	8
1717	Complexes between Activated Protein C and Protein C Inhibitor Measured with a New Method. *Thrombosis and Haemostasis*, **2001**, 86, 1400-1408	7	31
1716	Age-dependent Prevalence of Vascular Disease-associated Polymorphisms among 2689 Volunteer Blood Donors. **2001**, 47, 1879-1884		34
1715	Multisite Study for Genotyping of the Factor II (Prothrombin) G20210A Mutation by the Invader Assay. **2001**, 47, 2048-2050		9
1714	Laboratory Investigation of Thrombophilia. **2001**, 47, 1597-1606		98
1713	A rapid and cost-effective method for analysis of three common genetic risk factors for thrombosis. **2001**, 12, 33-6		1
1712	Risk of venous thromboembolism in carriers of factor V Leiden with a concomitant inherited thrombophilic defect: a retrospective analysis. **2001**, 12, 713-20		19
1711	Hemostatic and fibrinolytic parameters in survivors of myocardial infarction: a low plasma level of plasmin-alpha2-antiplasmin complex is an independent predictor of coronary re-events. **2001**, 12, 17-24		12
1710	Postnatal Screening for Thrombophilia in Women With Severe Pregnancy Complications. **2001**, 97, 753-759		42
1709	Coexistence of the methylenetetrahydrofolate reductase single-nucleotide polymorphism (C677T) in patients with the factor V Leiden or prothrombin G20210A polymorphisms. **2001**, 10, 111-5		3
1708	Outcome of noncatheter-related thrombosis in children: influence of underlying or coexisting factors. **2001**, 23, 159-64		42
1707	Heterozygous carrier of G20210A prothrombin mutation used oral contraceptive treatment for 23 years without thrombotic events, and developed cerebral venous thrombosis 1 month after resumption of the medication at the age of 50. **2001**, 12, 161-2		1
1706	Thrombosis in the intensive care unit: etiology, diagnosis, management, and prevention in adults and children. **2001**, 9, 173-82		7

1705	Comparative prevalence of antiphospholipid antibodies and thrombophilic genotypes in consecutive patients with venous thrombosis. **2001**, 12, 659-65		9
1704	Impact of plasma homocysteine and prothrombin G20210 A on primary antiphospholipid syndrome. **2001**, 12, 699-704		17
1703	Hypofibrinolysis, thrombophilia, osteonecrosis. **2001**, 19-33		176
1702	An update on hypercoagulable disorders. **2001**, 161, 1051-6		43
1701	Hormone replacement therapy, prothrombotic mutations, and the risk of incident nonfatal myocardial infarction in postmenopausal women. **2001**, 285, 906-13		111
1700	Familial thrombophilia and idiopathic intracranial hypertension. **2001**, 25, 135-141		6
1699	Thrombophilia and Obstetrical Outcomes. **2001**, 23, 683-689		
1698	Polymorphisms of clotting factors modify the risk for primary intracranial hemorrhage. *Blood*, **2001**, 97, 2979-82	2.2	72
1697	Genetic hypercoagulability: prevention suggests testing family members. *Blood*, **2001**, 98, 21-2	2.2	44
1696	A family history can display a synergistic effect of atherogenic and prothrombotic risk in pregnancy. **2001**, 80, 873-874		
1695	Thrombophilic DNA Mutations As Independent Risk Factors for Stroke and Avascular Necrosis in Sickle Cell Anemia. **2001**, 6, 347-53		3
1694	Hypercoagulability. **2001**, 94, 1013-1020		9
1693	A new global test for the evaluation of the activated factor II-antithrombin system. **2001**, 12, 405-10		1
1692	Prevalence of factor V Leiden and prothrombin 20210 A variant in Bulgarian patients with pulmonary thromboembolism and deep venous thrombosis. **2001**, 12, 639-42		12
1691	Genetic Approach to Thrombophilia. *Thrombosis and Haemostasis*, **2001**, 86, 92-103	7	60
1690	Natural coagulation inhibitor proteins in young patients with cerebral ischemia. **2001**, 12, 291-7		6
1689	Genetics of arterial prothrombotic risk states. **2001**, 226, 409-19		44
1688	Risk Factors in Venous Thromboembolism. *Thrombosis and Haemostasis*, **2001**, 86, 395-403	7	149

1687	Hemostatic Risk Factors and Arterial Thrombotic Disease. *Thrombosis and Haemostasis*, **2001**, 85, 584-595	7	111
1686	Oral Contraceptives, Hormone Replacement Therapy and Thrombosis. *Thrombosis and Haemostasis*, **2001**, 86, 112-123	7	80
1685	Inherited thrombophilia in ischemic stroke and its pathogenic subtypes. **2001**, 32, 1793-9		104
1684	Prothrombotic disorders in children with moyamoya syndrome. **2001**, 32, 1786-92		67
1683	Relentless progression of venous obstruction in a case of Budd-Chiari syndrome related to heterozygous protein C deficiency. **2001**, 24, 427-31		1
1682	The genetics of venous and arterial thromboembolism. **2001**, 3, 209-15		11
1681	Survey of factor V leiden and prothrombin gene mutations in systemic lupus erythematosus. **2001**, 20, 259-61		13
1680	Die Bedeutung von Mutationen in den Genen f□ □Faktor V, Faktor II und der Methylentetrahydrofolatreduktase bei habituellen Aborten. **2001**, 17, 42-47		2
1679	Genetic risk factors of venous thrombosis. **2001**, 109, 369-84		211
1678	Genetics University of Toronto Thrombophilia Study in Women (GUTTSI): genetic and other risk factors for venous thromboembolism in women. **2001**, 2, 141-149		29
1677	Symptomatic type 1 protein C deficiency caused by a de novo Ser270Leu mutation in the catalytic domain. **2001**, 113, 642-8		9
1676	The risk of recurrent venous thromboembolism among heterozygous carriers of the G20210A prothrombin gene mutation. **2001**, 113, 630-5		60
1675	High factor VIII levels contribute to the thrombotic risk in families with factor V Leiden. **2001**, 114, 380-6		31
1674	Venous thrombosis and anticoagulant therapy. **2001**, 114, 258-70		22
1673	Investigation and management of heritable thrombophilia. **2001**, 114, 512-28		214
1672	Increased thromboxane production in women with a history of venous thromboembolic event: effect of heparins. **2001**, 114, 655-9		2
1671	Marked elevation of thrombin generation in patients with elevated FVIII:C and venous thromboembolism. **2001**, 115, 687-91		39
1670	Gene polymorphisms of the haemostatic system and the risk of arterial thrombotic disease. **2001**, 115, 491-506		36

1669	Factor IX and thrombosis. **2001**, 115, 507-13	52
1668	A pilot study of the possible role of familial defects in anticoagulation as a cause for terminal limb reduction malformations. **2000**, 57, 197-204	33
1667	A family history can display a synergistic effect of atherogenic and prothrombotic risk in pregnancy. **2001**, 80, 873-874	
1666	Second-trimester maternal serum alpha-fetoprotein (MSAFP) is elevated in women with adverse pregnancy outcome associated with inherited thrombophilias. **2001**, 21, 658-61	7
1665	Primary thrombophilia in Mexico. II. Factor V G1691A (Leiden), prothrombin G20210A, and methylenetetrahydrofolate reductase C677T polymorphism in thrombophilic Mexican mestizos. **2001**, 66, 28-31	28
1664	Update on selected inherited venous thrombotic disorders. **2001**, 68, 256-68	46
1663	Hypercoagulability states in upper-extremity deep venous thrombosis. **2001**, 67, 15-9	48
1662	Two common genetic thrombotic risk factors: factor V Leiden and prothrombin G20210A in adult Turkish patients with thrombosis. **2001**, 67, 107-11	32
1661	Genotyping of thrombotic risk factors by MALDI-TOF mass spectrometry. **2001**, 34, 531-6	25
1660	Factor V Leiden mutation in Turkish patients with homozygous cystathionine beta-synthase deficiency. **2001**, 24, 367-9	3
1659	Duration of anticoagulation for venous thromboembolism. **2001**, 12, 59-65	11
1658	Hereditary thrombophilia as a cause of Budd-Chiari syndrome: a study from Western India. **2001**, 34, 666-70	97
1657	Heritable thrombophilia and childhood thrombosis. **2001**, 15, 181-9	14
1656	Association of factor V Leiden and prothrombin gene mutation with Beh□et's disease. **2001**, 293, 537-9	8
1655	Desmopressin in a long-term treatment of children with primary nocturnal enuresis--a symptomatic therapy?. **2001**, 160, 197-8	9
1654	Compound heterozygosity for factor V Leiden and prothrombin G20210A mutations in a child with Budd-Chiari syndrome. **2001**, 160, 198	2
1653	Stroke genomics: approaches to identify, validate, and understand ischemic stroke gene expression. **2001**, 21, 755-78	78
1652	An investigation of the association of the prothrombin G20210A gene mutation and inflammatory bowel disease: Factor II and IBD. **2001**, 7, 133-5	9

1651	Factor V Leiden and G20210A prothrombin mutations are risk factors for very early recurrent miscarriage. **2001**, 108, 1251-4	16
1650	Symposium in memory of Professor Inga Marie Nilsson. **2001**, 7, 401-410	
1649	Antiphospholipid antibodies and thrombophilic factors in giant cell arteritis. **2001**, 31, 12-20	36
1648	Maternal and fetal inherited thrombophilias are not related to the development of severe preeclampsia. **2001**, 185, 153-7	135
1647	Molecular and clinical characterisation of homocystinuria in two Austrian families with cystathionine beta-synthase deficiency. **2001**, 28, 145-51	3
1646	Atrial thrombus and central venous dialysis catheters. **2001**, 38, 631-9	65
1645	Increased rate of renal transplant failure in patients with the G20210A mutation of the prothrombin gene. **2001**, 38, 1061-4	32
1644	Genetic basis of inherited bleeding and thrombolic disorders. **2001**, 15, 213-228	
1643	Management of venous thromboembolism in pregnancy. **2001**, 15, 583-603	32
1642	Prevalence and significance of thrombophilia in peripheral arterial disease. **2001**, 22, 98-106	15
1641	The plasminogen activator inhibitor (PAI)-1 promoter 4G/4G genotype is not associated with ischemic stroke in a population of German children. Childhood Stroke Study Group. **2001**, 66, 57-62	31
1640	Impact of the factor II: G20210A variant on the risk of venous thromboembolism in relatives from families with the factor V: R506Q mutation. **2001**, 67, 165-9	4
1639	G20210A prothrombin gene mutation identified in patients with venous leg ulcers. **2001**, 5, 397-401	12
1638	Prothrombin Mutation: Employing the Electrochemiluminescence Technology of the Elecsys System for the Detection of the Point Mutation at Position 20210 in the 3Untranslated Region of the Prothrombin Gene. **2001**, 25, 26-30	6
1637	Preeclampsia and fetal loss in women with a history of venous thromboembolism. **2001**, 21, 874-9	59
1636	Factor V Leiden related Budd-Chiari syndrome. **2001**, 48, 264-8	115
1635	Familial clustering of high factor VIII levels in patients with venous thromboembolism. **2001**, 21, 289-92	62
1634	Low plasma levels of vitamin B(6) are independently associated with a heightened risk of deep-vein thrombosis. **2001**, 104, 2442-6	59

1633	Thrombomodulin promoter mutations, venous thrombosis, and varicose veins. **2001**, 21, 445-51		53
1632	Thrombophilic Disorders. *Laboratory Medicine*, **2001**, 32, 239-243	1.6	1
1631	Real-time polymerase chain reaction with fluorescent hybridization probes for the detection of prevalent mutations causing common thrombophilic and iron overload phenotypes. **2001**, 115, 439-47		43
1630	Pathologic Features of the Placenta in Women With Severe Pregnancy Complications and Thrombophilia. **2001**, 98, 1041-1044		48
1629	Low-Molecular-Weight Heparin for the Prevention of Obstetric Complications in Women with Thrombophilias. **2001**, 20, 35-44		113
1628	Prothrombin 20210 G: a mutation and Factor V Leiden mutation in women with a history of severe preeclampsia and (H)ELLP syndrome. **2001**, 20, 291-8		17
1627	Prothrombotic inherited abnormalities other than factor V Leiden mutation do not play a role in venous thrombosis in inflammatory bowel disease. **2001**, 96, 1448-54		50
1626	Anticoagulant therapy for osteonecrosis associated with heritable hypofibrinolysis and thrombophilia. **2001**, 10, 1309-16		23
1625	Thrombophilia: genetic polymorphisms and their association with retinal vascular occlusive disease. **2001**, 85, 883-6		17
1624	Potentielle genetische Polymorphismen der ven□ßen Thromboembolie. New Candidate Gene Polymorphisms in Venous Thrombosis. **2001**, 25, 277-283		
1623	Dissecting a population genome for targeted screening of disease mutations. **2001**, 10, 2961-72		39
1622	Venous thromboembolism in young patients from western India: a study. **2001**, 7, 158-65		49
1621	Stasis ulcers refractory to therapy--accelerated healing by treatment with clopidogrel +/- dalteparin: a preliminary report. **2001**, 7, 21-4		8
1620	Aspirin versus low-dose low-molecular-weight heparin: antithrombotic therapy in pediatric ischemic stroke patients: a prospective follow-up study. **2001**, 32, 2554-8		100
1619	Elevated factor VIII levels and the risk of thrombosis. **2001**, 21, 731-8		226
1618	G20210A prothrombin gene polymorphism and prothrombin activity in subjects with or without angiographically documented coronary artery disease. **2001**, 103, 2436-40		38
1617	Beh□et's disease and thrombophilia. **2001**, 60, 1081-5		39
1616	G20210A prothrombin gene mutation: prevalence in a recurrent miscarriage population. **2001**, 7, 25-8		30

1615	Homozygous patients with the 20210 G to A prothrombin polymorphism remain often asymptomatic in spite of the presence of associated risk factors. **2001**, 7, 122-5	8
1614	Factor V Leiden and prothrombin G20210A in relation to arterial and/or vein rethrombosis: two cases. **2001**, 7, 234-7	3
1613	Molecular biology of blood coagulation. **2001**, 27, 313-24	22
1612	Treatment of deep vein thrombosis. **2001**, 1, 43-54	6
1611	Venous thromboembolic disease: risk factors and laboratory investigation. **2001**, 1, 81-8	9
1610	Epidemiology of venous thromboembolism. **2001**, 1, 7-26	63
1609	Increased risk of intraventricular hemorrhage in preterm infants with thrombophilia. **2001**, 49, 643-6	75
1608	Venous thromboembolism in pediatrics. **2001**, 1, 111-22	42
1607	Absence of association of thrombophilia polymorphisms with intrauterine growth restriction. **2002**, 347, 19-25	219
1606	Laboratory thrombophilias and venous thromboembolism. **2002**, 7, 93-102	14
1605	Idiopathic non-cirrhotic intrahepatic portal hypertension in the West: a re-evaluation in 28 patients. **2002**, 51, 275-80	207
1604	Defects in pre-mRNA processing as causes of and predisposition to diseases. **2002**, 21, 803-18	71
1603	Protein C, antithrombin, and venous thromboembolism incidence: a prospective population-based study. **2002**, 22, 1018-22	54
1602	Primary thrombophilia in Mexico III: A prospective study of the sticky platelet syndrome. **2002**, 8, 273-7	16
1601	Paraoxonase 192 Gln-->Arg polymorphism: an independent risk factor for nonfatal arterial ischemic stroke among young adults. **2002**, 33, 1459-64	90
1600	Increased prevalence of the G20210A prothrombin gene variant in acute coronary syndromes without metabolic or acquired risk factors or with limited extent of disease. **2002**, 23, 26-30	31
1599	Venous thromboembolism in young women; role of thrombophilic mutations and oral contraceptive use. **2002**, 23, 984-90	44
1598	Metabolic characteristics of women who developed ovarian hyperstimulation syndrome. **2002**, 17, 1994-6	12

1597	Third-Trimester Unexplained Intrauterine Fetal Death Is Associated With Inherited Thrombophilia. **2002**, 99, 684-687		
1596	Hyperhomocysteinemia and other inherited prothrombotic conditions in young adults with a history of ischemic stroke. **2002**, 33, 51-6		98
1595	Pharmacogenomics in anticoagulant drug development. **2002**, 3, 823-8		8
1594	The risk of recurrent venous thromboembolism in heterozygous carriers of factor V Leiden and a first spontaneous venous thromboembolism. **2002**, 162, 2357-60		51
1593	[Thrombophilia--diagnostic steps and therapeutic consequences after deep vein thrombosis]. **2002**, 127, 273-8		2
1592	Risk factors and long-term follow-up of patients with the immune type of heparin-induced thrombocytopenia. **2002**, 8, 347-52		10
1591	Alveolar and postcranial bone density in postmenopausal women receiving hormone/estrogen replacement therapy: a randomized, double-blind, placebo-controlled trial. **2002**, 162, 1409-15		62
1590	A matrix-assisted laser desorption/ionization time-of-flight based method for screening the 1691G --> A mutation in the factor V gene. **2002**, 13, 117-22		8
1589	The use of coagulation activation markers (soluble fibrin polymer, TpP, prothrombin fragment 1.2, thrombin-antithrombin, and D-dimer) in the assessment of hypercoagulability in patients with inherited and acquired prothrombotic disorders. **2002**, 13, 199-205		21
1588	Mutations C677T and A1298C of the 5,10-methylenetetrahydrofolate reductase gene and fasting plasma homocysteine levels are not associated with the increased risk of venous thromboembolic disease. **2002**, 13, 423-31		40
1587	Prevalence of inherited thrombophilia in young thrombosis patients from the East Bohemian region. **2002**, 13, 569-73		5
1586	Detection of a novel point mutation of the prothrombin gene at position 20209. **2002**, 11, 152-6		39
1585	Pharmacogenetics of treatment with leukotriene modifiers. **2002**, 2, 395-401		8
1584	Comparative evaluation of five different methods for the measurement of plasma factor II levels in carriers of the 20210A prothrombin variant. **2002**, 13, 465-70		4
1583	Genetic risk factors in young adults with 'cryptogenic' ischemic cerebrovascular disease. **2002**, 13, 583-90		17
1582	Hereditary thrombophilia in elite athletes. **2002**, 34, 218-21		11
1581	Polycystic ovarian syndrome and thrombophilia. **2002**, 17, 314-9		43
1580	Oral anticoagulation reduces activated protein C less than protein C and other vitamin K-dependent clotting factors. *Blood*, **2002**, 100, 4232-3	2.2	10

1579	Factor V Leiden: a genetic risk factor for thrombotic microangiopathy in patients with normal von Willebrand factor-cleaving protease activity. *Blood*, **2002**, 99, 437-42	2.2	56
1578	The G20210A mutation does not affect the stability of prothrombin mRNA in vivo. *Blood*, **2002**, 100, 359-62		41
1577	Venous thrombosis: the history of knowledge. **2002**, 32, 209-12		17
1576	Unilateral chronic thromboembolic pulmonary disease associated with combined inherited thrombophilia. **2002**, 121, 286-9		20
1575	Effects of Hereditary and Acquired Risk Factors of Venous Thrombosis on a Thrombin Generation-Based APC Resistance Test. *Thrombosis and Haemostasis*, **2002**, 88, 5-11	7	82
1574	Abnormally short activated partial thromboplastin times are related to elevated plasma levels of TAT, F1+2, D-dimer and FVIII:C. **2002**, 32, 137-42		32
1573	Hypercoagulability: too many tests, too much conflicting data. **2002**, 2002, 353-68		33
1572	Prothrombotic Genotypes Are not Associated with Pre-eclampsia and Gestational Hypertension: Results from a Large Population-based Study and Systematic Review. *Thrombosis and Haemostasis*, **2002**, 87, 779-785	7	158
1571	The prothrombin G20210A polymorphism in patients with myocardial infarction. **2002**, 13, 603-8		6
1570	Risk factors for thromboembolism in teens: when should I test?. **2002**, 14, 370-8		23
1569	Hyperhomocysteinemia and venous thrombosis. **2002**, 1, 4-12		2
1568	Prevalence of genetic markers for thrombophilia in recurrent pregnancy loss. **2002**, 17, 1633-7		94
1567	Vascular involvement in Beh□et's disease: relation with thrombophilic factors, coagulation activation, and thrombomodulin. **2002**, 112, 37-43		136
1566	The epidemiology of peripheral vein infusion thrombophlebitis: a critical review. **2002**, 113, 146-51		191
1565	Simultaneous sequencing of multiple polymerase chain reaction products and combined polymerase chain reaction with cycle sequencing in single reactions. **2002**, 161, 27-33		9
1564	Elevated prothrombin is a risk factor for cerebral arterial ischemia in young adults. **2002**, 104, 285-8		11
1563	Thrombophilia is common in women with idiopathic pregnancy loss and is associated with late pregnancy wastage. **2002**, 77, 342-7		164
1562	Hereditary thrombophilias are not associated with a decreased live birth rate in women with recurrent miscarriage. **2002**, 78, 58-62		31

1561	Arterial wall thickness and the risk of recurrent ischemic events in carriers of the prothrombin G20210A mutation with clinical manifestations of atherosclerosis. **2002**, 163, 135-40		27
1560	Venous thromboembolism: implications for gene-based diagnosis and technology development. **2002**, 2, 576-86		1
1559	Rapid automated simultaneous screening of (G1691A) Factor V, (G20210A) prothrombin, and (C677T) methylenetetrahydrofolate reductase variants by multiplex PCR using fluorescence scanning technology. **2002**, 6, 233-6		4
1558	Early diagnosis of deep vein thrombosis in female patients who undergo total knee arthroplasty with measurement of P-selectin activation. **2002**, 35, 707-12		15
1557	Factor V Leiden and prothrombin G20210A mutations in pregnancies with adverse outcome. **2002**, 12, 267-73		32
1556	Pharmacogenetics, pharmacogenomics, and cardiovascular therapeutics: the way forward. **2002**, 2, 287-96		11
1555	Mutations in the factor V, prothrombin and MTHFR genes are not risk factors for recurrent fetal loss. **2002**, 11, 176-82		25
1554	Recurrent pulmonary embolism in a 13-year-old male homozygous for the prothrombin G20210A mutation combined with protein S deficiency and increased lipoprotein (a). *Thrombosis Research*, **2002**, 105, 49-53	8.2	15
1553	Pathological haemostasis and "prothrombotic state" in Beh□et's disease. *Thrombosis Research*, **2002**, 105, 125-33	8.2	97
1552	Factor V gene G1691A mutation, prothrombin gene G20210A mutation, and MTHFR gene C677T mutation are not risk factors for pulmonary thromboembolism in Chinese population. *Thrombosis Research*, **2002**, 106, 7-12	8.2	52
1551	Treatment of deep venous thrombosis with low-molecular-weight heparin during pregnancy. *Thrombosis Research*, **2002**, 106, 13-7	8.2	24
1550	Hyperhomocysteinemia and venous thromboembolism: a risk factor more prevalent in the elderly and in idiopathic cases. *Thrombosis Research*, **2002**, 106, 121-5	8.2	30
1549	CBS 844ins68, MTHFR TT677 and EPCR 4031ins23 genotypes in patients with deep-vein thrombosis. *Thrombosis Research*, **2002**, 107, 13-5	8.2	16
1548	Markers of activated coagulation in patients with factor V Leiden and/or G20210A prothrombin gene mutation. *Thrombosis Research*, **2002**, 107, 7-11	8.2	12
1547	Third-trimester unexplained intrauterine fetal death is associated with inherited thrombophilia. **2002**, 99, 684-7		66
1546	The relationship between FV Leiden and pulmonary embolism. **2002**, 3, 8		14
1545	The natural history of venous thromboembolism: impact on ventilation/perfusion scan reporting. **2002**, 32, 159-72		19
1544	The effect of the Val34Leu polymorphism in the factor XIII gene in infants with a birth weight below 1500 g. **2002**, 140, 688-92		17

1543	Genetic variants of the hemostatic system and development of transplant coronary artery disease. **2002**, 21, 629-36		8
1542	The PORtromb Project: prothrombin G20210A mutation and venous thromboembolism in young people. **2002**, 10, 45-8		5
1541	[Physiopathology of thrombotic diseases]. **2002**, 9 Suppl 2, 134s-136s		
1540	[Vascular complications of homocystinuria: a retrospective multicenter study]. **2002**, 23, 267-72		1
1539	[Cerebral-vein thrombosis: retrospective study of twenty seven cases]. **2002**, 23, 973-82		4
1538	Can screening for genetic markers improve peripheral artery bypass patency?. **2002**, 36, 1198-206		12
1537	Pulmonary embolism. **2002**, 12, 417-37, viii		1
1536	Pediatric thrombosis. **2002**, 49, 1257-83		29
1535	A novel method for SNP detection using a new duplex-specific nuclease from crab hepatopancreas. **2002**, 12, 1935-42		192
1534	No Association of Plasma Prothrombin Concentration or the G20210A Mutation with Incident Cardiovascular Disease. *Thrombosis and Haemostasis*, **2002**, 87, 614-621	7	36
1533	Multicentre Evaluation of IL Test™ Free PS: A Fully Automated Assay to Quantify Free Protein S. *Thrombosis and Haemostasis*, **2002**, 88, 975-983	7	6
1532	Resistance to activated protein C, factor V leiden and the prothrombin G20210A variant in patients with colorectal cancer. **2002**, 32, 2-7		26
1531	Synergistic Effect of Thrombomodulin Promoter -33G/A Polymorphism and Smoking on the Onset of Acute Myocardial Infarction. *Thrombosis and Haemostasis*, **2002**, 87, 86-91	7	32
1530	Thrombophilia in young women candidate to the pill: reasons for and against screening. **2002**, 32, 315-7		4
1529	Thromboplastin-thrombomodulin-mediated Time and Serum Folate Levels Are Genetically Correlated with the Risk of Thromboembolic Disease: Results from the GAIT Project. *Thrombosis and Haemostasis*, **2002**, 87, 68-73	7	12
1528	Factor V Leiden and Prothrombin Gene G20210A Mutation in Children with Venous Thromboembolism. *Thrombosis and Haemostasis*, **2002**, 87, 972-977	7	21
1527	Internal Quality Control of PCR-based Genotyping Methods in Research Studies and Patient Diagnostics. *Thrombosis and Haemostasis*, **2002**, 87, 812-816	7	19
1526	Prothrombin G20210A is a Bifunctional Gene Polymorphism. *Thrombosis and Haemostasis*, **2002**, 87, 846-853	7	39

1525	FV HR2 Haplotype as Additional Inherited Risk Factor for Deep Vein Thrombosis in Individuals with a High-Risk Profile. *Thrombosis and Haemostasis*, **2002**, 87, 32-36	7	29
1524	Interaction Between Hyperhomocysteinemia, Mutated Methylenetetrahydrofolatereductase (MTHFR) and Inherited Thrombophilic Factors in Recurrent Venous Thrombosis. *Thrombosis and Haemostasis*, **2002**, 88, 723-728	7	81
1523	Factor V Leiden (G1691A) and Prothrombin Gene G20210A Mutations as Potential Risk Factors for Venous Thromboembolism after Total Hip or Total Knee Replacement Surgery. *Thrombosis and Haemostasis*, **2002**, 87, 580-585	7	69
1522	Prevalence of Two Thrombophilia Predisposing Mutations: Factor V G1691A (R506Q; Leiden) and Prothrombin G20210A, among Healthy Lebanese. *Thrombosis and Haemostasis*, **2002**, 88, 691-692	7	44
1521	Anti-β-Glycoprotein I and Anti-Prothrombin Antibodies in Antiphospholipid-Negative Patients with Thrombosis. *Thrombosis and Haemostasis*, **2002**, 88, 729-732	7	19
1520	D-Dimer as a Risk Factor for Deep Vein Thrombosis: The Leiden Thrombophilia Study. *Thrombosis and Haemostasis*, **2002**, 87, 47-51	7	59
1519	Relatively Poor Performance of Clinical Laboratories for DNA Analyses in the Detection of Two Thrombophilic Mutations □A Cause for Concern. *Thrombosis and Haemostasis*, **2002**, 88, 690-691	7	37
1518	Inherited thrombophilia and stillbirth. **2002**, 26, 51-69		27
1517	Acquired and inherited thrombophilia in women with unexplained fetal losses. **2002**, 187, 1337-42		68
1516	Association of the G20210A mutation in the factor II gene with systemic embolism in nonvalvular atrial fibrillation. **2002**, 90, 545-7		17
1515	Thrombophilia and pregnancy loss. **2002**, 55, 163-80		45
1514	[Genetic risk factors of thrombosis]. **2002**, 51, 129-34		2
1513	Inherited risk factors for venous thromboembolism: implications for clinical practice. **2002**, 4, 18-30		10
1512	Frequent occurrence of anticardiolipin antibodies, Factor V Leiden mutation, and perturbed endothelial function in chronic myeloproliferative disorders. **2002**, 69, 185-91		32
1511	Prevalence of hereditary thrombophilia in patients with thrombosis in different venous systems. **2002**, 70, 126-32		88
1510	PAI-1 gene 4G/5G genotype: A risk factor for thrombosis in vessels of internal organs. **2002**, 71, 89-93		82
1509	Angiotropic large cell lymphoma presenting as fever of unknown origin. **2002**, 71, 234-5		3
1508	Prevalence and distribution of the prothrombin G20210A mutation. **2002**, 71, 235-6		1

1507	Persistent thrombocytopenia during remission in acute leukemia does not preclude long-term disease-free survival. **2002**, 71, 236-7	1
1506	Tumor lysis syndrome induced by hydroxyurea therapy for leukemic transformation of polycythemia vera. **2002**, 71, 237-8	4
1505	Prevalence of factor V G1691A (factor V-Leiden) and prothrombin G20210A gene mutations in a recurrent miscarriage population. **2002**, 71, 300-5	88
1504	Prospective study of the G20210A polymorphism in the prothrombin gene, plasma prothrombin concentration, and incidence of venous thromboembolism. **2002**, 71, 285-90	45
1503	Chronic pure red cell aplasia associated with parvovirus B19 infection in an immunocompetent patient. **2002**, 71, 238-9	4
1502	Ureteric obstruction by retroperitoneal lymphoplasmacytic lymphoma. **2002**, 71, 238	3
1501	Prevalence of thrombophilia and central venous catheter-associated neck vein thrombosis in 41 children with cancer--a prospective study. **2002**, 38, 405-10	45
1500	Impact of thrombophilic gene mutations on thrombosis risk in patients with gastrointestinal carcinoma. **2002**, 94, 3120-6	49
1499	Genetic polymorphism of the human ICOS gene. **2002**, 53, 1028-32	24
1498	Factor V Leiden and factor II G20210A in preeclampsia and HELLP syndrome. **2002**, 81, 1095-100	40
1497	Modifier genes in haemophilia: their expansion in the human genome. **2002**, 8, 250-4	13
1496	Paradoxical hyperfibrinolysis is associated with a more intensely haemorrhagic phenotype in severe congenital haemophilia. **2002**, 8, 768-75	35
1495	Prothrombin A19911G and G20210A polymorphisms' role in thrombosis. **2002**, 118, 610-4	28
1494	The investigation and management of neonatal haemostasis and thrombosis. **2002**, 119, 295-309	127
1493	Cardiac complications in Beh□et's disease. **2002**, 27, 651-3	11
1492	Multiple thrombophilic factors in a patient with Budd-Chiari syndrome. **2002**, 24, 61-3	7
1491	Sweet's syndrome in a woman with a prothrombin gene (G20210A) mutation. **2002**, 41, 596-7	3
1490	Anomalies constitutionnelles de l'h□mostase impliqu□es dans la thrombose veineuse. **2002**, 2002, 45-52	1

1489	Central retinal vein occlusion and thrombophilia. **2002**, 16, 98-106	56
1488	Is there an increased maternal-infant prevalence of Factor V Leiden in association with severe pre-eclampsia?. **2002**, 109, 191-6	5
1487	Thrombophilia and immunological disorders in pregnancies as risk factors for small for gestational age infants. **2002**, 109, 28-33	23
1486	Heterozygosity for factor V Leiden and G20210A prothrombin genotypes in a patient with mesenteric vein thrombosis. **2002**, 47, 601-6	3
1485	The association between inherited thrombophilia, antiphospholipid antibodies and lipoprotein A levels with obstetrical complications in pregnancy. **2002**, 14, 157-62	17
1484	Congenital thrombophilia associated to obstetric complications. **2002**, 14, 163-9	9
1483	TIPS is a useful long-term derivative therapy for patients with Budd-Chiari syndrome uncontrolled by medical therapy. **2002**, 35, 132-9	162
1482	Combined prothrombotic risk factors in a case of cardioembolic stroke. **2002**, 2, 172-175	
1481	Prothrombotic states in retinal artery and vein occlusions. **2002**, 2, 134-142	6
1480	Prothrombotic states in ischemic stroke. **2002**, 2, 90-101	1
1479	Pathophysiology and maternal biologic markers of preeclampsia. **2002**, 19, 113-25	15
1478	Atrial fibrillation and hypercoagulability: dependent on clinical factors or/and on genetic alterations?. **2003**, 16, 155-61	33
1477	Overview of inherited metabolic disorders causing cardiovascular disease. **2003**, 26, 245-57	15
1476	Polymorphisms in the genes for coagulation factor II, V, VII in patients undergoing coronary angiography. **2003**, 4, 369-73	5
1475	Neonatal thrombosis. **2003**, 70, 903-7	7
1474	Clinical significance of gene-diagnosis for defects in coagulation factors and inhibitors. **2003**, 115, 475-81	2
1473	Antiphospholipid syndrome: genetic review. **2003**, 5, 391-4	4
1472	Assessment of the 20210 G to A prothrombin variant in a sample of patients from the French Basque Country with various thrombophilic conditions. **2003**, 82, 353-6	2

1471	Idiopathic portal hypertension in a systemic sclerosis patient heterozygous for factor V Leiden mutation. **2003**, 23, 44-6	10
1470	Thrombosis in children with cardiac pathology: frequency of factor V Leiden and prothrombin G20210A mutations. **2003**, 24, 244-8	29
1469	Factor V Leiden and prothrombin 20210 G-A mutations in controls and in patients with thromboembolic events during pregnancy or the puerperium. **2003**, 268, 304-8	10
1468	Thrombosis in systemic lupus erythematosus: effect of inherited thrombophilic mutations. **2003**, 22, 336-8	1
1467	Superior mesenteric vein thrombosis after colectomy for inflammatory bowel disease: a not uncommon cause of postoperative acute abdominal pain. **2003**, 46, 643-8	56
1466	Inherited thrombophilia and venous thromboembolism. **2003**, 17, 413-25	23
1465	Pre-eclampsia and thrombophilia. **2003**, 17, 441-58	21
1464	The inherited thrombophilias: genetics, epidemiology, and laboratory evaluation. **2003**, 17, 397-411	32
1463	Inherited thrombophilias and anticoagulation in pregnancy. **2003**, 17, 471-89	13
1462	Blood coagulation. **2003**, 17, 369-83	57
1461	Thrombophilias and gynaecology. **2003**, 17, 509-28	15
1460	Inherited thrombophilias are not increased in "idiopathic" small-for-gestational-age pregnancies. **2003**, 188, 981-5	42
1459	The Ischemic Stroke Genetics Study (ISGS) Protocol. **2003**, 3, 4	43
1458	A prospective cohort study determining the prevalence of thrombotic events in children with acute lymphoblastic leukemia and a central venous line who are treated with L-asparaginase: results of the Prophylactic Antithrombin Replacement in Kids with Acute Lymphoblastic Leukemia Treated with Asparaginase (PARKAA) Study. **2003**, 97, 508-16	223
1457	Thrombophilic genotypes, natural anticoagulants, and plasma homocysteine in myeloproliferative disorders: relationship with splanchnic vein thrombosis and arterial disease. **2003**, 72, 75-81	38
1456	Factor V Leiden and prothrombin gene G20210A mutation in children with cerebral thromboembolism. **2003**, 73, 81-6	51
1455	Plasminogen activator inhibitor type 1 (PAI1) and platelet glycoprotein IIIa (PGIIIa) polymorphisms in Black South Africans with pre-eclampsia. **2003**, 82, 313-7	20
1454	Analyzes of three common thrombophilic gene mutations in German women with recurrent abortions. **2003**, 82, 942-7	38

1453	Factor V Leiden and prothrombin gene G20210A mutations in ocular Beh□□t disease. **2003**, 81, 283-5	25
1452	Venous thromboembolism, oral contraceptives and high prothrombin levels. **2003**, 1, 112-7	16
1451	Prospective study of the A455V polymorphism in the thrombomodulin gene, plasma thrombomodulin, and incidence of venous thromboembolism: the LITE Study. **2003**, 1, 88-94	30
1450	The epidemiology of venous thromboembolism in Caucasians and African-Americans: the GATE Study. **2003**, 1, 80-7	124
1449	The risk of recurrent venous thromboembolism among patients with high factor IX levels. **2003**, 1, 28-32	70
1448	Thromboprophylaxis improves the live birth rate in women with consecutive recurrent miscarriages and hereditary thrombophilia. **2003**, 1, 433-8	136
1447	Inter-relation of coagulation factors and d-dimer levels in healthy individuals. **2003**, 1, 516-22	27
1446	Clinical manifestations of the prothrombin G20210A mutation in children: a pediatric coagulation consortium study. **2003**, 1, 958-62	61
1445	Prekallikrein (PK) Tokushima: PK deficiency caused by a Gly401-->Glu mutation. **2003**, 1, 1314-6	13
1444	The early antiplatelet effects of clopidogrel loading for coronary stenting and the long-term stability of inhibition. **2003**, 1, 1319-21	6
1443	Heterogeneous distribution of factor V Leiden in patients from north India with venous thromboembolism. **2003**, 1, 1329-30	13
1442	Anticoagulation patterns and clinical decision-making following an intermediate ventilation-perfusion scan in pulmonary thromboembolism. **2003**, 1, 1321-3	
1441	Clotting and myocardial infarction: a cycle of insights. **2003**, 1, 640-2	13
1440	Procoagulant protein levels are differentially increased during human endotoxemia. **2003**, 1, 1019-23	39
1439	Estrogens, progestogens and thrombosis. **2003**, 1, 1371-80	129
1438	Common single nucleotide polymorphisms in the promoter region of the human factor XI gene. **2003**, 1, 1854-6	5
1437	Novel family-based approaches to genetic risk in thrombosis. **2003**, 1, 1391-7	81
1436	Linkage analysis of factor VIII and von Willebrand factor loci as quantitative trait loci. **2003**, 1, 1771-6	22

1435	Rebuttal to: Pros and cons of thrombophilia testing--cons. **2003**, 1, 1311-2	6
1434	Availability of technology to evaluate for pulmonary embolism in academic emergency departments in the United States. **2003**, 1, 2240-2	21
1433	Genetic studies in complex disease: the case pro association studies. **2003**, 1, 1679-80	7
1432	A common mutation in 5,10-methylenetetrahydrofolate reductase (MTHFR) gene in two Arab communities. **2003**, 1, 2246-8	3
1431	Functional characterization of transcription factor binding sites for HNF1-alpha, HNF3-beta (FOXA2), HNF4-alpha, Sp1 and Sp3 in the human prothrombin gene enhancer. **2003**, 1, 1688-98	24
1430	Screening of high factor VIII levels is not recommended in patients with recently diagnosed pulmonary embolism. **2003**, 1, 2239-40	0
1429	Very high TAFI antigen levels are associated with a lower risk of hard coronary events: the PRIME Study. **2003**, 1, 2243-4	34
1428	Role of the fibrinogen gamma-chain sequence gamma316-322 in platelet-mediated clot retraction. **2003**, 1, 2245-6	7
1427	Rebuttal to: LMWH vs. LMWH: superior, equivalent or non-inferior?. **2003**, 1, 2256-8; author reply 2259	
1426	Interaction between oral contraceptive use and coagulation factor levels in deep venous thrombosis. **2003**, 1, 2186-90	23
1425	Evidence of platelet activation due to tirofiban-dependent platelet antibodies: double trouble. **2003**, 1, 2248-50	8
1424	Prothrombin G20210A is not prevalent in North India. **2003**, 1, 2253-4	22
1423	A different view of "Toc", as I knew him. **2003**, 1, 2255	1
1422	Warfarin and acenocoumarol dose requirements according to CYP2C9 genotyping in North-Italian patients. **2003**, 1, 2252-3	8
1421	Factor VIII inhibitors development following introduction of B-domain-deleted recombinant factor VIII in four hemophilia A previously treated patients. **2003**, 1, 2445-2446	2
1420	Gene therapy for platelet disorders: studies with Glanzmann's thrombasthenia. **2003**, 1, 2300-11	25
1419	Factor VIII inhibitors development following introduction of B-domain-deleted recombinant factor VIII in four hemophilia A previously treated patients. **2003**, 1, 2450-1	17
1418	Factor V Leiden G1691A and prothrombin G20210A mutations are common in Tunisia. **2003**, 1, 2451-2	9

1417	Successful use of Arixtra in a patient with paroxysmal nocturnal hemoglobinuria, Budd-Chiari syndrome and heparin-induced thrombocytopenia. **2003**, 1, 2452-3	30
1416	Fibrinogen as predictor of ischemic stroke in patients with non-valvular atrial fibrillation. **2003**, 1, 2453-5	4
1415	Comparison among natural (Arg304Gln, Arg304Trp) and artificial (Arg290His, Arg290Lys) mutations in coagulation factor VII loops. **2003**, 1, 2455-7	2
1414	Is Upshaw-Schulman syndrome congenital thrombotic thrombocytopenic purpura or hemolytic-uremic syndrome? Yes to both. **2003**, 1, 2457-8	5
1413	Rebuttal: the French Gypsy mutation does not give rise to a particularly mild form of Glazmann's thrombasthenia. **2003**, 1, 2459	2
1412	Exercise-induced activation of coagulation in thrombophilia. **2003**, 1, 1312-3	6
1411	Prevalence of inherited bleeding disorders in cases of idiopathic menorrhagia: a case of five blind men describing an elephant. **2003**, 1, 2242-3	1
1410	LMWH contra LMWH: superior, equivalent or non-inferior? Reply to a rebuttal. **2003**, 1, 2259-2259	
1409	Budd-Chiari syndrome in a patient heterozygous for the point mutation C20221T of the prothrombin gene. **2003**, 1, 852-3	19
1408	Microthrombus formation enhances tumor necrosis factor-alpha production in the development of ischemia/reperfusion-induced liver injury in rats. **2003**, 1, 1316-7	7
1407	Antibodies to tissue factor pathway inhibitor are uncommonly detected in patients with infection-related antiphospholipid antibodies. **2003**, 1, 2250-1	6
1406	Interpretation of platelet inhibition by clopidogrel and the effect of non-responders. **2003**, 1, 1318-9	17
1405	Milder bleeding tendency in Glanzmann's thrombasthenia patients inheriting HPA-1b in the homozygous state. **2003**, 1, 2255-6	3
1404	Significant prevalence of the intron 1 factor VIII gene inversion among patients with severe hemophilia A in the Czech Republic. **2003**, 1, 1323-4	10
1403	Venous thromboembolism in asymptomatic carriers of factor V Leiden mutation from symptomatic families: any role for hormonal replacement treatment?. **2003**, 1, 1325-6	
1402	Spontaneous venous thrombosis in inflammatory bowel disease: relevance of factor V Leiden and the prothrombin gene mutation. **2003**, 1, 1326-8	7
1401	Homocysteine plasma levels after suspension of vitamin treatment. **2003**, 1, 1330-2	
1400	Absence of Factor V Leiden, thrombomodulin and prothrombin gene variants in Black South African women with pre-eclampsia and eclampsia. **2003**, 110, 327-328	20

1399	Effect of tamoxifen on venous thrombosis risk factors in women without cancer: the Breast Cancer Prevention Trial. **2003**, 120, 109-16		54
1398	Asymptomatic carriership of factor V Leiden and genotypes of the fibrinogen gene cluster. **2003**, 121, 632-8		4
1397	Prothrombotic coagulation defects and cardiovascular risk factors in young women with acute myocardial infarction. **2003**, 122, 471-8		28
1396	Pregnancy-associated venous thromboembolism (VTE) in combined heterozygous factor V Leiden (FVL) and prothrombin (FII) 20210 A mutation and in heterozygous FII single gene mutation alone. **2003**, 123, 327-34		26
1395	ACE DD genotype: an independent predisposition factor to venous thromboembolism. **2003**, 33, 642-7		32
1394	Elevated plasma levels of factor VIII in women with early recurrent miscarriage. **2003**, 1, 2536-9		21
1393	Rapid detection of the prothrombin C20209T variant by differential sensitivity to restriction endonuclease digestion. **2003**, 1, 2683-5		3
1392	The platelet glycoprotein Ia/IIa gene polymorphism C807T/G873A: a novel risk factor for retinal vein occlusion. **2003**, 17, 772-7		29
1391	Role of factor V Leiden and prothrombin 20210A in patients with retinal artery occlusion. **2003**, 17, 731-4		14
1390	Tricuspid valve thrombus and pulmonary embolus in an infant with homozygous thermolabile methylenetetrahydrofolate reductase and heterozygous prothrombin G20210A variant. **2003**, 23, 513-5		2
1389	¿Qu□'debe conocer el cirujano vascular sobre los estados de hipercoagulabilidad en las enfermedades venosas?. **2003**, 55, 109-119		
1388	Clinical and laboratory evaluation of thrombophilia. **2003**, 24, 153-70		21
1387	Prothrombin G20210A mutation, antithrombin, heparin cofactor II, protein C, and protein S defects. **2003**, 17, 9-36		36
1386	Prevention and management of venous thromboembolism in pregnancy. **2003**, 24, 123-37		22
1385	Thrombophilia does not increase risk for neonatal complications in preterm infants. *Thrombosis and Haemostasis*, **2003**, 90, 823-8	7	21
1384	The Simon Dack lecture. Cardiology: the past, the present, and the future. **2003**, 42, 2031-41		34
1383	Combined thrombophilic polymorphisms in women with idiopathic recurrent miscarriage. **2003**, 79, 1141-8		56
1382	Thrombophilia and pregnancy. **2003**, 1, 111		100

1381	Prevention of venous thromboembolism in pregnancy. **2003**, 16, 261-78		40
1380	Inherited thrombophilia and gestational venous thromboembolism. **2003**, 16, 243-59		45
1379	Duplex PCR-RFLP for simultaneous detection of factor V Leiden and prothrombin G20210A. **2003**, 17, 267-9		4
1378	Screening for multiple hereditary hypercoagulability factors using the amplification refractory mutation system. *Thrombosis Research*, **2003**, 111, 115-20	8.2	15
1377	A cross-sectional study evaluating post-thrombotic syndrome in children. *Thrombosis Research*, **2003**, 111, 227-33	8.2	158
1376	PT G20210A, factors V G1691A and 1299 His-Arg mutations and tamoxifen-associated thromboembolism in patients with breast cancer. *Thrombosis Research*, **2003**, 111, 317-9	8.2	8
1375	Template-directed dye-terminator incorporation with fluorescence polarization detection for analysis of single nucleotide polymorphisms associated with cardiovascular and thromboembolic disease. *Thrombosis Research*, **2003**, 111, 373-9	8.2	6
1374	Prevalence of hyperhomocysteinemia and the MTHFR C677T polymorphism in patients with arterial and venous thrombosis from North Western Russia. *Thrombosis Research*, **2003**, 111, 351-6	8.2	19
1373	Associated thrombophilic defects in essential thrombocythaemia: their relationship with clinical manifestations. *Thrombosis Research*, **2003**, 112, 131-5	8.2	8
1372	Association between factor V Leiden, prothrombin G20210A, and methylenetetrahydrofolate reductase C677T mutations and events of the arterial circulatory system: a meta-analysis of published studies. **2003**, 146, 948-57		260
1371	Activated protein C resistance acquired through liver transplantation and associated with recurrent venous thrombosis. **2003**, 38, 866-9		8
1370	Factor V Leiden--the commonest molecular defect in arterial and venous thrombophilia in India. *Thrombosis Research*, **2003**, 110, 19-21	8.2	20
1369	Does the MTHFR 677T allele alter the clinical phenotype in severe haemophilia A?. *Thrombosis Research*, **2003**, 109, 71-2	8.2	18
1368	Polymorphisms in coagulation factor genes and their impact on arterial and venous thrombosis. **2003**, 330, 31-55		83
1367	Comparative study of the effects of two once-a-month injectable contraceptives (Cyclofem and Mesigyna) and one oral contraceptive (Ortho-Novum 1/35) on coagulation and fibrinolysis. **2003**, 68, 159-76		8
1366	Factor V Leiden, prothrombin 20210G --> A, methylenetetrahydrofolate reductase 677C --> T and plasminogen activator inhibitor 4G/5G polymorphism in women with pregnancy-related venous thromboembolism. **2003**, 111, 157-63		27
1365	[Heterozygous prothrombin gene mutation G20210A and associated diseases]. **2003**, 24, 282-7		2
1364	Large volume donor plasmapheresis in inherited thrombophilia implicated in arterial thrombosis. **2003**, 28, 201-6		13

1363	Comprehensive hypercoagulable state testing is indicated in patients with a first idiopathic deep venous thrombosis. **2003**, 87, 1237-50		
1362	Prothrombin gene variants in non-Caucasians with fetal loss and intrauterine growth retardation. **2003**, 5, 250-3		24
1361	Congenital thrombophilic states associated with venous thrombosis: a qualitative overview and proposed classification system. **2003**, 138, 128-34		180
1360	Pediatric Hematology. **2003**,		
1359	Superficial thrombophlebitis and risk for recurrent venous thromboembolism. **2003**, 37, 834-8		55
1358	Caracter□sticas de la trombosis venosa profunda en pacientes con factor V de Leiden y mutaci□□ G20210A del gen de la protrombina. **2003**, 55, 322-330		
1357	Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. **2003**, 349, 631-9		609
1356	Measuring the outcomes and pharmacoeconomic consequences of venous thromboembolism prophylaxis in major orthopaedic surgery. **2003**, 21, 477-96		48
1355	Thrombophilia in Infancy: Factor V Leiden and MTHFR or Factor II Double Heterozygocity as a Risk Factor. **2003**, 20, 219-227		1
1354	Elevated prothrombin results in clots with an altered fiber structure: a possible mechanism of the increased thrombotic risk. *Blood*, **2003**, 101, 3008-13	2.2	133
1353	Genetic polymorphisms associated with acute pulmonary embolism and deep venous thrombosis. **2003**, 21, 25-30		38
1352	Mesenteric venous thrombosis in a patient with prothrombin 20210A mutation and antithrombin III deficiency: challenges to conventional anticoagulation--a case report. **2003**, 37, 293-6		2
1351	Risk factors for venous thromboembolism. **2003**, 107, I9-16		945
1350	Pulmonary arterial hypertension in children. **2003**, 21, 155-76		128
1349	A quantitative trait locus influencing free plasma protein S levels on human chromosome 1q: results from the Genetic Analysis of Idiopathic Thrombophilia (GAIT) project. **2003**, 23, 508-11		30
1348	Hyperhomocysteinemia and B-vitamin status after discontinuation of oral anticoagulation therapy in patients with a history of venous thromboembolism. **2003**, 41, 1493-7		4
1347	Factor V Leiden and prothrombin gene mutation may predispose to paradoxical embolism in subjects with patent foramen ovale. **2003**, 14, 261-8		81
1346	Diagnostic Single Nucleotide Polymorphism Analysis of Factor V Leiden and Prothrombin 20210G>A. **2003**, 119, 490-496		20

1345	Outcome of kidney transplantation in patients with inherited thrombophilia: data of a prospective study. **2003**, 14, 234-9		50
1344	The risk of venous thromboembolism associated with the factor V Leiden mutation and low B-vitamin status. **2003**, 41, 1357-62		7
1343	Guidelines for the laboratory investigation of inherited thrombophilias. Recommendations for the first level clinical laboratories. **2003**, 41, 382-91		17
1342	Genetic variations observed in arterial and venous thromboembolism--relevance for therapy, risk prevention and prognosis. **2003**, 41, 496-500		11
1341	Genetically Determined Procoagulant States and Heparin Use. **2003**, 7, 427-442		1
1340	Comparison of standard PCR and the LightCycler technique to determine the thrombophilic mutations: an efficiency and cost study. **2003**, 41, 482-5		4
1339	Exploiting the enzymatic recognition of an unnatural base pair to develop a universal genetic analysis system. **2003**, 49, 407-14		29
1338	Factor V Leiden and Prothrombin Gene 20210A Variant in Neonatal Thromboembolism and in Healthy Neonates and Adults: A Study in a Single Center. **2003**, 20, 627-634		20
1337	Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. **2003**, 348, 1425-34		629
1336	High incidence of two methylenetetrahydrofolate reductase mutations (C677T and A1298C) in Hispanics. **2003**, 7, 255-7		5
1335	Review article: inherited thrombophilia in inflammatory bowel disease. **2003**, 98, 1247-51		75
1334	Hyperhomocysteinemia in cerebral vein thrombosis. *Blood*, **2003**, 102, 1363-6	2.2	172
1333	Inherited and acquired risk factors for venous thromboembolic disease among women taking tamoxifen to prevent breast cancer. **2003**, 21, 3588-93		74
1332	Hypercoagulable state testing and malignancy screening following venous thromboembolic events. **2003**, 8, 33-46		13
1331	Effect of oral and transdermal estrogen replacement therapy on hemostatic variables associated with venous thrombosis: a randomized, placebo-controlled study in postmenopausal women. **2003**, 23, 1116-21		105
1330	. **2003**, 14, 328-332		7
1329	Algorithms for Hypercoagulation Testing. *Laboratory Medicine*, **2003**, 34, 216-222	1.6	
1328	Thrombophilia and stroke. **2003**, 10, 21-33		16

1327	Factor V Leiden detection by polymerase chain reaction-restriction fragment length polymorphism with mutagenic primers in a multiplex reaction with Pro G20210A--a novel technique. **2003**, 8, 73-5	4
1326	Venous thrombosis and changes of hemostatic variables during cross-sex hormone treatment in transsexual people. **2003**, 88, 5723-9	167
1325	Inherited thrombophilia, pregnancy, and oral contraceptive use: clinical implications. **2003**, 3, 47-60	14
1324	Prevention and treatment of arterial thrombosis in pregnancy. **2003**, 29, 155-64	10
1323	Inherited thrombophilia and gestational vascular complications. **2003**, 29, 185-94	15
1322	Oral contraceptives and inherited thrombophilia: a gene-environment interaction with a risk of venous thrombosis?. **2003**, 29, 219-26	6
1321	Association between inherited thrombophilias, antiphospholipid antibodies, and lipoprotein A levels and venous thromboembolism in pregnancy. **2003**, 20, 17-24	21
1320	Basic mechanisms of hemostasis. **2003**, 3, 3-12	14
1319	The impact of single nucleotide polymorphisms of the thrombin activatable fibrinolysis inhibitor (TAFI) gene on TAFI antigen levels in healthy children and pediatric oncology patients. **2003**, 29, 575-83	7
1318	Genetic Variations of the Hemostatic System as Risk Factors for Venous and Arterial Thrombotic Disease. **2003**, 4, 309-336	4
1317	D-dimer levels and risk of recurrent venous thromboembolism. **2003**, 290, 1071-4	221
1316	Neonatal thromboembolism. **2003**, 29, 227-34	48
1315	Prediction, prevention, and treatment of venous thromboembolic disease in pregnancy. **2003**, 29, 143-54	29
1314	Changes of hemostatic variables during oral contraceptive use. **2003**, 3, 61-8	19
1313	Genetics of preeclampsia: what are the challenges?. **2003**, 25, 578-85	14
1312	. **2003**, 14, 277-282	2
1311	Is recurrent venous thromboembolism more frequent in homozygous patients for the factor V Leiden mutation than in heterozygous patients?. **2003**, 14, 523-9	11
1310	Plasmatic coagulation and fibrinolytic system alterations in PNH: relation to clone size. **2003**, 14, 685-95	29

1309	Platelet receptor and clotting factor polymorphisms as genetic risk factors for thromboembolic complications in heparin-induced thrombocytopenia. **2003**, 13, 253-8	30
1308	Factor V Leiden mutation and PAI-1 gene 4G/5G genotype in thrombotic patients with Behcet's disease. **2003**, 14, 121-4	21
1307	The search for thrombophilic gene mutations in women with gestational hypertension does not help in predicting poor pregnancy outcome. **2003**, 21, 1915-20	12
1306	Coagulation factor V G allele and HR2 haplotype. **2003**, 14, 49-56	8
1305	Combined factor V leiden (G1691A) and prothrombin (G20210A) genotyping by multiplex real-time polymerase chain reaction using fluorescent resonance energy transfer hybridization probes on the Rotor-Gene 2000. **2003**, 14, 421-4	6
1304	Plasma factor II levels in carriers of the 20210A prothrombin variant. **2003**, 14, 513	
1303	Severe venous thromboembolism in a young man with Klinefelter's syndrome and heterozygosis for both G20210A prothrombin and factor V Leiden mutations. **2003**, 14, 95-8	25
1302	. **2003**, 14, 261-268	18
1301	High prevalence of combined thrombophilic abnormalities in patients with inflammatory bowel disease. **2003**, 15, 1157-63	38
1300	Hypercoagulable states and central retinal vein occlusion. **2003**, 9, 385-92	39
1299	Pharmacogenetic aspects of the use of oral contraceptives and the risk of thrombosis. **2003**, 13, 589-94	11
1298	Evaluation of the Roche LightCycler. **2003**, 14, 499-503	12
1297	Homocysteine is unlikely to be associated with the risk of thromboembolic complications in atrial fibrillation. **2003**, 14, 513-4	2
1296	Elevated clotting factor levels and venous thrombosis. **2003**, 33, 395-400	43
1295	Major Genetic Susceptibility for Venous Thromboembolism in Men: A Study of Danish Twins. **2003**, 14, 328-332	92
1294	Familial thrombophilia is an oligogenetic disease. **2003**, 14, 191-196	12
1293	Role of family history in identifying women with thrombophilia and higher risk of venous thromboembolism during oral contraception. **2003**, 163, 1105-9	34
1292	Severe Protein S Deficiency Associated with Heterozygous Factor V Leiden Mutation in a Child with Purpura Fulminans. **2003**, 20, 1-5	16

1291	Hypercoagulability, high tissue factor and low tissue factor pathway inhibitor levels in severe ovarian hyperstimulation syndrome: possible association with clinical outcome. **2003**, 14, 277-82		32
1290	Prothrombin G20210A mutation and sudden death. **2003**, 24, 377-80		5
1289	Screening for thrombophilia: a laboratory perspective. **2003**, 60, 39-51		9
1288	Risk of venous thromboembolism after air travel: interaction with thrombophilia and oral contraceptives. **2003**, 163, 2771-4		112
1287	Role of the geneticist in testing and counseling for inherited thrombophilia. **2003**, 5, 133-43		35
1286	Multiplex PCR for the detection of the factor V Leiden and prothrombin 20210A mutations. **2004**, 91, 79-87		1
1285	Combined carrier status of prothrombin 20210A and factor XIII-A Leu34 alleles as a strong risk factor for myocardial infarction: evidence of a gene-gene interaction. *Blood*, **2003**, 101, 3037-41	2.2	61
1284	Low levels of tissue factor pathway inhibitor (TFPI) increase the risk of venous thrombosis. *Blood*, **2003**, 101, 4387-92	2.2	195
1283	The APC-independent anticoagulant activity of protein S in plasma is decreased by elevated prothrombin levels due to the prothrombin G20210A mutation. *Blood*, **2003**, 102, 1686-92	2.2	21
1282	Association of maternal and/or fetal factor V Leiden and G20210A prothrombin mutation with HELLP syndrome and intrauterine growth restriction. **2003**, 105, 279-85		34
1281	Aetiology of pre-eclampsia and thrombophilic genetic mutations. **2003**, 105, 269-71		2
1280	Fibrin fragment D-dimer and the risk of future venous thrombosis. *Blood*, **2003**, 101, 1243-8	2.2	174
1279	Coinheritance of Factor V (FV) Leiden enhances thrombin formation and is associated with a mild bleeding phenotype in patients homozygous for the FVII 9726+5G>A (FVII Lazio) mutation. *Blood*, **2003**, 102, 4014-20	2.2	40
1278	Trend to efficacy and safety using antithrombin concentrate in prevention of thrombosis in children receiving l-asparaginase for acute lymphoblastic leukemia. Results of the PAARKA study. *Thrombosis and Haemostasis*, **2003**, 90, 235-44	7	118
1277	Air travel-associated venous thromboembolism. **2003**, 12, 73-80		9
1276	Frequency of the TAFI -438 G/A and factor XIIIA Val34Leu polymorphisms in patients with objectively proven pulmonary embolism. *Thrombosis and Haemostasis*, **2003**, 90, 439-45	7	20
1275	Rapid genotyping of haemostatic gene polymorphisms using the 5□nuclease assay. *Thrombosis and Haemostasis*, **2003**, 89, 936-942	7	11
1274	Effect of hemostatic risk factors on the individual probability of thrombosis during pregnancy and the puerperium. *Thrombosis and Haemostasis*, **2003**, 90, 77-85	7	53

1273	Venous thrombosis and multiple prothrombotic gene defects. *Hamostaseologie*, **2003**, 23, 117-120	1.9	
1272	Ven□se Thrombose und Thrombophilie. *Hamostaseologie*, **2003**, 23, 186-198	1.9	1
1271	Coronary heart disease among Circassians in Israel is not associated with mutations in thrombophilia genes. **2003**, 75, 57-68		3
1270	Haemophilia and thrombophilia. *Hamostaseologie*, **2003**, 23, 36-40	1.9	31
1269	PRE-ECLAMPSIA^|^mdash;STILL A DISEASE OF THEORIES. **2003**, 49, 69-115		21
1268	The deletion polymorphism in the angiotensin-converting enzyme gene is a moderate risk factor for venous thromboembolism. *Thrombosis and Haemostasis*, **2003**, 89, 847-852	7	22
1267	Prothrombin G20210A mutation and oral contraceptive use increase upper-extremity deep vein thrombotic risk. *Thrombosis and Haemostasis*, **2003**, 89, 452-457	7	53
1266	Myocardial infarction under the age of 36: prevalence of thrombophilic disorders. *Thrombosis and Haemostasis*, **2003**, 90, 272-8	7	34
1265	[Cerebral and systemic venous thrombosis associated to prothrombin G20210 mutation: case report]. **2003**, 61, 1042-4		3
1264	Low protein Z plasma levels are independently associated with acute coronary syndromes. *Thrombosis and Haemostasis*, **2003**, 90, 1173-8	7	46
1263	Allele 4G of gene PAI-1 associated with prothrombin mutation G20210A increases the risk for venous thrombosis. *Thrombosis and Haemostasis*, **2003**, 90, 1061-4	7	22
1262	Homozygous and double heterozygous Factor V Leiden and Factor II G20210A genotypes predispose infants to thromboembolism but are not associated with an increase of foetal loss. *Thrombosis and Haemostasis*, **2003**, 90, 628-35	7	17
1261	The ACE D/D genotype is protective against the development of idiopathic deep vein thrombosis and pulmonary embolism. *Thrombosis and Haemostasis*, **2003**, 90, 829-34	7	16
1260	Thrombophilic mutations in high-risk atrial fibrillation patients: high prevalence of prothrombin gene G20210A polymorphism and lack of correlation with thromboembolism. *Thrombosis and Haemostasis*, **2003**, 90, 1158-62	7	15
1259	Factor V gene (1691A and 4070G) and prothrombin gene 20210A mutations in patients with Beh□et's disease. **2003**, 33, 157-63		13
1258	Do prothrombotic factors influence clinical phenotype of severe haemophilia? A review of the literature. *Thrombosis and Haemostasis*, **2004**, 92, 305-10	7	59
1257	Liver transplantation for type 1 primary hyperoxaluria as a cure for combined thrombophilia. *Thrombosis and Haemostasis*, **2004**, 92, 1157-1158	7	2
1256	Factor II gene (prothrombin G20210A) mutation and neonatal cerebrovenous thrombosis. *Thrombosis and Haemostasis*, **2004**, 92, 719-721	7	5

1255	Eclampsia in a woman homozygous for the prothrombin G20210A mutation. *Thrombosis and Haemostasis*, **2004**, 91, 201-202	7	2
1254	Association after linkage analysis indicates that homozygosity for the 46C-->T polymorphism in the F12 gene is a genetic risk factor for venous thrombosis. *Thrombosis and Haemostasis*, **2004**, 91, 899-904	7	63
1253	Paediatric cerebral sinus vein thrombosis. A multi-center, case-controlled study. *Thrombosis and Haemostasis*, **2004**, 92, 713-8	7	67
1252	Antiphospholipid antibodies and thrombosis: association with acquired activated protein C resistance in venous thrombosis and with hyperhomocysteinemia in arterial thrombosis. *Thrombosis and Haemostasis*, **2004**, 92, 1312-9	7	15
1251	Acute myocardial infarction in a child: possible pathogenic role of patent foramen ovale associated with heritable thrombophilia. **2004**, 114, e255-8		21
1250	Coagulation Abnormalities in Stroke. **2004**, 707-724		
1249	Prothrombin 20210GA and factor V Leiden mutations in patients less than 55 years old with myocardial infarction. **2004**, 45, 505-12		21
1248	Hyperhomocysteinemia in patients with Cushing's syndrome. **2004**, 89, 3745-51		67
1247	Handbook of Clinical Laboratory Testing During Pregnancy. **2004**,		5
1246	mRNA Metabolism and hereditary disorders: a tale of surveillance and escape. **2004**, 216, 304-14		2
1245	Molekulargenetische und plasmatische Untersuchungen des Gerinnungssystems bei Frauen mit habitueller Abortneigung. **2004**, 64, 1061-1067		
1244	A C677T methylenetetrahydrofolate reductase (MTHFR) polymorphism and G20210A mutation in the prothrombin gene of sickle cell anemia patients from Northeast Brazil. **2004**, 28, 237-41		14
1243	G20210A prothrombin gene polymorphism and coronary ischaemic syndromes: a phenotype-specific meta-analysis of 12 034 subjects. **2004**, 90, 82-6		38
1242	Evaluation of the association between hereditary thrombophilias and recurrent pregnancy loss: a meta-analysis. **2004**, 164, 558-63		184
1241	Association of idiopathic hepatic sinusoidal dilatation with the immunological features of the antiphospholipid syndrome. **2004**, 53, 1516-9		35
1240	Factor V Leiden and prothrombin G20210A mutations and the risk of atherothrombotic events in systemic lupus erythematosus. **2004**, 10, 233-8		6
1239	Transient severe eosinophilia precipitating massive venous thrombosis in a patient with hereditary thrombophilia. **2004**, 112, 209-11		4
1238	Prevalence of factor V leiden, factor V cambridge, factor II G20210A and methylenetetrahydrofolate reductase C677T mutations in healthy and thrombophilic Serbian populations. **2004**, 112, 227-9		26

1237	The risk of recurrent venous thromboembolism in men and women. **2004**, 350, 2558-63		356
1236	Association of Thrombotic Disease with Genetic Polymorphism of Haemostatic Genes: Relevance to Pharmacogenetics. **2004**, 311-322		1
1235	Antithrombotic therapy in children: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. **2004**, 126, 645S-687S		317
1234	Hypercoagulability in athletes. **2004**, 3, 77-83		25
1233	Laboratory markers in the diagnosis of venous thromboembolism. **2004**, 109, I4-8		66
1232	Risk factors and recurrence rate of primary deep vein thrombosis of the upper extremities. **2004**, 110, 566-70		142
1231	Spinal dural arteriovenous fistulas are not associated with prothrombotic factors. **2004**, 35, 2069-71		26
1230	Analytical validation of the tag-it high-throughput microsphere-based universal array genotyping platform: application to the multiplex detection of a panel of thrombophilia-associated single-nucleotide polymorphisms. **2004**, 50, 2028-36		62
1229	Genetic and acquired thrombotic factors in chronic hepatitis C. **2004**, 99, 527-31		41
1228	Joint range-of-motion limitations among young males with hemophilia: prevalence and risk factors. *Blood*, **2004**, 103, 2467-73	2.2	201
1227	Hyperhomocysteinemia and other newly recognized inherited coagulation disorders (factor V Leiden and prothrombin gene mutation) in patients with idiopathic cerebral vein thrombosis. **2004**, 17, 153-9		51
1226	Hormones and pregnancy: thromboembolic risks for women. **2004**, 126, 443-54		56
1225	Intraindividual consistency of the activated protein C resistance phenotype. **2004**, 126, 405-9		7
1224	Activated protein C levels in Beh□et's disease and risk of venous thrombosis. **2004**, 126, 550-6		39
1223	A very rapid multiplex polymerase chain reaction for simultaneous detection of factor V Leiden and G20210A prothrombin mutation. **2004**, 26, 239-40		1
1222	FEIBA: mode of action. **2004**, 10 Suppl 2, 3-9		142
1221	G20210A is a functional mutation in the prothrombin gene; effect on protein levels and 3'-end formation. **2004**, 2, 119-27		71
1220	Impact of environmental and hereditary risk factors on the clinical manifestation of thrombophilia in homozygous carriers of factor V:G1691A. **2004**, 2, 430-6		23

1219	Genome scan of venous thrombosis in a pedigree with protein C deficiency. **2004**, 2, 868-73	24
1218	Polymorphisms in the 5'-UTR of the tissue factor gene are associated with altered expression in human endothelial cells. **2004**, 2, 1351-8	16
1217	The factor II G20210A gene polymorphism, but not factor V Arg506Gln, is associated with peripheral arterial disease: results of a case-control study. **2004**, 2, 1334-40	31
1216	Familial thrombophilia and lifetime risk of venous thrombosis. **2004**, 2, 1526-32	71
1215	Factor V Leiden, prothrombin G20210A and antibodies against phospholipids in recurrent spontaneous abortion. **2004**, 2, 1482-4	7
1214	The G20210A prothrombin gene mutation: is there room for screening families?. **2004**, 2, 1487-8	12
1213	Preeclampsia and its interaction with common variants in thrombophilia genes. **2004**, 2, 1588-93	50
1212	Does the genotype predict the phenotype? Evaluations of the hemostatic proteome. **2004**, 2, 1727-34	31
1211	Identification of an epitope on glycoprotein IIb-IIIa that is recognized by HLA-DRB1*0405-restricted CD4+'superior' T cells from a patient with immune thrombocytopenic purpura. **2004**, 2, 348-50	3
1210	A new heterozygous mutation in gamma fibrinogen gene leading to 326 Cys-->Ser substitution in fibrinogen C□Ēdoba is associated with defective polymerization and familial hypodysfibrinogenemia. **2004**, 2, 352-4	8
1209	The effect of a pneumatic tube transport system on PFA-100 trade mark closure time and whole blood platelet aggregation. **2004**, 2, 354-6	44
1208	Methods that increase FVIII recovery in cryoprecipitate. **2004**, 2, 356-7	1
1207	High-titer inhibitor development in hemophilia A: lack of product specificity. **2004**, 2, 358-9	6
1206	Risk of venous thromboembolism during pregnancy in homozygous carriers of the factor V Leiden mutation: are there any predictive factors?. **2004**, 2, 359-60	5
1205	Geography too determines the causes of inherited thrombophilia. **2004**, 2, 363-4	26
1204	Activated protein C levels in patients with severe sepsis: rebuttal. **2004**, 2, 366	
1203	Potential role of D-dimer to rule in pulmonary embolism: a rebuttal. **2004**, 2, 367-8; author reply 369-70	4
1202	Potential role of d-dimer to rule in pulmonary embolism: reply to a rebuttal. **2004**, 2, 369-370	1

1201	Rebuttal to: clinical manifestations of the prothrombin G20210A mutation in children. **2004**, 2, 370-1; author reply 371-2	
1200	Reply to rebuttal of: Clinical manifestations of the prothrombin G20210A mutation in children. **2004**, 2, 371-372	
1199	Measuring the binding strength of single ligand–receptor pairs on cells: rebuttal. **2004**, 2, 372-374	23
1198	Vitamin K antagonists and cancer: reply to rebuttal. **2004**, 2, 378-379	7
1197	Genetic studies in complex disease. **2004**, 2, 343-4	
1196	Heritability of plasma concentrations of clotting factors and measures of a prethrombotic state in a protein C-deficient family. **2004**, 2, 242-7	65
1195	Impact of procoagulant concentration on rate, peak and total thrombin generation in a model system. **2004**, 2, 402-13	135
1194	Familial segregation of venous thromboembolism. **2004**, 2, 731-6	91
1193	Assessment of three chromogenic and one clotting assays for the measurement of synthetic pentasaccharide fondaparinux (Arixtra) anti-Xa activity. **2004**, 2, 346-8	35
1192	Serum levels of interleukin-10 are inversely related to future events in patients with acute myocardial infarction. **2004**, 2, 350-2	17
1191	The prevalence of factor V G1691A but not of prothrombin G20210A and methylenetetrahydrofolate reductase C677T is remarkably low in French Basques. **2004**, 2, 361-2	13
1190	The relationship between adherence and quality of treatment with vitamin K antagonists. **2004**, 2, 362-3	2
1189	Effect of bezafibrate on plasma homocysteine concentration in men with lower extremity arterial disease. **2004**, 2, 364-5	10
1188	Measuring the binding strength of single ligand–receptor pairs on cells: reply to a rebuttal. **2004**, 2, 374-377	22
1187	Vitamin K antagonists and cancer: rebuttal. **2004**, 2, 377-8; author reply 378-9	23
1186	Genetic studies in complex disease. **2004**, 2, 342	1
1185	Genetic studies in complex disease. **2004**, 2, 342-3	0
1184	Genetic studies in complex disease. **2004**, 2, 344-5	

1183	A negative personal and family history for venous thrombotic events is not sufficient to exclude thrombophilia in patients with cerebral venous thrombosis. **2004**, 11, 555-8	6
1182	Thrombophilia and stillbirth: possible connection by intrauterine growth restriction. **2004**, 111, 780-3	11
1181	The role of genetics in the risk of thromboembolism: prothrombin 20210A and oral contraceptive therapy. **2004**, 16, 106-15, 138	2
1180	Prospective analysis of presenting symptoms among 265 patients with radiographic evidence of Chiari malformation type I with or without syringomyelia. **2004**, 16, 134-8	39
1179	Cerebral venous sinus thrombosis in a neonate with homozygous prothrombin G20210A genotype. **2004**, 24, 797-9	8
1178	Severe central nervous system thrombotic events in hemoglobin Sabine patient. **2004**, 72, 67-70	9
1177	Tinzaparin sodium for thrombosis treatment and prevention during pregnancy. **2004**, 190, 495-501	68
1176	The implications of using mutagenic primers in combination with Taq polymerase having proofreading activity. **2004**, 32, 84-7	
1175	Trombofilie: risicofactoren voor veneuze trombo-embolie. **2004**, 20, 398-405	3
1174	Thrombophilia and pregnancy complications. **2004**, 191, 412-24	158
1173	Factor V G1691A, prothrombin G20210A, and methylenetetrahydrofolate reductase [MTHFR] C677T gene polymorphism in angiographically documented coronary artery disease. **2004**, 17, 199-205	35
1172	Thrombophilic polymorphisms--factor V Leiden, prothrombin G20210A, and methylenetetrahydrofolate reductase C677T mutations--and preterm birth. **2004**, 116, 622-6	21
1171	Subclavian vein thrombosis: A case report and review of the literature. **2004**, 13, 45-48	
1170	Prothrombin G20210A gene mutation with LightCycler polymerase chain reaction in venous thrombosis and healthy population in the southeast of Turkey. **2004**, 19, 164-6	12
1169	Pulmonary arterial hypertension in children. **2004**, 38, 2-22	123
1168	A proteomic analysis of changes in prothrombin and plasma proteins associated with the G20210A mutation. **2004**, 4, 2151-9	9
1167	Increased CD11b neutrophil expression in Budd-Chiari syndrome or portal vein thrombosis secondary to polycythaemia vera. **2004**, 124, 329-35	19
1166	High plasma levels of factor VIII and risk of recurrence of venous thromboembolism. **2004**, 124, 504-10	81

1165	Comparison of 1 month with 3 months of anticoagulation for a first episode of venous thromboembolism associated with a transient risk factor. **2004**, 2, 743-9	108
1164	Haplotypes of the EPCR gene, plasma sEPCR levels and the risk of deep venous thrombosis. **2004**, 2, 1305-10	97
1163	Incidence and risk factors of early venous thrombosis associated with permanent pacemaker leads. **2004**, 15, 1258-62	130
1162	Factor V Leiden and prothrombin gene G20210A mutations in Italian patients with Beh□et's disease and deep vein thrombosis. **2004**, 51, 177-83	30
1161	MTHFR C677T polymorphism and its relation to ischemic stroke in the Black Sea Turkish population. **2004**, 76, 40-3	16
1160	Molecular basis of inherited antithrombin deficiency in Portuguese families: identification of genetic alterations and screening for additional thrombotic risk factors. **2004**, 76, 163-71	9
1159	Factor V-Leiden, prothrombin G20210A, and MTHFR C677T mutations among patients with sickle cell disease in Eastern Saudi Arabia. **2004**, 76, 307-9	21
1158	Primary upper-extremity deep vein thrombosis: high prevalence of thrombophilic defects. **2004**, 76, 330-7	46
1157	An improved electronic microarray-based diagnostic assay for identification of MEFV mutations. **2004**, 23, 621-8	22
1156	Pronto ThromboRisk--a novel primer-extension ELISA based assay for the detection of mutations associated with increased risk for thrombophilia. **2004**, 18, 259-64	4
1155	Real-time genotyping with oligonucleotide probes containing locked nucleic acids. **2004**, 324, 143-52	125
1154	Multiplex PCR-RFLP assay for detection of factor V Leiden and prothrombin G20210A. **2004**, 8, 381-3	10
1153	Hypercoagulability in renal transplant recipients. Identifying patients at risk of renal allograft thrombosis and evaluating strategies for prevention. **2004**, 4, 139-49	56
1152	Genotyping of single-nucleotide polymorphisms by high-resolution melting of small amplicons. **2004**, 50, 1156-64	510
1151	Genetic thrombophilia. **2004**, 31, 685-709, xi	10
1150	Screening and management of inherited thrombophilias in the setting of adverse pregnancy outcome. **2004**, 31, 783-805, vii	37
1149	[Celiac disease and IgA nephropathy: a double face coin?]. **2004**, 122, 158-9	1
1148	[Mutation of the prothrombin gene (G20210A) in a patient with cerebral venous sinus thrombosis and bilateral deep vein thrombosis]. **2004**, 122, 158	2

1147	Thromboses veineuses des membres inf□rieurs et de la veine cave inf□rieure. **2004**, 1, 80-96	3
1146	Rapid combined genotyping of factor V, prothrombin and methylenetetrahydrofolate reductase single nucleotide polymorphisms using minor groove binding DNA oligonucleotides (MGB probes) and real-time polymerase chain reaction. **2004**, 42, 1364-9	13
1145	Thromboembolic disease in pregnancy. **2004**, 31, 319-44, vi	14
1144	Cardiovascular Pharmacogenetics. **2004**,	
1143	Pregnancy outcome in patients with a history of recurrent spontaneous miscarriages and documented thrombophilias. **2004**, 57, 127-31	14
1142	Detection of genomic polymorphisms associated with venous thrombosis using the invader biplex assay. **2004**, 6, 137-44	22
1141	Venous thromboembolic disease in users of low-estrogen combined estrogen-progestin oral contraceptives. **2004**, 70, 3-10	102
1140	Fetal inherited thrombophilias influence the severity of preeclampsia, IUGR and placental abruption. **2004**, 113, 31-5	18
1139	Thrombophilia and fetal growth restriction. **2004**, 113, 36-40	31
1138	Inherited risk of thrombosis of the fetus and intrauterine fetal death. **2004**, 117, 45-8	10
1137	Adverse pregnancy outcomes are associated with multiple maternal thrombophilic factors. **2004**, 117, 144-7	35
1136	□valuation en routine d'une nouvelle m□thode pour le g□notypage de la mutation 1691G>A du facteur V Leiden et du variant 20210G>A du facteur II par la technologie Invader□ . **2004**, 19, 110-116	
1135	□tude du g□ne de la prothrombine : □tude comparative de deux techniques PCR-RFLP / PCR all□les sp□cifiques. **2004**, 19, 177-179	
1134	Platelet GPIaC807T polymorphism is associated with negative outcome of sudden hearing loss. **2004**, 191, 41-8	23
1133	Placental pathology in fetal thrombophilia. **2004**, 35, 729-33	66
1132	Four-color multiplex 5' nuclease assay for the simultaneous detection of the factor V Leiden and the prothrombin G20210A mutations. **2004**, 18, 161-6	7
1131	Cerebral venous sinus thrombosis and thrombophilia presenting as pseudo-tumour syndrome following mild head injury. **2004**, 11, 924-7	9
1130	Portal vein thrombosis in children and adolescents: the low prevalence of hereditary thrombophilic disorders. **2004**, 39, 1356-61	43

1129	Risk factors and clinical presentation of portal vein thrombosis in patients with liver cirrhosis. **2004**, 40, 736-41		412
1128	Genetic and environmental determinants of fibrin structure and function: relevance to clinical disease. **2004**, 24, 1558-66		118
1127	Factor V Leiden and prothrombin G20210A mutations in young adults with cryptogenic ischemic stroke. *Thrombosis and Haemostasis*, **2004**, 91, 1031-4	7	54
1126	The hereditary stomatocytoses: genetic disorders of the red cell membrane permeability to monovalent cations. **2004**, 41, 165-72		73
1125	Prevalence of thrombophilia in women with severe ovarian hyperstimulation syndrome and cost-effectiveness of screening. **2004**, 81, 989-95		46
1124	Trombofilia venosa. Clasificaci?n, implicaciones cl?nicas y terap?uticas. **2004**, 9, 1393-1400		
1123	Pulmonary embolism. **2004**, 363, 1295-305		305
1122	Spontaneous subdural haemorrhage in newborn babies. **2004**, 363, 2001-2		6
1121	Pulmonary Embolism in Orthopaedic Patients: Diagnosis and Treatment. **2004**, 19, 317-326		
1120	Importance of hemostatic gene polymorphisms for susceptibility to and outcome of severe sepsis. **2004**, 32, S313-9		79
1119	Prothrombin gene mutation G20210A, homocysteine, antiphospholipid antibodies and other hypercoagulable states in ocular thrombosis. **2004**, 15, 393-7		13
1118	THE 2003 MARSHALL R. URIST AWARD PAPER: Genetic Background of Osteonecrosis. **2004**, 422, 251-255		48
1117	Molecular Diagnosis of Hypercoagulable States. *Laboratory Medicine*, **2004**, 35, 214-221	1.6	1
1116	Symptomatic pulmonary embolism and the risk of recurrent venous thromboembolism. **2004**, 164, 92-6		95
1115	Clinical and laboratory evaluation of Turkish children with thrombosis for homozygous factor V G1691A mutation. **2004**, 15, 343-6		4
1114	-455G/A beta-fibrinogen gene polymorphism, factor V Leiden, prothrombin G20210A mutation and MTHFR C677T, and placental vascular complications. **2004**, 15, 139-47		18
1113	No effect of the prothrombin G20210A mutation on protein C activation in a large kindred with type I protein C deficiency. **2004**, 15, 573-6		
1112	Analysis of some clinical and laboratory aspects of adolescent patients with thrombosis. **2004**, 15, 657-62		15

1111	Factor V Leiden and Prothrombin Gene Mutation. **2004**, 425, 168-172		69
1110	Symptomatic thrombosis in Turkish neonates. **2004**, 26, 417-20		8
1109	Inherited Thrombophilia in Pregnancy. **2004**, 24, 1-6		
1108	The Top 12 Advances in Vascular Medicine. **2004**, 11, II-21-II-31		1
1107	The intronic prothrombin 19911A>G polymorphism influences splicing efficiency and modulates effects of the 20210G>A polymorphism on mRNA amount and expression in a stable reporter gene assay system. *Blood*, **2004**, 103, 586-93	2.2	54
1106	Hyperprothrombinemia associated with prothrombin G20210A mutation inhibits plasma fibrinolysis through a TAFI-mediated mechanism. *Blood*, **2004**, 103, 2157-61	2.2	61
1105	The prothrombin 3'end formation signal reveals a unique architecture that is sensitive to thrombophilic gain-of-function mutations. *Blood*, **2004**, 104, 428-35	2.2	64
1104	Thrombin-activatable fibrinolysis inhibitor and the risk for recurrent venous thromboembolism. *Blood*, **2004**, 103, 3773-6	2.2	127
1103	A shortened activated partial thromboplastin time is associated with the risk of venous thromboembolism. *Blood*, **2004**, 104, 3631-4	2.2	143
1102	49, XXXXY syndrome with unilateral renal aplasia, proteinuria, and venous thromboembolism. **2004**, 43, 1186-90		4
1101	2 Between bleeding and thrombosis or beyond. **2005**, 15-30		
1100	How frequent is altered gene expression among susceptibility genes to human complex disorders?. **2005**, 7, 83-96		18
1099	The John Charnley Award: heritable thrombophilia and development of thromboembolic disease after total hip arthroplasty. **2005**, 441, 40-55		43
1098	Another lesson from the factor V Leiden mouse: thrombin generation drives arterial disease. **2005**, 111, 1733-4		9
1097	The association between the 4G/5G polymorphism in the promoter of the plasminogen activator inhibitor-1 gene and deep venous thrombosis in young people. **2005**, 20, 48-52		9
1096	Affections h□matologiques et accidents vasculaires c□r□braux. **2005**, 2, 1-7		
1095	Association of the protein C promoter CG haplotype and the factor II G20210A mutation is a risk factor for cerebral venous thrombosis. **2005**, 16, 495-500		9
1094	Molecular genetic testing of polymorphisms associated with venous thrombosis: a review of molecular technologies. **2005**, 14, 193-202		8

1093	Legg-perthes disease and heritable thrombophilia. **2005**, 25, 456-9		25
1092	The role of factor V Leiden and prothrombin G20210A mutations in sudden sensorineural hearing loss. **2005**, 26, 599-601		26
1091	Genetic thrombophilias and preeclampsia: a meta-analysis. **2005**, 105, 182-92		146
1090	Thromboembolism in heart transplantation: role of prothrombin G20210A and factor V Leiden. **2005**, 80, 590-4		14
1089	Thromboprophylaxis after cesarean delivery: a decision analysis. **2005**, 106, 733-40		29
1088	Portal vein thrombosis: what is the role of genetics?. **2005**, 17, 705-7		18
1087	Prevalence of factor V Leiden, prothrombin G20210A, and MTHFR G677A among 594 thrombotic Jordanian patients. **2005**, 16, 417-21		11
1086	Proteases and Human Disorders. **2005**,		
1085	Hypercoagulable states and stroke: a selective review. **2005**, 10, 567-78		33
1084	The relationship between the prothrombin upstream sequence element and the G20210A polymorphism: the influence of a competitive environment for mRNA 3'-end formation. **2005**, 33, 1010-20		16
1083	Thrombophilic gene mutations in cirrhotic patients with portal vein thrombosis. **2005**, 17, 339-43		52
1082	Prevalence of hyperhomocysteinaemia, activated protein C resistance and prothrombin gene mutation in inflammatory bowel disease. **2005**, 17, 739-44		38
1081	Reduced plasma fibrinolytic potential is a risk factor for venous thrombosis. *Blood*, **2005**, 105, 1102-5	2.2	221
1080	Genetic variation in the fibrinogen gamma gene increases the risk for deep venous thrombosis by reducing plasma fibrinogen gamma' levels. *Blood*, **2005**, 106, 4176-83	2.2	199
1079	Pulmonary thromboembolism associated with air travel in Japan. **2005**, 69, 1297-301		10
1078	Practical applications of snake venom toxins in haemostasis. **2005**, 45, 1171-81		148
1077	A systematic review of the association between factor V Leiden or prothrombin gene variant and intrauterine growth restriction. **2005**, 192, 694-708		108
1076	Absence of association of inherited thrombophilia with unexplained third-trimester intrauterine fetal death. **2005**, 192, 742-6		26

1075	A role of TNF-alpha gene variant on juvenile ischemic stroke: a case-control study. **2005**, 12, 989-93	48
1074	Thrombophilic risk factors in patients with severe carotid atherosclerosis. **2005**, 3, 502-7	18
1073	Risk of a first venous thrombotic event in carriers of a familial thrombophilic defect. The European Prospective Cohort on Thrombophilia (EPCOT). **2005**, 3, 459-64	147
1072	The G20210A prothrombin-gene mutation and the plasminogen activator inhibitor (PAI-1) 5G/5G genotype are associated with early onset of severe preeclampsia. **2005**, 3, 686-91	35
1071	Functional analysis of two polymorphisms in the 3'-UTR of the human prothrombin gene. **2005**, 3, 806-8	8
1070	The plasma hemostatic proteome: thrombin generation in healthy individuals. **2005**, 3, 1472-81	72
1069	Budd-Chiari syndrome in a paroxysmal nocturnal hemoglobinuria patient with coexistence of factor II and MTHFR mutations. **2005**, 3, 1111	2
1068	HR2 haplotype in Arab population and patients with venous thrombosis in Kuwait. **2005**, 3, 1467-71	18
1067	Determinants of the APTT- and ETP-based APC sensitivity tests. **2005**, 3, 1488-94	72
1066	Prothrombotic conditions, oral contraceptives, and the risk of ischemic stroke. **2005**, 3, 1213-7	87
1065	Homocysteine and tissue factor pathway inhibitor levels in patients with Fabry's disease. **2005**, 3, 2117-9	10
1064	Prolonged prothrombin time is not common in bird flu infection: a summary from Thailand. **2005**, 3, 2127-8	2
1063	An Arab selective gradient in the distribution of factor V G1691A (Leiden), prothrombin G20210A, and methylenetetrahydrofolate reductase (MTHFR) C677T. **2005**, 3, 2126-7	18
1062	Characterization of a novel prothrombin variant, Prothrombin C20209T, as a modifier of thrombotic risk among African-Americans. **2005**, 3, 2357-9	10
1061	Thrombin generation profiles in deep venous thrombosis. **2005**, 3, 2497-505	117
1060	Common genomic sequence variation of the prothrombin gene and risk of non-fatal myocardial infarction in white women. **2005**, 3, 2809-11	2
1059	The post-thrombotic syndrome: risk factors and impact on the course of thrombotic disease. **2005**, 3, 2671-6	231
1058	A new PCR-SSP typing method for six single-nucleotide polymorphisms impairing the blood-clotting cascade as well as T-cell stimulation. **2005**, 66, 650-5	4

1057	Factor V Leiden, prothrombin 20210A and the risk of venous thrombosis among cancer patients. **2005**, 128, 386-8	30
1056	Protein Z-dependent protease inhibitor W303X mutation in venous thrombosis. **2005**, 129, 561-2; author reply 562	8
1055	Mutation screening for the prothrombin variant G20210A by melting point analysis with the Light Cycler system: atypical results, detection of the variant C20209T and possible clinical implications. **2005**, 27, 343-6	9
1054	Prevalence of inherited prothrombotic abnormalities and central venous catheter-related thrombosis in haematopoietic stem cell transplants recipients. **2005**, 36, 885-9	26
1053	Inherited thrombophilias and adverse pregnancy outcome: screening and management. **2005**, 29, 150-63	44
1052	Disseminated intravascular coagulation in an ambulatory young woman. **2005**, 146, 192-6	2
1051	Prevalence, incidence, and risk factors for venous thromboembolism in medical-surgical intensive care unit patients. **2005**, 20, 309-13	43
1050	Prevalence of the Factor V G1691A and the Factor II/prothrombin G20210A gene polymorphisms among Tamilians. **2005**, 79, 9-13	22
1049	Risk factors for thrombophilia in extrahepatic portal vein obstruction. **2005**, 41, 603-8	162
1048	Primary thrombophilia in Mexico. V. A comprehensive prospective study indicates that most cases are multifactorial. **2005**, 78, 21-6	25
1047	Factor V G1691A (Leiden) and prothrombin G20210A single-nucleotide polymorphisms in type 2 diabetes mellitus. **2005**, 80, 84-6	5
1046	Association between adverse pregnancy outcomes and maternal factor V G1691A (Leiden) and prothrombin G20210A genotypes in women with a history of recurrent idiopathic miscarriages. **2005**, 80, 12-9	26
1045	Outcome in children with purpura fulminans: report on 16 patients. **2005**, 80, 20-5	30
1044	Protein C system defects in Indian children with thrombosis. **2005**, 84, 85-8	15
1043	Evaluation of thrombotic children with malignancy. **2005**, 84, 395-9	30
1042	Thrombosis and priapism in a patient with Henoch-Schonlein purpura. **2005**, 25, 472-4	14
1041	Factor V Leiden and the prothrombin 20210A gene mutation and osteonecrosis of the knee. **2005**, 125, 51-5	50
1040	An update in recurrent spontaneous abortion. **2005**, 272, 95-108	152

1039	Trombofilie en zwangerschap. **2005**, 73, 130-135		
1038	A case control study on the contribution of factor V-Leiden, prothrombin G20210A, and MTHFR C677T mutations to the genetic susceptibility of deep venous thrombosis. **2005**, 19, 189-96		44
1037	Varied prevalence of factor V G1691A (Leiden) and prothrombin G20210A single nucleotide polymorphisms among Arabs. **2005**, 20, 163-8		37
1036	Risk factors for thromboembolic complications in inflammatory bowel disease: the role of hyperhomocysteinaemia. **2005**, 50, 235-40		56
1035	Prevalence of Factor V Leiden and other thrombophilic traits among Cretan children with malignancy. **2005**, 44, 386-9		12
1034	Epidemiology of Pulmonary Embolism in Japan. **2005**, 3-12		
1033	Influence of the 4600A/G and 4678G/C polymorphisms in the endothelial protein C receptor (EPCR) gene on the risk of venous thromboembolism in carriers of factor V Leiden. *Thrombosis and Haemostasis*, **2005**, 94, 389-94	7	34
1032	Severe clinical presentation of protein C deficiency in a type I/II compound heterozygote newborn. *Thrombosis and Haemostasis*, **2005**, 94, 216-218	7	5
1031	HELLP syndrome with fetal growth retardation in a woman homozygous for the prothrombin gene variant 20210A. *Thrombosis and Haemostasis*, **2005**, 93, 787-788	7	2
1030	Effect of oral contraceptives on the anticoagulant activity of protein S in plasma. *Thrombosis and Haemostasis*, **2005**, 93, 853-9	7	40
1029	Rapid detection of the prothrombin C20209T transition by Light Cycler analysis. *Thrombosis and Haemostasis*, **2005**, 94, 1114-5	7	2
1028	Prothrombin T165M and the Factor V R485K Polymorphism are Associated with an Increase Risk of Coronary Artery Disease in Koreans. **2005**, 35, 429		1
1027	Association of anticardiolipin antibody and C677T in methylenetetrahydrofolate reductase mutation in women with recurrent spontaneous abortions: a new path to thrombophilia?. **2005**, 123, 15-20		10
1026	Venous thromboembolism during pregnancy is not associated with persistent elevated activated protein C (APC) sensitivity ratio based on the endogenous thrombin potential. *Thrombosis and Haemostasis*, **2005**, 93, 306-10	7	3
1025	Venous Thrombosis: The Role of Genes, Environment, and Behavior. **2005**, 2005, 1-12		21
1024	Hemostatic abnormalities. **2005**, 310-348		7
1023	Tiefe Beinvenenthrombose: Pathogenese, Diagnostik und Therapie. **2005**, 34, 5-14		2
1022	Gene Discovery Underlying Stroke. **2005**, 18, 336-376		

1021	Molecular Diagnostic Approaches to Hemostasis. 18-28		
1020	Lipoprotein (a) and other prothrombotic risk factors in Caucasian women with unexplained recurrent miscarriage. Results of a multicentre case-control study. *Thrombosis and Haemostasis*, **2005**, 93, 867-71	7	23
1019	Hemostatic Disorders of the Newborn. **2005**, 1145-1179		4
1018	Erratum: PROTHROMBIN G20210A MUTATION IN TURKISH CHILDREN WITH THROMBOSIS AND THE FREQUENCY OF PROTHROMBIN C20209T. **2005**, 22, 541-542		1
1017	Osteonecrosis of the metacarpal head in a patient with a prothrombin 20210A gene mutation. **2005** , 39, 379-81		7
1016	Thrombophilia is significantly associated with severe preeclampsia: results of a large-scale, case-controlled study. **2005**, 46, 1270-4		120
1015	Malignancies, prothrombotic mutations, and the risk of venous thrombosis. **2005**, 293, 715-22		1304
1014	Improved method for isolating cell-free DNA. **2005**, 51, 1561-3		51
1013	Laboratory detection of inherited thrombophilia: a historical perspective. **2005**, 31, 5-10		26
1012	Genetic factors in fetal growth restriction and miscarriage. **2005**, 31, 334-45		33
1011	Venous thrombosis: the role of genes, environment, and behavior. **2005**, 1-12		110
1010	Regulation of protease and protease inhibitor gene expression: the role of the 3'-UTR and lessons from the plasminogen activating system. **2005**, 80, 169-215		
1009	Issues concerning the laboratory investigation of inherited thrombophilia. *Molecular Diagnosis and Therapy*, **2005**, 9, 181-6		9
1008	Prothrombin 20210A and oral contraceptive use as risk factors for cerebral venous thrombosis. **2005**, 19, 49-52		43
1007	Thrombophilia, clinical factors, and recurrent venous thrombotic events. **2005**, 293, 2352-61		381
1006	A review of the clinical and diagnostic utility of laboratory tests for the detection of congenital thrombophilia. **2005**, 31, 25-32		33
1005	Genetic testing for thrombophilia mutations. **2005**, 31, 33-8		29
1004	Thrombosis in inflammatory bowel diseases: role of inherited thrombophilia. **2005**, 100, 2036-41		74

1003	Recurrent miscarriage syndrome and infertility due to blood coagulation protein/platelet defects: a review and update. **2005**, 11, 1-13		53
1002	Drospirenone in the treatment of severe premenstrual cerebral edema in a woman with antiphospholipid syndrome, lateral sinus thrombosis, situs inversus and epileptic seizures. **2005**, 21, 243-7		4
1001	Genetic risk factors associated with thrombosis in children with congenital neurologic disorders. **2005**, 20, 509-12		2
1000	Genetic Risk Factors Associated With Thrombosis in Children With Congenital Neurologic Disorders. **2005**, 20, 509-512		2
999	Third trimester nonrecurrent fetal loss is associated with factor V Leiden and prothrombin gene mutations. **2005**, 18, 299-304		1
998	Fetal genotype for specific inherited thrombophilias is not associated with severe preeclampsia. **2005**, 12, 198-201		12
997	Genetic determinants of cardiovascular disease risk in familial hypercholesterolemia. **2005**, 25, 1475-81		42
996	Prothrombotic factors in children with stroke or porencephaly. **2005**, 116, 447-53		64
995	Reference materials (RMs) for analysis of the human factor II (prothrombin) gene G20210A mutation. **2005**, 43, 862-8		3
994	Fatal stroke in a child with severe iron deficiency anemia and multiple hereditary risk factors for thrombosis. **2005**, 44, 175-80		9
993	Thrombosis Risk Testing in the Clinical Laboratory. *Laboratory Medicine*, **2005**, 36, 115-118	1.6	1
992	Deep vein thrombosis. **2005**, 365, 1163-74		367
991	Influence of methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism, B vitamins and other factors on plasma homocysteine and risk of thromboembolic disease in Chinese. **2005**, 68, 560-5		502
990	Molecular aspects of thrombosis and antithrombotic drugs. **2005**, 42, 249-77		16
989	Transhepatic catheter-directed thrombectomy and thrombolysis of acute superior mesenteric venous thrombosis. **2005**, 16, 1685-91		84
988	Microarrays in Clinical Diagnostics. **2005**,		1
987	Molecular diagnostic testing for inherited thrombophilia using Invader. **2005**, 114, 107-19		1
986	The factor IXa heparin-binding exosite is a cofactor interactive site: mechanism for antithrombin-independent inhibition of intrinsic tenase by heparin. **2005**, 44, 3615-25		24

985	Multiplex single strand conformation polymorphism analysis by capillary electrophoresis with on-the-fly fluorescence lifetime detection. **2005**, 59, 335-9		9
984	The polymorphism of platelet membrane integrin alpha2beta1 (alpha2807TT) is associated with premature onset of fetal loss. *Thrombosis and Haemostasis*, **2005**, 93, 124-9	7	18
983	Neonatal renal venous thrombosis: clinical outcomes and prevalence of prothrombotic disorders. **2005**, 146, 811-6		93
982	High prevalence of thrombophilia among young patients with myocardial infarction and few conventional risk factors. **2005**, 98, 421-4		36
981	A whole-blood homogeneous assay for the multiplex detection of the factor V G1691A and the prothrombin G20210A mutations. **2005**, 19, 290-7		5
980	Molecular analysis of homocystinuria in Brazilian patients. **2005**, 362, 71-8		11
979	Prevalence of antiphospholipid antibodies, factor V G1691A (Leiden) and prothrombin G20210A mutations in early and late recurrent pregnancy loss. **2005**, 119, 164-70		27
978	Affections h□matologiques et accidents vasculaires c□r□braux. **2005**, 2, 339-348		
977	Factor V Leiden, prothrombin 20210A, methylenetetrahydrofolate reductase 677T, and population genetics. **2005**, 86, 91-9		62
976	State-of-the-art lectures. *Thrombosis Research*, **2005**, 115, 1-107	8.2	5
975	Role of thrombophilic risk factors in children with non-stroke cerebral palsy. *Thrombosis Research*, **2005**, 116, 133-7	8.2	14
974	Role of thrombophilic gene polymorphisms in branch retinal vein occlusion. **2005**, 112, 1910-5		38
973	Thromboepidemiology: identifying patients with heritable risk for thrombin-mediated thromboembolic events. **2005**, 149, S9-18		3
972	[Renal venous thrombosis in a neonate carrying the G20210A mutation of the prothrombin gene]. **2005**, 62, 480-2		1
971	[Portal-splenic-mesenteric venous thrombosis secondary to a mutation of the prothrombin gene]. **2005**, 28, 329-32		2
970	Atypical melting curve resulting from genetic variation in the 3' untranslated region at position 20218 in the prothrombin gene analyzed with the LightCycler factor II (prothrombin) G20210A assay. **2005**, 51, 1560-1		12
969	Trombofilia, ¿cu□□do, qu□'pruebas y a qui□h?. **2005**, 6, 133-143		1
968	The Medicolegal Evaluation of Fatal Pulmonary Thromboembolism. **2005**, 285-302		5

967	Thrombophilic risk factors for symptomatic peripheral arterial disease. **2005**, 41, 255-60	48
966	Oral contraceptives and the risk of venous thromboembolism. **2005**, 2 Suppl A, S3-9	16
965	Magnetically responsive carboxylated magnetite-polydipyrrole/polydicarbazole nanocomposites of core-shell morphology. Preparation, characterization, and use in DNA hybridization. **2005**, 127, 11998-2006	43
964	Platelet Function. **2005**,	7
963	Polydipyrrole- and polydicarbazole-nanorods as new nanosized supports for DNA hybridization. **2005**, 4357-9	14
962	Hypercoagulable states: a review. **2005**, 39, 123-33	29
961	Technical standards and guidelines: venous thromboembolism (Factor V Leiden and prothrombin 20210G >A testing): a disease-specific supplement to the standards and guidelines for clinical genetics laboratories. **2005**, 7, 444-53	33
960	Immunology of Pregnancy. **2006**,	6
959	Inherited thrombophilia. **2006**, 43, 249-90	52
958	Phenotypic Heterogeneity in Patients with Homozygous Prothrombin 20210AA Genotype. A paper from the 2005 William Beaumont Hospital Symposium on Molecular Pathology. **2006**, 8, 420-5	19
957	Clinical applications of bioinformatics, genomics, and pharmacogenomics. **2006**, 316, 159-77	6
956	Genetic thrombophilic mutations among couples with recurrent miscarriage. **2006**, 21, 1161-5	53
955	Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke: co-sponsored by the Council on Cardiovascular Radiology and Intervention: the American Academy of Neurology affirms the value of this guideline. **2006**, 37, 577-617	1174
954	Seven haemostatic gene polymorphisms in coronary disease: meta-analysis of 66,155 cases and 91,307 controls. **2006**, 367, 651-8	334
953	Inherited thrombophilias. **2006**, 33, 357-74	7
952	What does it take to make the perfect clot?. **2006**, 26, 41-8	290
951	Pathophysiology of venous thrombosis, thrombophilia, and the diagnosis of deep vein thrombosis-pulmonary embolism in the elderly. **2006**, 22, 75-92, viii-ix	18
950	The scientific basis for evaluation and management of thrombotic disorders. **2006**, 16, 435-43	1

949	Thrombophilia and the risk for venous thromboembolism during pregnancy, delivery, and puerperium. **2006**, 33, 413-27	39
948	[Pharmacogenetics in the treatment of asthma]. **2006**, 64, 221-3	0
947	Mutations in Human Genetic Disease. **2006**,	2
946	Fetal and neonatal thrombophilia. **2006**, 33, 457-66	13
945	Evaluation of factor V Leiden, prothrombin and methylenetetrahydrofolate reductase gene mutations in patients with severe pregnancy complications in northern Finland. **2006**, 62, 28-32	19
944	Investigation of a thrombotic tendency. **2006**, 441-463	
943	Thrombophilic gene polymorphisms in puerperal cerebral veno-sinus thrombosis. **2006**, 249, 25-30	19
942	D-dimer testing to determine the duration of anticoagulation therapy. **2006**, 355, 1780-9	493
941	Endogenous thrombin potential for predicting risk of venous thromboembolism in carriers of factor V Leiden. **2006**, 35, 435-9	17
940	Family history for venous thromboembolism and the risk for recurrence. **2006**, 119, 50-3	47
939	Maternal IVS1-401 T allele of the estrogen receptor alpha is an independent predictor of late fetal loss. **2006**, 86, 448-53	4
938	Hypercoagulability markers in young asymptomatic heterozygous carriers of factor V Leiden (G1691A) or prothrombin (G20210A) variant. **2006**, 365, 304-9	2
937	Models of blood coagulation. **2006**, 36, 108-17	85
936	Relationship between polymorphisms in thrombophilic genes and preeclampsia in a Brazilian population. **2006**, 37, 107-10	33
935	Should coagulation tests be used to determine which oral contraceptive users have an increased risk of thrombophlebitis?. **2006**, 73, 4-5	0
934	Does use of hormonal contraceptives among women with thrombogenic mutations increase their risk of venous thromboembolism? A systematic review. **2006**, 73, 166-78	49
933	Population screening for single genes that codetermine common diseases in adulthood had limited effects. **2006**, 59, 358-64	2
932	Genomic medicine and thrombotic risk: who, when, how and why?. **2006**, 106, 3-9	23

931	Prothrombotic abnormalities in childhood ischaemic stroke. *Thrombosis Research*, **2006**, 118, 67-74	8.2	80
930	Recurrent cerebral venous thrombosis: an Arg359X mutation in the antithrombin gene in a Taiwanese family. *Thrombosis Research*, **2006**, 118, 235-40	8.2	2
929	Endogenous or exogenous coagulation factor level and the response to activated protein C. *Thrombosis Research*, **2006**, 118, 269-73	8.2	6
928	The prevalence of the prothrombin gene variant C20209T in African-Americans and Caucasians and lack of association with venous thromboembolism. *Thrombosis Research*, **2006**, 118, 767-8	8.2	15
927	Guidelines for Prevention of Stroke in Patients With Ischemic Stroke or Transient Ischemic Attack. **2006**, 113,		347
926	Prevalence of hereditary risk factors for thrombophilia in Bel□m, Brazilian Amazon. **2006**, 29, 38-40		3
925	Etiology and consequences of thrombosis in abdominal vessels. **2006**, 12, 1165-74		71
924	Ethnic differences in the prevalence of inherited thrombophilic polymorphisms in an asymptomatic Australian prenatal population. **2006**, 78, 403-12		7
923	Genetics of perinatal brain injury in the preterm infant. **2006**, 11, 1371-87		45
922	Chronisch-arterielle Verschlusskrankheit der Beine im Stadium IIb-IV. *Hamostaseologie*, **2006**, 26, 197-200	1.9	1
921	Thrombophilic abnormalities, oral contraceptives, and risk of cerebral vein thrombosis: a meta-analysis. *Blood*, **2006**, 107, 2766-73	2.2	189
920	Prothrombin 20210G>A is an ancestral prothrombotic mutation that occurred in whites approximately 24,000 years ago. *Blood*, **2006**, 107, 4666-8	2.2	42
919	A prospective cohort study on the absolute incidence of venous thromboembolism and arterial cardiovascular disease in asymptomatic carriers of the prothrombin 20210A mutation. *Blood*, **2006**, 108, 2604-7	2.2	54
918	Recurrent miscarriage syndrome and infertility caused by blood coagulation protein/platelet defects. 55-74		1
917	Retinal vein occlusion associated with antithrombin deficiency secondary to a novel G9840C missense mutation. **2006**, 124, 1165-9		4
916	Hereditary and acquired thrombophilia in pregnancy. 122-199		
915	Venous Thrombosis: Genetics. **2006**,		
914	Thrombosis in infants and children. **2006**, 2006, 86-96		16

913	Factor V Leiden and increased risk for arterial thrombotic disease in young Brazilian patients. **2006**, 17, 271-5		31
912	Thrombophilia in Pregnancy: Maternal and Fetal Implications. **2006**, 2, 51-59		3
911	E□tiologie des thromboses h□ þatiques et portales. **2006**, 1, 1-5		
910	Mutation 20210 A du facteur II. **2006**, 1, 1-3		
909	Hyperhomocysteinaemia and factor V Leiden mutation are associated with Budd-Chiari syndrome. **2006**, 18, 917-20		8
908	Thromboses veineuses des membres inf□ hieurs et de la veine cave inf□ hieure. **2006**, 1, 1-11		
907	Gene polymorphisms in patients below 35 years of age who underwent coronary artery bypass surgery. **2006**, 17, 35-9		12
906	The search for a common thrombophilic state during the active state of inflammatory bowel disease. **2006**, 40, 809-13		18
905	Should we screen patients for inherited thrombophilia before starting thalidomide?. **2006**, 29, 100-1		0
904	Thromboembolic disease after total hip arthroplasty: who is at risk?. **2006**, 453, 211-24		43
903	Risk of recurrent venous thrombosis in patients with G20210A mutation in the prothrombin gene or factor V Leiden mutation. **2006**, 17, 23-8		25
902	Abnormal melt curve profile during prothrombin 20210G --> A analysis due to the 20209C --> T variant. **2006**, 17, 599-602		6
901	Hereditary thrombophilia. *Thrombosis Journal*, **2006**, 4, 15	5.6	134
900	Successful renal transplantation in a patient with heterozygous prothrombin gene, factor V Leiden mutation and heparin-induced thrombocytopenia using r-hirudin as anticoagulant. **2006**, 10, 114-8		9
899	The role of tamoxifen in breast cancer prevention: issues sparked by the NSABP Breast Cancer Prevention Trial (P-1). **2001**, 949, 99-108		30
898	Metabolic and genetic risk factors for migraine in children. **2006**, 26, 731-7		50
897	Hyperhomocysteinemia and low B vitamin levels are independently associated with venous thromboembolism: results from the EDITH study: a hospital-based case-control study. **2006**, 4, 793-9		59
896	The prothrombin 20209 C-->T mutation in Jewish-Moroccan Caucasians: molecular analysis of gain-of-function of 3' end processing. **2006**, 4, 1078-85		24

895	D-dimer, factor VIII coagulant activity, low-intensity warfarin and the risk of recurrent venous thromboembolism. **2006**, 4, 1208-14		66
894	Genetic determinants of normal variation in coagulation factor (F) IX levels: genome-wide scan and examination of the FIX structural gene. **2006**, 4, 1537-45		21
893	Functional analysis of two prothrombin 3'-untranslated region variants: the C20209T variant, mainly found among African-Americans, and the C20209A variant. **2006**, 4, 2285-7; author reply 2288-9		11
892	Hormonal factors and risk of recurrent venous thrombosis: the prevention of recurrent venous thromboembolism trial. **2006**, 4, 2199-203		69
891	Low protein Z levels and risk of occurrence of deep vein thrombosis. **2006**, 4, 2417-22		38
890	Platelet activation in subjects carrying factor V Leiden or factor II A20210 mutations. **2006**, 4, 2496-8		3
889	Prothrombin A19911G polymorphism and the risk of venous thromboembolism. **2006**, 4, 2582-6		29
888	The association of prothrombin A19911G polymorphism with plasma prothrombin activity and venous thrombosis: results of the MEGA study, a large population-based case-control study. **2006**, 4, 2587-92		31
887	Oral contraceptives' effects on the vascular component. Thrombophilic parameters. **2000**, 900, 228-36		1
886	Can haematological tests predict cardiovascular risk? The 2005 Kettle Lecture. **2006**, 133, 232-50		71
885	ABO blood group but not haemostasis genetic polymorphisms significantly influence thrombotic risk: a study of 180 homozygotes for the Factor V Leiden mutation. **2006**, 135, 697-702		21
884	Prevalence of factor V Leiden and prothrombin G20210A mutations in Chinese patients with deep venous thrombosis and pulmonary embolism. **2006**, 28, 111-6		49
883	Comparative study between the Light Cycler and the PCR-restriction fragment length polymorphism in detecting factor V Leiden and factor II 20210G>A mutations. **2006**, 39, 767-9		5
882	The Genetics of fetal growth restriction: Implications for management. **2006**, 6, 99-105		3
881	Genetic risk factors for deep vein thrombosis among Japanese: importance of protein S K196E mutation. *International Journal of Hematology*, **2006**, 83, 217-23	2.3	59
880	Single-Nucleotide Polymorphisms. **2006**, 111-120		
879	Molecular Diagnostics in Coagulation. **2006**, 311-320		1
878	Prediction of maternal complications and adverse infant outcome at admission for temporizing management of early-onset severe hypertensive disorders of pregnancy. **2006**, 195, 495-503		77

877	Thrombophilias--practical implications and testing caveats. **2006**, 21, 7-15	33
876	Thrombophile Gerinnungsst□ □ungen bei peripherer arterieller Verschlusskrankheit. **2006**, 11, 325-333	1
875	Henoch-Schonlein purpura: polymorphisms in thrombophilia genes. **2006**, 21, 1117-21	11
874	Functional polymorphisms of FGA, encoding alpha fibrinogen, are associated with susceptibility to venous thromboembolism in a Taiwanese population. **2006**, 119, 84-91	19
873	Large-scale characterization of public database SNPs causing non-synonymous changes in three ethnic groups. **2006**, 119, 75-83	14
872	A systematic analysis of disease-associated variants in the 3' regulatory regions of human protein-coding genes I: general principles and overview. **2006**, 120, 1-21	131
871	Prothrombin G20210A gene variant is not associated with idiopathic portal vein thrombosis in an area endemic for portal vein thrombosis. **2006**, 85, 126-8	9
870	Thrombophilic mutations in Iranian patients with infertility and recurrent spontaneous abortion. **2006**, 85, 268-71	47
869	Hypercoagulable states and strokes. **2006**, 8, 324-9	21
868	From normal to pathological hemostasis. **2006**, 53, S2-11	33
867	Estrogen therapy and thrombotic risk. **2006**, 111, 792-807	17
866	The prevalence of thrombophilia in patients with symptomatic peripheral vascular disease. **2006**, 93, 577-81	12
865	Prothrombotic risk factors in patients with recurrent thrombosis of the arteriovenous fistula. **2006**, 35, 715-730	
864	Hereditary thrombophilia in ethnic Omani patients. **2006**, 81, 101-6	16
863	Distinct association of factor V-Leiden and prothrombin G20210A mutations with deep venous thrombosis in Tunisia and Lebanon. **2006**, 81, 641-3	21
862	A prospective study of the prevalence of heparin-induced antibodies and other associated thromboembolic risk factors in pediatric patients undergoing hemodialysis. **2006**, 81, 328-34	16
861	Inherited thrombophilia is associated with deep vein thrombosis in a Colombian population. **2006**, 81, 933-7	17
860	Thrombophilias and recurrent pregnancy loss. **2006**, 24, 54-66	54

859	Deep vein thrombosis in an athletic military cadet. **2006**, 36, 686-97	15
858	Epidemiology and risk factors of venous thromboembolism. **2006**, 32, 651-8	92
857	Prophylaxis and treatment of venous thromboembolism in individuals with inherited thrombophilia. **2006**, 32, 767-80	24
856	Venous thrombosis and oral contraceptives: current status. **2006**, 2, 761-72	8
855	Disorders of coagulation in stroke. **2006**, 26, 57-64	7
854	Inherited thrombophilia and venous thromboembolism. **2006**, 32, 700-8	52
853	Mutations and polymorphisms in genes affecting haemostasis components in children with thromboembolic events. **2006**, 35, 392-7	7
852	Perinatal renal venous thrombosis: presenting renal length predicts outcome. **2006**, 91, F273-8	60
851	Homozygosity in the single nucleotide polymorphism Ser128Arg in the E-selectin gene associated with recurrent venous thromboembolism. **2006**, 166, 1655-9	28
850	Livedoid vasculopathy: further evidence for procoagulant pathogenesis. **2006**, 142, 1413-8	119
849	Travel-related venous thrombosis: results from a large population-based case control study (MEGA study). **2006**, 3, e307	113
848	Pharmacogenetics of antithrombotic drugs. **2006**, 12, 2425-35	12
847	Hereditary and acquired thrombophilic disorders. **2006**, 12, 125-35	20
846	Common genetic variation in the prothrombin gene, hormone therapy, and incident nonfatal myocardial infarction in postmenopausal women. **2006**, 163, 600-7	5
845	Lack of association between inherited thrombophilic risk factors and idiopathic sudden sensorineural hearing loss in Italian patients. **2006**, 115, 195-200	26
844	[Coagulation factor mutations and thrombosis]. **2006**, 22, 985-9	2
843	Factor V Leiden mutation in venous thrombosis in southeast Turkey. **2006**, 57, 193-6	8
842	Utility of thrombin-generation assay in the screening of factor V G1691A (Leiden) and prothrombin G20210A mutations and protein S deficiency. **2006**, 52, 665-70	30

841	Genetics of coagulation: considerations for cardiac surgery. **2006**, 10, 297-313	5
840	Brain Embolism. **2006**,	9
839	Factor V Leiden, prothrombin G20210A substitution and hormone therapy: indications for molecular screening testing / Faktor-V-Leiden, Prothrombin G20210A Substitution und Hormontherapie: Indikationen f□□molekulare Screening Tests. **2006**, 30, 317-325	
838	Prevalence of prothrombin gene mutation (G-A 20210 A) in general population: a pilot study. **2006**, 12, 223-6	3
837	Elevated alpha1-antitrypsin is a risk factor for arterial ischemic stroke in childhood. **2006**, 115, 186-91	6
836	Factor V Leiden, prothrombin G20210A substitution and hormone therapy: indications for molecular screening. **2006**, 44, 514-21	9
835	3' end processing of the prothrombin mRNA in thrombophilia. **2006**, 115, 192-7	26
834	Inherited thrombophilia: treatment during pregnancy. **2006**, 21, 281-6	20
833	Study of association between hypertensive disorders of pregnancy and the human coagulation factor XI gene. **2006**, 25, 21-31	7
832	Conjugated equine estrogen, esterified estrogen, prothrombotic variants, and the risk of venous thrombosis in postmenopausal women. **2006**, 26, 2807-12	16
831	Combined Factor V Leiden (R506Q) and prothrombin G20210A genotyping in young patients presenting with deep venous thrombosis. **2006**, 21, 24-27	2
830	Effect of Factor V Leiden and prothrombin G20210-->A mutations on thromboembolic risk in the national surgical adjuvant breast and bowel project breast cancer prevention trial. **2006**, 98, 904-10	48
829	Prediction of coronary heart disease risk using a genetic risk score: the Atherosclerosis Risk in Communities Study. **2007**, 166, 28-35	222
828	Molecular analysis of factor V Leiden, factor V Hong Kong, factor II G20210A, methylenetetrahydrofolate reductase C677T, and A1298C mutations related to Turkish thrombosis patients. **2007**, 13, 435-8	16
827	Longitudinal myelitis in patient with systemic lupus erythematosus, homozygous prothrombin G20210A and heterozygous MTHFR 677T. **2007**, 16, 517-20	6
826	Lupus anticoagulant is significantly associated with inflammatory reactions in patients with suspected deep vein thrombosis. **2007**, 67, 270-9	15
825	Lower contribution of factor V Leiden or G202104 mutations to ischemic stroke in patients with clinical risk factors: pair-matched case-control study. **2007**, 13, 188-93	7
824	The factor V Leiden, prothrombin gene 20210GA, methylenetetrahydrofolate reductase 677CT and platelet glycoprotein IIIa 1565TC mutations in patients with acute ischemic stroke and atrial fibrillation. **2007**, 38, 1069-71	33

823	Major and potential prothrombotic genotypes in patients with venous thrombosis and in healthy subjects from Slovenia. **2008**, 36, 58-63	17
822	Genomics and proteomics in venous thromboembolism: building a bridge toward a rational personalized medicine framework. **2007**, 33, 759-70	11
821	Thrombophilia: an update. **2007**, 33, 563-72	41
820	Do thrombophilias cause placenta-mediated pregnancy complications?. **2007**, 33, 597-603	20
819	Thrombophilic factors and the formation of dural arteriovenous fistulas. **2007**, 107, 56-9	24
818	Identifying women at high risk of venous thrombosis before administration of hormone therapy. **2007**, 3, 131-4	
817	Inherited thrombophilia and gestational venous thromboembolism. **2007**, 3, 215-25	
816	Emerging technologies and quality assurance: the United Kingdom National External Quality Assessment Scheme perspective. **2007**, 33, 243-9	39
815	Thrombophilia and venous thromboembolism: implications for testing. **2007**, 33, 573-81	64
814	Arterial thrombosis and the role of thrombophilia. **2007**, 33, 588-96	76
813	Hemostatic dysfunction in paraproteinemias and amyloidosis. **2007**, 33, 339-49	55
812	Incidence of deep vein thrombosis related to peripherally inserted central catheters in children and adolescents. **2007**, 177, 1185-90	65
811	Mutations in clotting factors and inflammatory bowel disease. **2007**, 102, 338-43	41
810	Intracardiac thrombosis and acute right ventricular failure following complex reoperative cardiac surgery with aprotinin and deep hypothermic circulatory arrest. **2007**, 11, 177-84	4
809	JAK2 V617F mutation in patients with catastrophic intra-abdominal thromboses. **2007**, 127, 736-43	38
808	Obstetric complications in patients with hereditary thrombophilia identified using the LCx microparticle enzyme immunoassay: a controlled study of 5,000 patients. **2007**, 127, 68-75	42
807	Relationship between thrombophilic disorders and type of severe early-onset hypertensive disorder of pregnancy. **2007**, 26, 433-45	14
806	Association of genetic variations with nonfatal venous thrombosis in postmenopausal women. **2007**, 297, 489-98	144

805	Basilar artery thrombosis in a child heterozygous for prothrombin gene G20210A mutation. **2007**, 22, 329-31		6
804	Plasma homocysteine cutoff values for venous thrombosis. **2007**, 45, 232-6		21
803	Gain-of-function gene mutations and venous thromboembolism: distinct roles in different clinical settings. **2007**, 44, 412-6		37
802	Thrombophilia and cerebral vein thrombosis. **2008**, 23, 55-76		4
801	A sequence variation scan of the coagulation factor VIII (FVIII) structural gene and associations with plasma FVIII activity levels. *Blood*, **2007**, 109, 3713-24	2.2	76
800	Thrombophilia: common questions on laboratory assessment and management. **2007**, 127-35		82
799	Antiphospholipid antibodies in Turkish children with thrombosis. **2007**, 18, 347-52		19
798	Evaluation of the presence of hereditary and acquired thrombophilias in Brazilian children and adolescents with diagnoses of portal vein thrombosis. **2012**, 55, 599-604		17
797	Severe pregnancy complications are associated with elevated factor VIII plasma activity. **2012**, 23, 184-8		5
796	Procoagulant activity in hemostasis and thrombosis: Virchow's triad revisited. **2012**, 114, 275-85		181
795	Polymorphisms in antithrombin and in tissue factor pathway inhibitor genes are associated with recurrent pregnancy loss. *Thrombosis and Haemostasis*, **2012**, 108, 693-700	7	8
794	Broadening the factor V Leiden paradox: pulmonary embolism and deep-vein thrombosis as 2 sides of the spectrum. *Blood*, **2012**, 120, 933-46	2.2	71
793	[Risk factor for residual deep vein thrombosis after fondaparinux administration in patients with postoperative replacement arthroplasty]. **2012**, 132, 683-7		
792	Low borderline plasma levels of antithrombin, protein C and protein S are risk factors for venous thromboembolism. **2012**, 10, 1783-91		46
791	PROC c.574_576del polymorphism: a common genetic risk factor for venous thrombosis in the Chinese population. **2012**, 10, 2019-26		39
790	Candidate gene study of genetic thrombophilic polymorphisms in pre-eclampsia and recurrent pregnancy loss in Sinhalese women. **2012**, 38, 1168-76		24
789	Thrombin generation: what have we learned?. **2012**, 26, 197-203		121
788	The G534E-polymorphism of the gene encoding the factor VII-activating protease is a risk factor for venous thrombosis and recurrent events. *Thrombosis Research*, **2012**, 130, 441-4	8.2	26

787	Testing for heritable thrombophilia in children at Starship Children's Hospital: an audit of requests between 2004 and 2009. **2012**, 48, 921-5		7
786	High prevalence of three prothrombotic polymorphisms among Palestinians: factor V G1691A, factor II G20210A and methylenetetrahydrofolate reductase C677T. **2012**, 34, 383-7		12
785	The frequency of factor V Leiden and prothrombin G20210A mutations in Slovak and Roma (Gypsy) ethnic group of Eastern Slovakia. **2012**, 34, 406-9		7
784	[A rare trauma-associated cause of central retinal vein occlusion in a young subject]. **2012**, 35, 426-31		6
783	Thrombosis in Hb Taybe [codons 38/39 (-ACC) (Ⅱ)]. **2012**, 36, 600-4		3
782	Activated protein C plasma levels in the fasting and postprandial states among patients with previous unprovoked venous thromboembolism. *Thrombosis Research*, **2012**, 129, 502-7	8.2	2
781	Haplotypes of the endothelial protein C receptor gene and Beh□et's disease. *Thrombosis Research*, **2012**, 129, 459-64	8.2	6
780	Characteristics of fibrin formation and clot stability in individuals with congenital type IIb protein C deficiency. *Thrombosis Research*, **2012**, 129, e142-6	8.2	7
779	Clinical and biological factors that contribute to thrombin generation in prothrombin G20210A carriers: a case-control study in a single Thrombophilia Center. *Thrombosis Research*, **2012**, 129, e266-8	8.2	5
778	Prevalence of factor V Leiden and G20210A prothrombin mutation in the Dutch Famine Birth Cohort: a possible survival advantage?. *Thrombosis and Haemostasis*, **2012**, 108, 399-401	7	7
777	Multiplex primer extension reaction and capillary electrophoresis to study the frequency of thrombophilia-related mutations in a spanish population. **2012**, 413, 1255-8		
776	Thrombophilia testing for prevention of recurrent venous thromboembolism. **2012**, 12, CD007069		13
775	Extrahepatic portal venous system thrombosis in recurrent acute and chronic alcoholic pancreatitis is caused by local inflammation and not thrombophilia. **2012**, 107, 1579-85		30
774	Upper extremity deep vein thrombosis presenting to a chiropractic clinic: a description of 2 cases. **2012**, 11, 286-92		4
773	A Duplex PCR-RFLP Assay for Simultaneous Detection of FV Leiden and Prothrombin G20210A Mutations in Women with Recurrent Miscarriage. **2012**, 4, 194-196		1
772	Prothrombin time, activated partial thromboplastin time and dilute Russell's Viper Venom times are not shorter in patients with the prothrombin G20210A mutation, and dilute Russell's Viper Venom time may be longer. *Thrombosis Research*, **2012**, 130, e134-8	8.2	
771	Risk factors for venous thromboembolism in pre-and postmenopausal women. *Thrombosis Research* , **2012**, 130, 596-601	8.2	28
770	Single Nucleotide Polymorphisms in Molecular Diagnostics. **2012**, 168-180		2

769	Thrombophilia: Assays and Interpretation. **2012**, 492-508		2
768	Factor Eight Inhibitor Bypassing Activity. **2012**, 49-63		1
767	Management of patients undergoing rhinoplasty while receiving anticoagulant therapy. **2012**, 36, 1087-9		1
766	Molecular-Genetic Analysis of Genetic Predisposition to Myocardial Infarction and Comparison of Risk Factor Population Rates in Different Countries. **2012**, 111-125		1
765	Hemocoagulative Problems in the Critically Ill Patient. **2012**,		3
764	Genetic background analysis of protein C deficiency demonstrates a recurrent mutation associated with venous thrombosis in Chinese population. *PLoS ONE*, **2012**, 7, e35773	3.7	33
763	Lack of Association between Recurrent Pregnancy Loss and Inherited Thrombophilia in a Group of Colombian Patients. **2012**, 2012, 367823		10
762	Factor V-Leiden Mutation: A Common Risk Factor for Venous Thrombosis among Lebanese Patients. **2012**, 2012, 380681		11
761	Differential haemostatic risk factors for pregnancy-related deep-vein thrombosis and pulmonary embolism: a population-based case-control study. *Thrombosis and Haemostasis*, **2012**, 108, 1165-71	7	13
760	Childhood Pulmonary Arterial Hypertension. **2012**, 1003-1018		
759	Stroke in Women - Oral Contraception, Pregnancy, and Hormone Replacement Therapy. **2012**, 11, 58-73		
758	27 Einzelfaktoren und Inhibitoren der plasmatischen Gerinnung. **2012**,		
757	A prospective study of thrombophilia in trauma patients with pulmonary embolism. **2012**, 72, 247-50		6
756	The Means of Progress in Improving the Results of in vitro Fertilization Based on the Identification and Correction of the Pathology of Hemostasis. **2012**,		2
755	Flow-simulated thrombin generation profiles as a predictor of thrombotic risk among pre-menopausal women. *Thrombosis and Haemostasis*, **2012**, 108, 258-65	7	5
754	Biomarkers of deep venous thrombosis. **2012**, 34, 335-46		29
753	Prevalence of coagulation factor II G20210A and factor V G1691A Leiden polymorphisms in Chechans, a genetically isolated population in Jordan. **2012**, 39, 9133-8		7
752	Thrombophilia - how far and how much to investigate?. **2012**, 74, 157-62		7

751	Relation between maternal thrombophilia and stillbirth according to causes/associated conditions of death. **2012**, 88, 251-4	15
750	Are thrombophilia more multifactorial than we thought: report of mosaicism for FII G20210A and novel FII T20061C gene variants. **2012**, 10, 301-3	
749	Artificially depleted plasmas are not necessarily commutable with native patient plasmas for International Sensitivity Index calibration and International Normalized Ratio derivation. **2012**, 10, 303-5	6
748	Dynamic APTT parameters: applications in thrombophilia. **2012**, 10, 244-50	8
747	The JAK2 V617F mutation in patients with cerebral venous thrombosis. **2012**, 10, 998-1003	50
746	Inherited thrombophilia and IVF failure: the impact of coagulation disorders on implantation process. **2012**, 68, 189-98	25
745	Risk of placenta-mediated pregnancy complications or pregnancy-related VTE in VTE-asymptomatic families of probands with VTE and heterozygosity for factor V Leiden or G20210 prothrombin mutation. **2012**, 89, 250-5	4
744	Factor XIII Val34Leu mutation accelerates the development of fibrosis in patients with chronic hepatitis B and C. **2012**, 42, 668-76	7
743	Elevated factor VIII levels and risk of venous thrombosis. **2012**, 157, 653-63	174
742	Prothrombin G20210A and factor V Leiden polymorphisms in stroke. **2012**, 46, 210-6	10
741	Preventing thrombophilia-related complications of pregnancy: an update. **2013**, 6, 287-300	8
740	Hormontherapie bei Thrombophilie. **2013**, 46, 170-175	
739	Genetics of coagulation: what the cardiologist needs to know. **2013**, 29, 75-88	4
738	Genome-wide linkage scan in affected sibling pairs identifies novel susceptibility region for venous thromboembolism: Genetics In Familial Thrombosis study. **2013**, 11, 1474-84	18
737	Diagnostic Molecular Genetics. **2013**, 1-31	
736	Human Gene Mutation in Inherited Disease. **2013**, 1-48	1
735	Should factor V Leiden mutation and prothrombin gene polymorphism testing be done in women with recurrent miscarriage from North India?. **2013**, 287, 375-81	13
734	Thrombophilia differences in splanchnic vein thrombosis and lower extremity deep venous thrombosis in North America. **2013**, 48, 1111-8	16

733	Prevalence of factor V Leiden (G1619A) and prothrombin gene (G20210A) mutation in Egyptian children with sickle cell disease. **2013**, 22, 697-702		2
732	Risk of venous thromboembolism associated with single and combined effects of Factor V Leiden, Prothrombin 20210A and Methylenetethraydrofolate reductase C677T: a meta-analysis involving over 11,000 cases and 21,000 controls. **2013**, 28, 621-47		90
731	Quality Issues in Heritable Thrombophilia Testing. **2013**, 217-232		
730	Overview and assessment of risk factors for pulmonary embolism. **2013**, 7, 171-91		11
729	Thrombin. **2013**, 2915-2932		4
728	Hemophilias and Other Disorders of Hemostasis. **2013**, 1-33		9
727	Common Genetic Determinants of Coagulation and Fibrinolysis. **2013**, 1-20		
726	Inherited thrombophilia in children. **2013**, 43, 163-8		4
725	The skin and hypercoagulable states. **2013**, 69, 450-62		45
724	Pathologies at the nexus of blood coagulation and inflammation: thrombin in hemostasis, cancer, and beyond. **2013**, 91, 1257-71		64
723	Prevalence of genetic risk factors related with thrombophilia and hypofibrinolysis in patients with osteonecrosis of the femoral head in Poland. **2013**, 14, 264		13
722	[Purpura fulminans, venous thrombosis and constitutional thrombophilia in an infant]. **2013**, 20, 499-502		1
721	Synergistic effect of MTHFR C677T and F2 G20210A polymorphisms on ischemic stroke. **2013**, 29, 725-30		7
720	Splanchnic vein thrombosis in myeloproliferative neoplasms. **2013**, 162, 730-47		45
719	Impaired pre-mRNA processing and altered architecture of 3' untranslated regions contribute to the development of human disorders. *International Journal of Molecular Sciences*, **2013**, 14, 15681-94	6.3	22
718	Genetic variants in pre-eclampsia: a meta-analysis. **2013**, 19, 289-303		86
717	Myocardial infarction marker levels are influenced by prothrombin and tumor necrosis factor-β gene polymorphisms in young patients. **2013**, 61, 218-22		6
716	Polymorphisms in Factor II and Factor V thrombophilia genes among Circassians in Jordan. **2013**, 35, 83-9		7

715	Common genetic risk factors for venous thrombosis in the Chinese population. **2013**, 92, 177-87		40
714	Normal reference ranges of antithrombin, protein C and protein S: effect of sex, age and hormonal status. *Thrombosis Research*, **2013**, 132, e152-7	8.2	23
713	Deciphering the combination principles of Traditional Chinese Medicine from a systems pharmacology perspective based on Ma-huang Decoction. **2013**, 150, 619-38		78
712	A brief review of 50 years of perioperative thrombosis and hemostasis management. **2013**, 50, 79-87		9
711	Correlation between thrombophilia and recurrent pregnancy loss in patients with polycystic ovary syndrome: a comparative study. **2013**, 76, 282-8		28
710	Comparative analysis of associations between polymorphic variants of the F2, F5, GP1BA, and ACE genes and the risk of developing stroke in Russian and Ukrainian populations. **2013**, 28, 8-14		2
709	Genetic polymorphisms associated with retinal vein occlusion: a Greek case-control study and meta-analysis. *Ophthalmic Genetics*, **2013**, 34, 130-9	1.2	13
708	Emerging haemostatic agents and patient blood management. **2013**, 27, 141-60		7
707	Lack of association between factor V Leiden and prothrombin G20210A polymorphisms in Tunisian subjects with a history of myocardial infarction. **2013**, 22, 39-41		8
706	Prevalence of factor V G1691A, factor II G20210A, methylenetetrahydrofolate reductase C677T and endothelial protein C receptor 23 bp insertion polymorphisms in indigenous population of Nepal. **2013**, 92, 261-2		2
705	Next-generation sequencing study finds an excess of rare, coding single-nucleotide variants of ADAMTS13 in patients with deep vein thrombosis. **2013**, 11, 1228-39		41
704	A novel prothrombin mutation in two families with prominent thrombophilia--the first cases of antithrombin resistance in a Caucasian population. **2013**, 11, 1936-9		42
703	Thrombophilic Mutations in Iranian Patients With Thrombophilia. *Laboratory Medicine*, **2013**, 44, e62-e68	1.6	
702	Pregnancy and venous thromboembolism. **2013**, 39, 549-58		65
701	Risk of venous thromboembolism in patients with inflammatory bowel disease. **2013**, 39, 461-8		37
700	PLA2 polymorphism of platelet glycoprotein IIb/IIIa but not Factor V Leiden and prothrombin G20210A polymorphisms is associated with venous thromboembolism and more recurrent events in central Iran. **2013**, 24, 471-6		8
699	Factor II activity is similarly increased in patients with elevated apolipoprotein CIII and in carriers of the factor II 20210A allele. **2013**, 2, e000440		21
698	Thrombophilia. **2013**, 19, 177-87		5

697	Fetoplacental discrepancy with normal karyotype in amniotic fluid and two different cell lines in placenta. **2013**, 2013, 951710		
696	Elevated prothrombin promotes venous, but not arterial, thrombosis in mice. **2013**, 33, 1829-36		34
695	Thrombosis in women: what are the knowledge gaps in 2013?. **2013**, 11 Suppl 1, 180-91		34
694	Current knowledge on the genetics of incident venous thrombosis. **2013**, 11 Suppl 1, 111-21		32
693	Influence of proband's characteristics on the risk for venous thromboembolism in relatives with factor V Leiden or prothrombin G20210A polymorphisms. *Blood*, **2013**, 122, 2555-61	2.2	8
692	Two targets for the price of one. *Blood*, **2013**, 122, 2529-31	2.2	7
691	Genotype of proband and thrombophilia screening. *Blood*, **2013**, 122, 2528-9	2.2	1
690	Hemorheological parameters as independent predictors of venous thromboembolism. **2013**, 53, 131-41		24
689	Predisposition to Thrombophilia and Hypofibrinolysis in Pulmonary Embolism: Analysis of Inherited Factors. *Journal of Biomedical and Clinical Research*, **2013**, 6, 73-81	0	
688	Stroke in Women - Oral Contraception, Pregnancy, and Hormone Replacement Therapy. **2013**, 11, 58-73		8
687	Familial intracranial dural arteriovenous fistulas. **2013**, 72, E310-3; discussion E313		8
686	Axial spondylectomy and circumferential reconstruction via a posterior approach. **2013**, 72, 300-8; discussion 308-9		8
685	Genotipos frecuentemente asociados a trombofilias. **2013**, 34, 132		3
684	Prevalence of variants that confer risk for venous thromboembolism in an elderly population of northeastern Brazil. **2013**, 12, 3698-707		6
683	Activated protein C anticoagulant system dysfunction and thrombophilia in Asia. **2013**, 33, 8-13		17
682	Genetic Bleeding Risk Score (GBRS) for Patients on Oral Anticoagulant Therapy. **2013**, 1,		1
681	Thrombosis from a prothrombin mutation conveying antithrombin resistance. *Japanese Journal of Thrombosis and Hemostasis*, **2013**, 24, 402-406	0	
680	Integrative bioinformatics links HNF1B with clear cell carcinoma and tumor-associated thrombosis. *PLoS ONE*, **2013**, 8, e74562	3.7	31

679	Venous Thromboembolism. **2013**, 1021-1037		
678	The role of thrombophilia in pregnancy. **2013**, 2013, 516420		41
677	Blood and Coagulation. **2013**, 615-627		
676	Thrombophilia: Clinical and Laboratory Assessment and Management. **2013**, 205-239		8
675	Genetics and Molecular Pathophysiology of Thrombotic States. **2013**,		
674	Thrombophilia in Assisted Reproductive Technology Place and Needs of Thromboprophylaxis. **2013**,		1
673	Association between thrombophilia gene polymorphisms and preeclampsia: a meta-analysis. *PLoS ONE*, **2014**, 9, e100789	3.7	17
672	Single nucleotide polymorphisms other than factor V Leiden are associated with coagulopathy and osteonecrosis of the femoral head in Chinese patients. *PLoS ONE*, **2014**, 9, e104461	3.7	13
671	Influence of single nucleotide polymorphisms on thrombin generation in factor V Leiden heterozygotes. *Thrombosis and Haemostasis*, **2014**, 111, 438-46	7	8
670	Hypercoagulable states: an algorithmic approach to laboratory testing and update on monitoring of direct oral anticoagulants. **2014**, 49, 85-94		51
669	Evaluation of chromosomal abnormalities and common trombophilic mutations in cases with recurrent miscarriage. **2014**, 14, 216-22		2
668	Survival with near Total Small Intestinal Loss Associated with Mesenteric Vein Thrombosis: A Report of Prothrombin G20210A Mutation. **2014**, 80, 147-149		
667	A novel method for predicting the risk of thrombosis and thromboembolism. **2014**, 30, 189-204		
666	Biomarkers for arterial and venous thrombotic disorders. *Hamostaseologie*, **2014**, 34, 115-20, 122-6, 128-30, passim	1.9	7
665	The real value of thrombophilia markers in identifying patients at high risk of venous thromboembolism. **2014**, 7, 757-65		11
664	Pharmacodynamic Pharmacogenomics. **2014**, 365-383		2
663	Comparison of the performance of the Cepheid Xpert HemosIL Factor II and Factor V and the ViennaLab FV-PTH-MTHFR StripAssay kits for molecular thrombophilia profiling. **2014**, 18, 183-6		
662	Comparison of high-resolution melting analysis to denaturing high performance liquid chromatography in the detection of point mutations in MEFV, F5, and F2 genes. **2014**, 44, 713-9		1

661	The 3'end prothrombin gene variants in patients with different thrombotic events. *Laboratory Medicine*, **2014**, 45, 309-14	1.6	3
660	Long-term clinical and ultrasonographic evaluation of thrombophilic patients with deep venous thrombosis. **2014**, 13, 18-26		0
659	Testing for thrombophilia: clinical update. **2014**, 64, e120-2		6
658	Inherited Thrombophilia. **2014**, 27, 227-33		12
657	Difference in fibrinolytic capacity in young patients with venous thrombosis or ischaemic stroke. **2014**, 25, 61-6		5
656	Association between prothrombin gene polymorphisms and hereditary thrombophilia in Xinjiang Kazakhs population. **2014**, 25, 114-8		3
655	Venous and Arterial Thrombosis. **2014**, 277-296		4
654	Successful living donor kidney transplantation in a patient with prothrombin gene mutation: Case report and literature review. **2014**, 30, 106-8		2
653	Influence of acquired and genetic risk factors on the prevention, management, and treatment of thromboembolic disease. **2014**, 2014, 859726		5
652	Genetic aspects of preeclampsia and the HELLP syndrome. **2014**, 2014, 910751		49
651	Detection of genetic variations in coagulopathy-related genes using ramified rolling circle amplification. **2014**, 2014, 641090		1
650	Bilateral Upper Extremity DVT in a 43-Year-Old Man: Is It Thoracic Outlet Syndrome?!. **2014**, 2014, 758010		1
649	A deep vein thrombosis caused by 20209C>T mutation in homozygosis of the prothrombin gene in a Caucasian patient. **2014**, 24, 159-66		2
648	Molecular Basis of Thrombophilia / MOLEKULARNE OSNOVE TROMBOFILIJE. **2014**, 33, 22-27		4
647	Laboratory Investigation of Thrombophilia / LABORATORIJSKO ISPITIVANJE TROMBOFILIJA. **2014**, 33, 28-46		4
646	Atypical erythrocytes and platelets in a patient with a pro-thrombin mutation. **2014**, 25, 461-2		8
645	Prothrombin G20210A mutation is associated with young-onset stroke: the genetics of early-onset stroke study and meta-analysis. **2014**, 45, 961-7		30
644	Optic nerve sheath fenestration for the treatment of papilledema secondary to cerebral venous thrombosis. **2014**, 34, 67-9		14

643	Associations of coagulation factor V Leiden and prothrombin G20210A mutations with Budd-Chiari syndrome and portal vein thrombosis: a systematic review and meta-analysis. **2014**, 12, 1801-12.e7	65
642	Vasculopat□a livedoide. **2014**, 29, 139-148	2
641	Combined genetic mutations have remarkable effect on deep venous thrombosis and/or pulmonary embolism occurence. **2014**, 536, 171-6	21
640	Isolated cortical vein thrombosis associated with prothrombin gene mutation. **2014**, 23, 791-3	2
639	Meta-analysis of hypercoagulability genetic polymorphisms in Perthes disease. **2014**, 32, 1-7	26
638	Elevated lipoprotein(a) levels and homozygous human platelet antigen 1b (HPA-1b) genotype are risk factors for intrauterine growth restriction (IUGR). **2014**, 37, 107-17	4
637	Modeling thrombin generation: plasma composition based approach. **2014**, 37, 32-44	18
636	Inherited risk factors for venous thromboembolism. **2014**, 11, 140-56	84
635	The role of genetic risk factors in arterial ischemic stroke in pediatric and adult patients: a critical review. **2014**, 41, 4241-51	15
634	Branch retinal vein occlusion and vitreovascular traction: a preliminary spectral domain OCT case-control study. **2014**, 252, 375-81	10
633	Algorithm for anticoagulation management in geriatric hip fracture patients--Surgeons save Blood. **2014**, 47, 95-104	8
632	[Importance of thrombophilia screening]. **2014**, 55, 529-30, 532-4, 536	2
631	Estrogen receptor alpha augments changes in hemostatic gene expression in HepG2 cells treated with estradiol and phytoestrogens. **2014**, 21, 155-8	9
630	Thrombophilic states. **2014**, 120, 1061-71	13
629	Evaluation of GenoFlow Thrombophilia Array Test Kit in its detection of mutations in Factor V Leiden (G1691A), prothrombin G20210A, MTHFR C677T and A1298C in blood samples from 113 Turkish female patients. **2014**, 18, 717-21	5
628	Multilocus genetic risk scores for venous thromboembolism risk assessment. **2014**, 3, e001060	44
627	Diagnosis and management of heritable thrombophilias. **2014**, 349, g4387	33
626	Microfluidic genotyping by rapid serial PCR and high-speed melting analysis. **2014**, 60, 1306-13	19

625	Ven□se Thromboembolien, Thrombophilie und Thromboseprophylaxe in Gyn□kologie und Geburtshilfe. **2014**, 47, 501-513		1
624	Influence of the β haplotype and α-thalassemia on stroke development in a Brazilian population with sickle cell anaemia. **2014**, 93, 1123-9		24
623	Influence of coronary artery disease-associated genetic variants on risk of venous thromboembolism. *Thrombosis Research*, **2014**, 134, 426-32	8.2	15
622	Increased activation of blood coagulation in pregnant women with the Factor V Leiden mutation. *Thrombosis Research*, **2014**, 134, 837-45	8.2	3
621	Inherited and acquired thrombophilias. **2014**, 21, 167-82		16
620	Hereditary hypercoagulable state and Takotsubo cardiomyopathy: a possible link. **2014**, 174, e108-9		4
619	Sex, thrombosis and inherited thrombophilia. **2014**, 28, 123-33		39
618	Study of some genetic predisposition in pulmonary embolism. **2014**, 63, 1039-1046		
617	Reduction of prothrombin and Factor V levels following supplementation with omega-3 fatty acids is sex dependent: a randomised controlled study. **2014**, 25, 997-1002		9
616	Pylephlebitis: incidence and prognosis in a tertiary hospital. **2014**, 32, 350-4		9
615	Thrombin generation in patients with idiopathic sudden sensorineural hearing loss. *Thrombosis Research*, **2014**, 133, 1130-4	8.2	7
614	[Prevalence of protein-energy undernutrition evaluated by the measurement of triceps skinfold thickness and mid-arm muscle circumference of 103 adults with cirrhosis of the liver hospitalized in the department of hepatology and gastroenterology of the Lom□ 'Campus University Hospital (Togo)]. **2014**, 24, 208-13		3
613	Circulating microparticles in carriers of prothrombin G20210A mutation. *Thrombosis and Haemostasis*, **2014**, 112, 432-7	7	10
612	A meta-analysis of genome-wide association studies identifies ORM1 as a novel gene controlling thrombin generation potential. *Blood*, **2014**, 123, 777-85	2.2	14
611	Genetics in thrombophilia. An update. *Hamostaseologie*, **2015**, 35, 47-51	1.9	17
610	De Gruyter. **2015**, 23,		
609	Genetic risk factors in patients with deep venous thrombosis, a retrospective case control study on Iranian population. *Thrombosis Journal*, **2015**, 13, 35	5.6	11
608	Thrombosis in pregnancy and maternal outcomes. **2015**, 105, 159-66		26

607	Effects of recombinant human prothrombin on thrombin generation in plasma from patients with hemophilia A and B. **2015**, 13, 1293-300		2
606	Genetics of Venous Thrombosis: update in 2015. *Thrombosis and Haemostasis*, **2015**, 114, 910-9	7	66
605	Treatable high homocysteine alone or in concert with five other thrombophilias in 1014 patients with thrombotic events. **2015**, 26, 736-42		7
604	Prothrombin G20210A and methylenetetrahydrofolate reductase C677T polymorphisms in peripheral capillary nonperfusion: a case report. **2015**, 26, 682-4		
603	Dissecting the genetic determinants of hemostasis and thrombosis. **2015**, 22, 428-36		6
602	9. Ven□Se Thromboembolien: Ursachen und Pr□Vention.		
601	Lack of association between the prothrombin rs1799963 polymorphism and juvenile myoclonic epilepsy. **2015**, 73, 289-92		1
600	Diagnostic ramifications of ocular vascular occlusion as a first thrombotic event associated with factor V Leiden and prothrombin gene heterozygosity. **2015**, 9, 591-600		15
599	Genetic aspects of thrombotic disease. *Thrombosis and Haemostasis*, **2015**, 114, 883-4	7	2
598	Coagulopathies. **2015**, 1223-1235		
597	Frequency of Factor II G20210A and Factor V Leiden Mutations in Algerian Patients with Venous Thromboembolism. **2015**, 06,		
596	Haemostaseome-associated SNPs: has the thrombotic phenotype a greater influence than ethnicity? GMT study from Aquitaine including Basque individuals. *Thrombosis and Haemostasis*, **2015**, 113, 66-76	7	1
595	Common Gene Polymorphisms Associated with Thrombophilia. **2015**,		1
594	Evaluation of a high throughput method for the detection of mutations associated with thrombosis and hereditary hemochromatosis in Brazilian blood donors. *PLoS ONE*, **2015**, 10, e0125460	3.7	2
593	Thrombophilia Associated with Anti-DFS70 Autoantibodies. *PLoS ONE*, **2015**, 10, e0138671	3.7	12
592	Family history of venous thromboembolism as a risk factor and genetic research tool. *Thrombosis and Haemostasis*, **2015**, 114, 890-900	7	28
591	Ethnic diversity in the genetics of venous thromboembolism. *Thrombosis and Haemostasis*, **2015**, 114, 901-9	7	37
590	Classic thrombophilic gene variants. *Thrombosis and Haemostasis*, **2015**, 114, 885-9	7	72

589	The Contributions of Thrombophilic Mutations to Genetic Susceptibility to Deep Venous Thrombosis in Iraqi Patients. **2015**, 19, 500-4		2
588	Differential expression of plasma miRNAs in patients with unprovoked venous thromboembolism and healthy control individuals. *Thrombosis Research*, **2015**, 136, 566-72	8.2	43
587	Shortened Activated Partial Thromboplastin Time Is Associated With Acute Ischemic Stroke, Stroke Severity, and Neurological Worsening. **2015**, 24, 2270-6		15
586	Cardiogenic embolism in the cat. **2015**, 17 Suppl 1, S202-14		8
585	High prophylactic LMWH dose successfully suppressed hemostatic activation in pregnant woman with a new prothrombin c.1787G>A mutation. *Thrombosis Research*, **2015**, 135, 420-2	8.2	2
584	Factor V Leiden mutation and high FVIII are associated with an increased risk of VTE in women with breast cancer during adjuvant tamoxifen - results from a prospective, single center, case control study. **2015**, 26, 63-7		15
583	Global assays of hemostasis in the diagnostics of hypercoagulation and evaluation of thrombosis risk. *Thrombosis Journal*, **2015**, 13, 4	5.6	62
582	The role of hypercoagulability in ischemic colitis. **2015**, 50, 848-55		12
581	Prothrombin G20210A mutation is associated with recurrent pregnancy loss: a systematic review and meta-analysis update. *Thrombosis Research*, **2015**, 135, 339-46	8.2	22
580	Genetics of ischaemic stroke in young adults. **2015**, 3, 96-106		22
579	Role of thrombophilia testing: con. **2015**, 39, 379-91		1
578	The Prevalence of the Prothrombin (F2) 20210G>A Mutation in a Cohort of Sri Lankan Patients with Thromboembolic Disorders. **2015**, 31, 356-61		3
577	Prothrombotic genetic risk factors are associated with an increased risk of liver fibrosis in the general population: The Rotterdam Study. **2015**, 63, 1459-65		21
576	Association between red cell distribution width and risk of venous thromboembolism. *Thrombosis Research*, **2015**, 136, 590-4	8.2	23
575	Investigation of the Annexin A5 M2 haplotype in 500 white European couples who have experienced recurrent spontaneous abortion. **2015**, 31, 681-8		14
574	Prophylaxis and treatment of venous thrombosis and pulmonary embolism in pregnancy. **2015**, 3, 24-30		1
573	Disorders of Thrombosis and Hemostasis in Pregnancy. **2015**,		
572	Natural anticoagulants deficiency and the risk of venous thromboembolism: a meta-analysis of observational studies. *Thrombosis Research*, **2015**, 135, 923-32	8.2	50

571	[The genetics of thrombosis in cancer]. **2015**, 144 Suppl 1, 26-30		1
570	Viscoelasticity and Ultrastructure in Coagulation and Inflammation: Two Diverse Techniques, One Conclusion. **2015**, 38, 1707-26		19
569	Prevalence and significance of two major inherited thrombophilias in infective endocarditis. **2015**, 10, 587-94		6
568	Prevalence of Hereditary Thrombophilia in Patients Older Than 75 Years With Venous Thromboembolism Referred for Thrombophilia Screening. **2015**, 70, 977-81		4
567	Prevalence of JAK2V617F mutation in deep venous thrombosis patients and its clinical significance as a thrombophilic risk factor: Indian perspective. **2015**, 21, 579-83		2
566	Tobacco smoking strongly modifies the association of prothrombin G20210A with undetermined stroke: consecutive survivors and population-based controls. **2015**, 240, 446-52		7
565	Low molecular weight heparin modulates maternal immune response in pregnant women and mice with thrombophilia. **2015**, 73, 417-27		15
564	Coagulopathies and pediatric stroke. **2015**, 08, 283-289		
563	Novel insights into the development of portal vein thrombosis in cirrhosis patients. **2015**, 9, 1421-32		22
562	Prothrombin G20210A mutation and lower extremity peripheral arterial disease: a systematic review and meta-analysis. **2015**, 50, 232-40		10
561	Thrombin generation and international normalized ratio in inherited thrombophilia patients receiving thromboprophylactic therapy. *Thrombosis Research*, **2015**, 136, 1291-8	8.2	9
560	Association between the prothrombin G20210A mutation and sudden sensorineural hearing loss in European population: a meta-analysis. *Thrombosis Research*, **2015**, 135, 73-7	8.2	
559	The early-onset preeclampsia is associated with MTHFR and FVL polymorphisms. **2015**, 291, 1303-12		24
558	Patent Foramen Ovale. **2015**,		
557	Prevalence of genetic prothrombotic risk factors: 1691G > A FV, 20210G > A PT and 677C > T MTHFR mutations in the Bosnian population. **2015**, 42, 576-80		4
556	Causes and consequences of portal vein thrombosis in 1,243 patients with cirrhosis: results of a longitudinal study. **2015**, 61, 660-7		252
555	7. Molekulargenetische Diagnostik.		
554	Matching genes with constitution and environment. *Thrombosis and Haemostasis*, **2016**, 116, 592-4	7	

553	Understanding Genetic Variations as Risk Factors for Development Venous Thrombo-Embolism (VTE). **2016**, 05,		1
552	The Efficacy of Low Molecular Weight Heparin for the Prevention of Venous Thromboembolism after Hip Fracture Surgery in Korean Patients. **2016**, 57, 1209-13		1
551	Pulmonary embolism: the diagnosis, risk-stratification, treatment and disposition of emergency department patients. **2016**, 3, 117-125		41
550	Common genetic risk factors of venous thromboembolism in Western and Asian populations. **2016**, 15, 15017644		8
549	Retinal vascular occlusion: a window to diagnosis of familial and acquired thrombophilia and hypofibrinolysis, with important ramifications for pregnancy outcomes. **2016**, 10, 1479-86		4
548	Hereditary Thrombophilic Factors in Glaucoma. **2016**, 25, 203-7		4
547	Thrombophilic risk of individuals with rare compound factor V Leiden and prothrombin G20210A polymorphisms: an international case series of 100 individuals. **2016**, 97, 353-60		9
546	Association Between Thrombophilic Gene Mutations and the Risk of Vascular Access Thrombosis in Hemodialysis Patients. **2016**, 20, 107-11		4
545	Molecular Diagnostic Approaches to Hemostasis. **2016**, 27-41		1
544	Association of and prothrombin polymorphisms with susceptibility to myocardial infarction. **2016**, 5, 361-366		6
543	Inherited thrombophilia: a double-edged sword. **2016**, 2016, 1-9		46
542	Antiplatelet agents for the treatment of deep venous thrombosis. **2016**,		2
541	Imaging and laboratory diagnosis. 78-128		
540	Trombofilia y trombosis. **2016**, 12, 1284-1292		
539	Duration of oral contraceptive use and the risk of venous thromboembolism. A case-control study. *Thrombosis Research*, **2016**, 141, 153-7	8.2	4
538	Vitamin K-Dependent Protein Activity and Incident Ischemic Cardiovascular Disease: The Multi-Ethnic Study of Atherosclerosis. **2016**, 36, 1037-42		17
537	Congenital and Acquired Hypercoagulable States. **2016**, 435-452		0
536	Processing and transcriptome expansion at the mRNA 3' end in health and disease: finding the right end. **2016**, 468, 993-1012		26

535	Prenatal Screening for Thrombophilias: Indications and Controversies, an Update. **2016**, 36, 421-34		8
534	New Prothrombin Mutation (Arg596Trp, Prothrombin Padua 2) Associated With Venous Thromboembolism. **2016**, 36, 1022-9		38
533	Coagulation disorders and their cutaneous presentations: Pathophysiology. **2016**, 74, 783-92; quiz 793-4		7
532	Polymorphisms of the coagulation system and risk of cancer. *Thrombosis Research*, **2016**, 140 Suppl 1, S49-54	8.2	10
531	Bilateral Superficial Femoral Artery Thrombosis in a 15-Year-Old Caucasian Male with Homozygous Prothrombin G20210A Genotype and Associated Antiphospholipid Syndrome. **2016**, 25, e100-e105		2
530	Frequency and association of 1691 (G>A) FVL, 20210 (G>A) PT and 677 (C>T) MTHFR with deep vein thrombosis in the population of Bosnia and Herzegovina. **2016**, 19, 43-50		5
529	Pregnancy outcome after a first episode of cerebral vein thrombosis. **2016**, 14, 2386-2393		12
528	Calciphylaxis: A Disease of Pannicular Thrombosis. **2016**, 91, 1395-1402		33
527	Association of Mycobacterium infections in patients with Mendelian susceptibility to mycobacterial disease with venous thromboembolism. **2016**, 60, 678-686		1
526	Hereditary risk factors for thrombophilia and probability of venous thromboembolism during pregnancy and the puerperium. *Blood*, **2016**, 128, 2343-2349	2.2	45
525	Epidemiology of Familial Aggregation of Venous Thromboembolism. **2016**, 42, 821-832		7
524	Genetic Risk Factors in Venous Thromboembolism. *Advances in Experimental Medicine and Biology*, **2017**, 906, 253-272	3.6	27
523	Genetic risk factors for venous thrombosis in the elderly in a case-control study. **2016**, 14, 1759-64		7
522	Disseminated intravascular coagulation at diagnosis is a strong predictor for thrombosis in acute myeloid leukemia. *Blood*, **2016**, 128, 1854-1861	2.2	47
521	Rolling Circle Amplification (RCA). **2016**,		2
520	Environmental and Genetic Risk Factors Associated with Venous Thromboembolism. **2016**, 42, 808-820		70
519	Pathology, anatomy, and pathophysiology of stroke. 19-54		1
518	Non-atherosclerotic vasculopathies. 386-438		0

517	Associations of recurrent miscarriages with chromosomal abnormalities, thrombophilia allelic polymorphisms and/or consanguinity in Saudi Arabia. **2016**, 17, 69		18
516	Retrospective evaluation of shortened prothrombin time or activated partial thromboplastin time for the diagnosis of hypercoagulability in dogs: 25 cases (2006-2011). **2016**, 26, 398-405		17
515	Periprocedural Anticoagulation Management of Patients with Thrombophilia. **2016**, 129, 986-92		2
514	Association Between the G20210A Polymorphism of Prothrombin Gene and Myocardial Infarction in Tunisian Population. **2016**, 54, 653-64		1
513	[Hereditary thrombophilia testing and its therapeutic impact on venous thromboembolism disease: Results from a retrospective single-center study of 162´patients]. **2016**, 37, 661-666		2
512	Pediatric Thromboembolism in Japan. **2016**, 83, 1077-81		
511	Global prevalence of prothrombin gene mutation G20210A and implications in women's health: a systematic review. **2016**, 27, 481-9		15
510	Issues in the Diagnosis and Management of Hereditary Antithrombin Deficiency. **2016**, 50, 758-67		25
509	Genetic association of PROC variants with pulmonary embolism in Northern Chinese Han population. **2016**, 5, 147		1
508	Two-panel molecular testing for genetic predisposition for thrombosis using multi-allele visual biosensors. **2016**, 408, 1943-52		5
507	High coagulation factor VIII and von Willebrand factor in patients with lymphoma and leukemia. *International Journal of Hematology*, **2016**, 103, 189-95	2.3	6
506	Lifetime Risk of Venous Thromboembolism in Two Cohort Studies. **2016**, 129, 339.e19-26		62
505	Effects of MTHFR c.677C>T, F2 c.20210G>A and F5 Leiden Polymorphisms in Gastroschisis. **2016**, 29, 88-92		11
504	Primary thrombophilia in Mexico: a single tertiary referral hospital experience. **2016**, 27, 920-924		1
503	Hematologic Disorders and Stroke. **2016**, 680-694.e5		
502	Seeing through thick and through thin: Retinal manifestations of thrombophilic and hyperviscosity syndromes. **2016**, 61, 236-47		18
501	The European Hematology Association Roadmap for European Hematology Research: a consensus document. **2016**, 101, 115-208		46
500	Guidance for the evaluation and treatment of hereditary and acquired thrombophilia. **2016**, 41, 154-64		158

499	Tissue Factor Pathway Inhibitor Gene Polymorphism -33T´->´C Predicts Improved Disease-Free Survival in Colorectal Cancer. **2016**, 23, 2274-80		4
498	Principles of Critical Care in Obstetrics. **2016**,		
497	Association of thrombogenic genes polymorphisms with hepatocellular carcinoma in HCV Egyptian patients. **2016**, 580, 37-40		2
496	A Study on Hereditary Thrombophilia and Stroke in a Cohort from Sri Lanka. **2016**, 25, 102-9		1
495	Pulmonary Thromboembolism. **2016**, 1001-1030.e10		3
494	Variant alleles in factor V, prothrombin, plasminogen activator inhibitor-1, methylenetetrahydrofolate reductase and risk of thromboembolism in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab. **2017**, 17, 331-336		6
493	Genetic Risk Factors of Venous Thromboembolism in the East Algerian Population. **2017**, 23, 105-115		3
492	Frequency of three prothrombotic polymorphisms among Syrian population: factor V G1691A, prothrombin G20210A and methylenetetrahydrofolate reductase C677T. **2017**, 44, 70-73		2
491	Impact of Thrombophilia on the Risk of Hypoxic-Ischemic Encephalopathy in Term Neonates. **2017**, 23, 266-273		4
490	Fibrinogen and Fibrin in Hemostasis and Thrombosis. **2017**, 37, e13-e21		154
489	Thrombophilia Screening: Universal, Selected, or Neither?. **2017**, 23, 893-899		15
488	Atherosclerotic and thrombotic genetic and environmental determinants in Egyptian coronary artery disease patients: a pilot study. **2017**, 17, 26		14
487	New clotting disorders that cast new light on blood coagulation and may play a role in clinical practice. **2017**, 44, 71-75		4
486	Association Between the 20210G>A Prothrombin Gene Polymorphism and Arterial Ischemic Stroke in Children and Young Adults-Two Meta-analyses of 3586 Cases and 6440 Control Subjects in Total. **2017**, 69, 93-101		7
485	Gender-related differences in the outcome of patients with venous thromboembolism and thrombophilia. *Thrombosis Research*, **2017**, 151 Suppl 1, S11-S15	8.2	4
484	An Unexpectedly High Rate of Thrombophilia Disorders in Patients with Superficial Vein Thrombosis of the Lower Extremities. **2017**, 43, 272-277		2
483	Optimal utilization of thrombophilia testing. **2017**, 39 Suppl 1, 104-110		10
482	Genetics of suspected thrombophilia in Serbian females with infertility, including three cases, homozygous for FII 20210A or FV 1691A mutations. **2017**, 20, 132-139		10

481	Do Factor V Leiden and Prothrombin G20210A Mutations Predict Recurrent Venous Thromboembolism in Older Patients?. **2017**, 130, 1220.e17-1220.e22		5
480	Deep Vein Thrombosis in the Elderly. **2017**, 79-94		
479	Genetic markers for inherited thrombophilia are associated with fetal growth retardation in the population of Central Russia. **2017**, 43, 1139-1144		20
478	Genome Analysis and Human Health. **2017**,		
477	The role of FV 1691G>A, FII 20210G>A mutations and MTHFR 677C>T; 1298A>C and 103G>T FXIII gene polymorphisms in pathogenesis of intraventricular hemorrhage in infants born before 32 weeks of gestation. **2017**, 33, 1201-1208		8
476	Deep Venous Thrombosis of the Upper and Lower Extremity. **2017**, 40, 230-236		10
475	Pathogenesis and Epidemiology of Venous Thromboembolic Disease. **2017**, 40, 191-200		4
474	Hematological Disorders in Children. **2017**,		2
473	The effects of Factor II (rs1799963) polymorphism on recurrent pregnancy loss in Iranian Azeri women. **2017**, 13, 37-40		7
472	Plasminogen activator inhibitor-1 4G/5G genotype and residual venous occlusion following acute unprovoked deep vein thrombosis of the lower limb: A prospective cohort study. *Thrombosis Research*, **2017**, 153, 71-75	8.2	1
471	Genetic Analysis of Venous Thromboembolism in UK Biobank Identifies the ZFPM2 Locus and Implicates Obesity as a Causal Risk Factor. **2017**, 10,		52
470	Vascular Disease in Older Adults. **2017**,		1
469	Copy number variation profile in the placental and parental genomes of recurrent pregnancy loss families. *Scientific Reports*, **2017**, 7, 45327	4.9	15
468	A genetic risk factor for thrombophilia in a Han Chinese family. **2017**, 15, 1668-1672		3
467	Bias from depletion of susceptibles: the example of hormone replacement therapy and the risk of venous thromboembolism. **2017**, 26, 554-560		26
466	Gene Variations in the Protein C and Fibrinolytic Pathway: Relevance for Severity and Outcome in Pediatric Sepsis. **2017**, 43, 36-47		1
465	Outcome of Patients with Venous Thromboembolism and Factor V Leiden or Prothrombin 20210 Carrier Mutations During the Course of Anticoagulation. **2017**, 130, 482.e1-482.e9		5
464	Incidence, risk factors, and outcomes of central venous catheter-related thromboembolism in breast cancer patients: the CAVECCAS study. **2017**, 6, 2732-2744		19

463	Is there a link among thrombophilia factors and preeclampsia?. **2017**, 44, 516-518		3
462	Prothrombin G20210A (rs1799963) polymorphism increases myocardial infarction risk in an age-related manner: A systematic review and meta-analysis. *Scientific Reports*, **2017**, 7, 13550	4.9	9
461	Are Prothrombotic Mutations a Time-to-Event Risk Factor?. *Laboratory Medicine*, **2017**, 48, 326-331	1.6	
460	Factor XIII levels and factor XIII B subunit polymorphisms in patients with venous thromboembolism. *Thrombosis Research*, **2017**, 158, 93-97	8.2	9
459	Epidemiology, Pathophysiology, Stratification, and Natural History of Pulmonary Embolism. **2017**, 20, 135-140		53
458	Clinical significance of prothrombin G20210A mutation in homozygous patients. **2017**, 92, E618-E620		4
457	Does exist a correlation between endometriosis and thrombophilic disorders? A pilot study. **2017**, 56, 371-373		
456	Risk of recurrent venous thromboembolism in COPD patients: results from a prospective cohort study. **2017**, 50,		8
455	An Overview of Thrombophilia and Associated Laboratory Testing. **2017**, 1646, 113-135		21
454	Risks of Factor V rs6020 or Methylenetetrahydrofolate Reductase rs12121543 Polymorphism with Hyperhomocysteinemia in the Development of Osteonecrosis of the Femoral Head. **2017**, 01, 061-066		3
453	In vitro exploration of latent prothrombin mutants conveying antithrombin resistance. *Thrombosis Research*, **2017**, 159, 33-38	8.2	6
452	Primary Thrombophilia in M□xico XI: Activated Protein C Resistance Phenotypes are Multifactorial. **2017**, 33, 375-379		0
451	Pharmacogenomics and pharmacogenetics for the intensive care unit: a narrative review. **2017**, 64, 45-64		24
450	Red cell distribution width and the risk of cerebral vein thrombosis: A case-control study. **2017**, 38, 46-51		9
449	A novel mutation in exon 2 of FGB caused by c.221G>T substitution, predicting the replacement of the native Arginine at position 74 with a Leucine (p.Arg74Leu) in a proband from a Kurdish family with dysfibrinogenaemia and familial venous and arterial thrombosis. **2017**, 43, 263-270		3
448	Thrombosis and Embolism: from Research to Clinical Practice. *Advances in Experimental Medicine and Biology*, **2017**,	3.6	0
447	Prevalence of Factor V Leiden-G1691A and MTHFR-C677T Thrombosis Gene Modifier in Iron Deficiency Anemia: A Pathophysiological Effect in Indian Isolates. **2017**, 32, 103-105		2
446	Frequency of Thrombophilic Gene Mutations in Patients with Deep Vein Thrombosis and in Women with Recurrent Pregnancy Loss. **2017**, 12, 162-166		5

445	Plasma fibrin clot properties in the G20210A prothrombin mutation carriers following venous thromboembolism: the effect of rivaroxaban. *Thrombosis and Haemostasis*, **2017**, 117, 1739-1749	7	15
444	New findings on venous thrombogenesis. *Hamostaseologie*, **2017**, 37, 25-35	1.9	31
443	10. Thromboseneigung in der Schwangerschaft. **2017**, 243-270		
442	Personalized Medicine for Coagulopathies. **2017**, 473-483		
441	Inherited Thrombophilia in Pediatric Venous Thromboembolic Disease: Why and Who to Test. **2017**, 5, 50		26
440	Whole exome sequencing in thrombophilic pedigrees to identify genetic risk factors for venous thromboembolism. *PLoS ONE*, **2017**, 12, e0187699	3.7	8
439	Rare Genetic Causes of Stroke. **2017**, 545-554		
438	The c.1787G>T and c.1787G>A Mutations are not Found in the Prothrombin Gene in a Spanish Population. **2017**, 09,		
437	Investigation of a Thrombotic Tendency. **2017**, 410-424		
436	Genetic tests for low- and middle-income countries: a literature review. **2017**, 16,		5
435	Risk of colorectal cancer and clotting factor gene polymorphisms in Moroccan Population. **2017**, 5, 1141-1146		2
434	Molecular and Cytogenetic Analysis. **2017**, 126-164		2
433	High prevalence of factor V Leiden and prothrombin G20101A mutations in Kashmiri patients with venous thromboembolism. **2018**, 654, 1-9		5
432	Optimisation of antithrombin resistance assay as a practical clinical laboratory test: Development of prothrombin activator using factors Xa/Va and automation of assay. **2018**, 40, 312-319		2
431	Prothrombin gene mutation in Budd-Chiari syndrome-The first case report from India. **2018**, 37, 174-175		1
430	The Personal Genome Project Canada: findings from whole genome sequences of the inaugural 56 participants. **2018**, 190, E126-E136		37
429	Structure-function studies of prothrombin Amrita, a dysfunctional prothrombin characterized by point mutation at Arg553 -> Gln. **2018**, 110, 550-557		6
428	Family history of venous thromboembolism predicts the diagnosis of acute pulmonary embolism in the emergency department. **2018**, 36, 1550-1554		2

427	Advances in predicting venous thromboembolism risk in children. **2018**, 180, 654-665		8
426	Prothrombin: Another Clotting Factor After FV That Is Involved Both in Bleeding and Thrombosis. **2018**, 24, 845-849		4
425	Prothrombotic genotypes and risk of venous thromboembolism in cancer. *Thrombosis Research*, **2018**, 164 Suppl 1, S12-S18	8.2	11
424	Anomal□as constitucionales de la coagulaci□ñ que predisponen a la trombosis venosa. *EMC - Tratado De Medicina*, **2018**, 22, 1-8	0	
423	Recurrent thrombosis in patients with antiphospholipid antibodies treated with vitamin K antagonists or rivaroxaban. **2018**, 103, e315-e317		18
422	Association of genetic variants of hemostatic genes with myocardial infarction in Egyptian patients. **2018**, 641, 212-219		3
421	Platelet to Lymphocyte Ratio and Neutrophil to Lymphocyte Ratio as Risk Factors for Venous Thrombosis. **2018**, 24, 808-814		32
420	Hereditary thrombophilia in trauma patients with venous thromboembolism: Is routine screening necessary?. **2018**, 84, 330-333		6
419	Thrombotic and Hemorrhagic Conditions Due to a Gain of Function of Coagulation Proteins: A Special Type of Clotting Disorders. **2018**, 24, 560-565		1
418	The fine art of vascular wall maintenance. Carriership of XPC, TP53 and APOE polymorphisms may be a risk factor for cerebral vascular accidents in the Bulgarian population. **2018**, 32, 1558-1566		1
417	Fibrinogen and factor XIII: newly recognized roles in venous thrombus formation and composition. **2018**, 25, 358-364		14
416	Vitamin K-Dependent Coagulation Factors That May be Responsible for Both Bleeding and Thrombosis (FII, FVII, and FIX). **2018**, 24, 42S-47S		14
415	Single Nucleotide Polymorphism in Patients with Vein Thrombosis in the Population of Latvia. **2018** , 14,		1
414	Venous thromboembolism laboratory testing (factor V Leiden and factor II c.*97G>A), 2018 update: a technical standard of the American College of Medical Genetics and Genomics (ACMG). **2018**, 20, 1489-1498		13
413	Genetics. **2018**, 125-189		
412	Hemostasis and Thrombosis. **2018**, 57-105.e4		3
411	Elevated coagulation factor levels affect the tissue factor-threshold in thrombin generation. *Thrombosis Research*, **2018**, 172, 104-109	8.2	7
410	Risk factors for deep vein thrombosis of lower extremities in Sudanese women. **2018**, 14, 157-164		2

409	Hematologic Disorders. **2018**, 36, 553-565		1
408	Common Conditions Requiring Long-Term Anticoagulation in Neurosurgical Patients. **2018**, 29, 529-535		
407	Alpha 2-macroglobulin 5 bp insertion/deletion polymorphism increases the risk of recurrent venous thromboembolism. **2018**, 13, 104-109		
406	Large-scale identification of functional microRNA targeting reveals cooperative regulation of the hemostatic system. **2018**, 16, 2233-2245		15
405	Risk of venous thromboembolism in association with factor V leiden in cancer patients - The EDITH case-control study. *PLoS ONE*, **2018**, 13, e0194973	3.7	5
404	The association between cardiovascular disease gene mutations and recurrent pregnancy loss in the Lebanese population. **2018**, 45, 911-916		3
403	Next-generation DNA sequencing to identify novel genetic risk factors for cerebral vein thrombosis. *Thrombosis Research*, **2018**, 169, 76-81	8.2	2
402	Gerinnungsst□ □ungen der Frau. **2018**, 12, 231-249		
401	Factor V Leiden G1691A and prothrombin G20210A mutations among Palestinian patients with sickle cell disease. **2018**, 18, 1		12
400	Management of Low-Risk Pulmonary Embolism. **2018**, 39, 561-568		2
399	Elevated plasma levels of P-selectin glycoprotein ligand-1-positive microvesicles in patients with unprovoked venous thromboembolism. **2018**, 16, 1546		7
398	Epidemiology, Pathophysiology, and Natural History of Pulmonary Embolism. **2018**, 35, 92-98		48
397	Molecular Basis of Hemostatic and Thrombotic Diseases. **2018**, 277-297		1
396	Influence of tissue factor polymorphisms (603A>G and 5466A>G) on plasma tissue factor levels and their impact on deep vein thrombosis risk in young Indian population. **2018**, 46, 88-94		
395	Neonatal Bleeding and Thrombotic Disorders. **2018**, 1121-1138.e4		
394	Factor V levels and risk of venous thrombosis: The MEGA case-control study. *Research and Practice in Thrombosis and Haemostasis*, **2018**, 2, 320-326	5.1	7
393	Do hospital doctors test for thrombophilia in patients with venous thromboembolism?. **2018**, 46, 238-243		3
392	Increased Activated Protein C Response Rates Reduce the Thrombotic Risk of Factor V Leiden Carriers But Not of Prothrombin 20210G>A Carriers. **2019**, 125, 523-534		4

391	Thrombophilieabkl□□ung im Hinblick auf □□strogenhaltige Kontrazeptiva und Hormonersatztherapie. **2019**, 17, 139-147		
390	High risk of thrombosis recurrence in patients with homozygous and compound heterozygous factor V R506Q (Factor V Leiden) and prothrombin G20210A. *Thrombosis Research*, **2019**, 182, 75-78	8.2	9
389	Genotype phenotype correlation in a pediatric population with antithrombin deficiency. **2019**, 178, 1471-1478		4
388	Alternative cleavage and polyadenylation in health and disease. **2019**, 20, 599-614		137
387	Elevated Complement C3 and C4 Levels are Associated with Postnatal Pregnancy-Related Venous Thrombosis. *Thrombosis and Haemostasis*, **2019**, 119, 1481-1488	7	2
386	Molecular coagulation and thrombophilia. **2019**, 207-220		
385	Genome-wide association analysis of venous thromboembolism identifies new risk loci and genetic overlap with arterial vascular disease. **2019**, 51, 1574-1579		56
384	Diagnostic potential of circulating micro RNA hsa-miR-320 in patients of high altitude induced deep vein thrombosis: An Indian study. **2019**, 17, 100550		2
383	Assessment of genetic and non-genetic risk factors for venous thromboembolism in glioblastoma - The predictive significance of B blood group. *Thrombosis Research*, **2019**, 183, 136-142	8.2	2
382	Thrombophilie und Alter □wann ist eine Hormontherapie in der Postmenopause trotzdem m□□glich?. **2019**, 17, 154-160		
381	Clinical and laboratory manifestations of the prothrombin gene mutation in women of reproductive age. **2019**, 10, 255-263		8
380	Genetics of Vascular Diseases. **2019**, 245-269		
379	Advances in understanding the molecular mechanisms of venous thrombosis. **2019**, 186, 13-23		14
378	Thrombotic events in severe FXII deficiency in comparison with unaffected family members during a long observation period. **2019**, 47, 481-485		8
377	Effect of prothrombotic genotypes on the risk of venous thromboembolism in patients with and without ischemic stroke. The Troms□□Study. **2019**, 17, 749-758		3
376	Thrombophilia, risk factors and prevention. **2019**, 12, 147-158		23
375	Genetics of venous thromboembolism revised. *Blood*, **2019**, 134, 1568-1570	2.2	6
374	How I treat patients with hereditary antithrombin deficiency. *Blood*, **2019**, 134, 2346-2353	2.2	8

373	Rare bleeding disorders and advances in gene therapy. **2019**, 30, 371-378		0
372	A Successful Collaborative Approach to the Perioperative Management After Hip Arthroscopy of a Patient with Heterozygous Prothrombin G20210A Mutation: A Case Report. **2019**, 9, e0376		1
371	Thrombophilia evaluation in pulmonary embolism. **2019**, 34, 603-609		6
370	Influence of Blood Count, Cardiovascular Risks, Inherited Thrombophilia, and JAK2 V617F Burden Allele on Type of Thrombosis in Patients With Philadelphia Chromosome´Negative Myeloproliferative Neoplasms. **2019**, 19, 53-63		15
369	Human Genomic Variants and Inherited Disease: Molecular Mechanisms and Clinical Consequences. **2019**, 125-200		0
368	Direct blood PCR: TaqMan-probe based detection of the venous thromboembolism associated mutations factor V Leiden and prothrombin c.20210G>A without DNA extraction. **2019**, 488, 221-225		3
367	The influence of specific mutations in the AT gene (SERPINC1) on the type of pregnancy related complications. *Thrombosis Research*, **2019**, 173, 12-19	8.2	9
366	High levels of coagulation factors and venous thrombosis risk: strongest association for factor´VIII and von Willebrand factor. **2019**, 17, 99-109		43
365	Blood and Coagulation. **2019**, 837-848		
364	[Risk factors for thromboembolic disease in young women-the role of hormones]. **2019**, 36, 219-226		1
363	Diagnostic Molecular Genetics. **2019**, 165-203		
362	Thrombophilia: Clinical and Laboratory Assessment and Management. **2019**, 242-265		1
361	Antiphospholipid antibodies are associated with positive screening for common mental disorders in women with previous pregnancy loss. The NOHA-PSY observational study. **2019**, 20, 51-63		8
360	Venous Thrombosis in Pediatric Inflammatory Bowel Disease. **2020**, 216, 213-217		0
359	Thrombotic disorders and laboratory assessment. **2020**, 720-745		
358	Venous thromboembolism GWAS reported genetic makeup and the hallmarks of cancer: Linkage to ovarian tumour behaviour. **2020**, 1873, 188331		5
357	Coagulation and bleeding disorders. **2020**, 341-352		
356	17β-Estradiol and the glucocorticoid clobetasol propionate affect the blood coagulation cascade in zebrafish. **2020**, 259, 113808		5

355	Prothrombin Arg541Trp Mutation Leads to Defective PC (Protein C) Pathway Activation and Constitutes a Novel Genetic Risk Factor for Venous Thrombosis. **2020**, 40, 483-494		5
354	Label-Free Oligonucleotide-Based SPR Biosensor for the Detection of the Gene Mutation Causing Prothrombin-Related Thrombophilia. **2020**, 20,		2
353	Association between congenital thrombophilia and outcomes in pulmonary embolism patients. **2020**, 4, 5958-5965		6
352	Double-homozygosity for Factor V Leiden and Prothrombin c.*97G > A Mutation in a Young Female with Recurrent Fetal Losses and no Venous Thromboembolism. **2020**, 22, 200425		1
351	Genetic risk factors for venous thromboembolism. **2020**, 13, 971-981		11
350	Coagulation Changes during Central Hypovolemia across Seasons. **2020**, 9,		2
349	Prothrombotic genotypes and risk of major bleeding in patients with incident venous thromboembolism. *Thrombosis Research*, **2020**, 191, 82-89	8.2	1
348	Guidelines on the laboratory aspects of assays used in haemostasis and thrombosis. **2020**, 191, 347-362		5
347	Evaluation of factor VIII value in normal women and whom encountered recurrent pregnancy loss: is there any significant difference?. **2020**, 9, 1034		
346	Emerging Roles of RNA 3'-end Cleavage and Polyadenylation in Pathogenesis, Diagnosis and Therapy of Human Disorders. **2020**, 10,		21
345	Oxidative Stress and Thrombosis during Aging: The Roles of Oxidative Stress in RBCs in Venous Thrombosis. *International Journal of Molecular Sciences*, **2020**, 21,	6.3	22
344	Targeted gene expression study using TaqMan low density array to gain insights into venous thrombo-embolism (VTE) pathogenesis at high altitude. **2020**, 82, 102421		2
343	Genomic susceptibility in practice: The regulatory trajectory of non-rare thrombophilia (NRT) genetic tests in the clinical management of venous thrombo-embolism (VTE). **2020**, 112903		2
342	Small ubiquitin-related modifier (SUMO) 3 and SUMO4 gene polymorphisms in Parkinson's disease. **2020**, 42, 451-457		1
341	Workflow for the Implementation of Precision Genomics in Healthcare. **2020**, 11, 619		1
340	Dataset of GWAS-identified variants underlying venous thromboembolism susceptibility and linkage to cancer aggressiveness. **2020**, 30, 105399		2
339	Loop-mediated isothermal amplification (LAMP)-based method for detecting factor V Leiden and factor II G20210A common variants. **2020**, 50, 908-912		1
338	Structure, mechanical properties, and modeling of cyclically compressed pulmonary emboli. **2020**, 105, 103699		5

337	The Silence Speaks, but We Do Not Listen: Synonymous c.1824C>T Gene Variant in the Last Exon of the Prothrombin Gene as a New Prothrombotic Risk Factor. **2020**, 66, 379-389		4
336	The relationship of a Prothrombin G20210A mutation or a factor V Leiden mutation and on-aspirin platelet (re-)activity. **2020**, 19, 127-130		
335	Managing thromboembolic risk in patients with hereditary and acquired thrombophilias. *Blood*, **2020**, 135, 344-350	2.2	9
334	Thrombophilia screening revisited: an issue of personalized medicine. **2020**, 49, 618-629		16
333	Two sides of the same medal: Noncoding mutations reveal new pathological mechanisms and insights into the regulation of gene expression. **2021**, 12, e1616		0
332	Role of prothrombin 19911 A>G polymorphism, blood group and male gender in patients with venous thromboembolism: Results of a German cohort study. **2021**, 51, 494-501		2
331	Partial F8 gene duplication (factor VIII Padua) associated with high factor VIII levels and familial thrombophilia. *Blood*, **2021**, 137, 2383-2393	2.2	3
330	The utility of thrombophilia and hematologic screening in live liver donation. **2021**, 35, e14159		1
329	ADAMTS13 activity, high VWF and FVIII levels in the pathogenesis of deep vein thrombosis. *Thrombosis Research*, **2021**, 197, 132-137	8.2	3
328	Coagulation Characterization of Prothrombin 20209C > T Variant: About 27 New Cases. *Thrombosis and Haemostasis*, **2021**, 121, 246-249	7	
327	Education Case: Hereditary Thrombophilia With Double Heterozygous Factor V Leiden and Factor II c.*97G>A Mutations. **2021**, 8, 2374289521990788		
326	Genetic and Clinical Predictors of Left Atrial Thrombus: A Single Center Case-Control Study. **2021**, 27, 10760296211021171		1
325	Association of venous thromboembolism and myocardial infarction with Factor V Leiden and Factor II gene mutations among Libyan patients. **2021**, 16, 1857525		
324	Early-onset ischaemic stroke in patient with novel F2 c.1824C>T gene variant and PAI-1 4G/4G, MTHFR 677TT genotype. **2021**, 66-66		
323	Neonatal Thrombosis. **2021**, 312-328		
322	Venous thromboembolism is caused by prothrombin p.Arg541Trp mutation in Japanese individuals. **2021**, 8, 13		1
321	Prevalence of thrombophilia-associated genetic risk factors in blood donors of a regional hospital in southern Brazil. **2021**,		1
320	Levels of Lipid Parameters in Children with Arterial Ischemic Stroke and Headache: Case-Control Study and Meta-Analysis. **2021**, 11,		0

319	Venous Thromboembolism: Genetics and Thrombophilias. **2021**, 42, 271-283		0
318	Inherited Thrombophilias in Thrombosis Advancement in Microvascular Flap Surgery. **2021**, 75, 113-120		
317	Severe thrombophilia in a factor V-deficient patient homozygous for the Ala2086Asp mutation (FV Besan□□n). **2021**, 19, 1186-1199		2
316	Impact of double heterozygosity for Factor V Leiden and Prothrombin G20210A on the thrombotic phenotype. *Thrombosis Research*, **2021**, 200, 121-127	8.2	1
315	Diagnosis and Management of Pediatric Venous Thromboembolism: New Therapies on the Horizon. **2021**, 37, 273-279		
314	Rare variants in MTHFR predispose to occurrence and recurrence of pulmonary embolism. **2021**, 331, 236-242		3
313	Thrombophilia in obstetric practice. **2021**, 99, 15-20		
312	Epidemiology and Genetics of Venous Thromboembolism and Chronic Venous Disease. **2021**, 128, 1988-2002		3
311	Pregnancy complications in G20210A mutation carriers associated with high prothrombin activity. *Thrombosis Journal*, **2021**, 19, 41	5.6	2
310	Non-invasive imaging of gene expression and protein secretion dynamics in living mice uncovers ectopic prothrombin expression as driver of thrombosis in cancer.		
309	PlA2 Polymorphism of Platelet Glycoprotein IIb/IIIa and C677T Polymorphism of Methylenetetrahydrofolate Reductase (), but Not Factor V Leiden and Prothrombin G20210A Polymorphisms, Are Associated with More Severe Forms of Legg-Calv□□Perthes Disease. **2021**, 8,		1
308	Factor V Leiden G1691A and Prothrombin Gene G20210A Mutations on Pregnancy Outcome. *Cureus*, **2021**, 13, e17185	1.2	0
307	Mutations in cis that affect mRNA synthesis, processing and translation. **2021**, 1867, 166166		1
306	Prevalence of thrombophilia-associated mutations and their clinical significance in a large cohort of Lebanese patients. **2021**, 29, 100936		
305	Acute Pulmonary Embolism. **2022**, 700-722		
304	Hematologic Disorders and Stroke. **2022**, 592-603.e6		
303	Research Progress on Thrombosis Mechanism in High Altitude Environment. *Advances in Clinical Medicine*, **2021**, 11, 2361-2367	0	
302	Inherited Thrombophilias and Early Pregnancy Loss. **2006**, 229-243		1

301	Coagulation Disorders. **2006**, 871-882	2
300	Hypercoagulable State. **2007**, 2423-2438	1
299	Coagulation Disorders. **2016**, 203-223	2
298	DNA Nanotechnology. **2009**, 405-427	2
297	Die Patientin mit thrombophiler Blutgerinnungsst□□ung. **2014**, 157-172	1
296	Molecular and Cellular Hemostasis and Fibrinolysis. **2002**, 287-318	1
295	Symptomatic Onset of severe Hemophilia A in Childhood is dependent on the Presence of Prothrombotic Risk Factors. **2002**, 77-80	1
294	Diseases of the Blood Vessels. **2000**, 881-954	2
293	DVT and Pregnancy. **2016**, 177-195	2
292	Coagulation Disorders After Central Nervous System Injury. **2012**, 227-236	1
291	Molecular and cytogenetic analysis. **2006**, 555-594	1
290	HEMATOLOGY: COAGULATION PROBLEMS. **2004**, 1139-1160	1
289	Neurological Manifestations of Hematological Disorders. **2008**, 227-263	1
288	Pulmonary Thromboembolism. **2010**, 1186-1223	1
287	Laboratory Approach to Thrombotic Risk. **2011**, 823-829	0
286	PAI-1 promoter 4G/5G genotype as an additional risk factor for venous thrombosis in subjects with genetic thrombophilic defects. **2000**, 111, 122-8	66
285	Identification of mutations in 15 Hungarian families with hereditary protein C deficiency. **2000**, 111, 129-35	10
284	Abdominal venous thrombosis in neonates and infants: role of prothrombotic risk factors - a multicentre case-control study. For the Childhood Thrombophilia Study Group. **2000**, 111, 534-9	105

283	A comparison of polymorphism in the 3'-untranslated region of the prothrombin gene between Chinese and Caucasians in Australia. **2000**, 111, 1253-5		9
282	The risk of venous thromboembolism in family members with mutations in the genes of factor V or prothrombin or both. **2000**, 111, 1223-9		75
281	Symposium in memory of Professor Inga Marie Nilsson. **2001**, 7, 401-410		1
280	[Susceptibility genetics of common conditions in clinical practice]. **2020**, 36, 515-520		1
279	Risk factors for venous thrombosis in Swedish children and adolescents. **2005**, 94, 717-722		13
278	Factor V Leiden and pulmonary embolism in a young woman taking an oral contraceptive. **1998**, 19, 362-7		5
277	Inherited thrombophilia and pregnancy. **1998**, 10, 135-44		55
276	. **1999**, 19, 84-87		15
275	Primary gastric plasmacytoma: a rare cause of hypertrophic gastritis in an adolescent. **1999**, 29, 424-30		9
274	Heritable coagulopathies in pregnancy. **1999**, 54, 754-65		59
273	Papillophlebitis associated with coexisting factor V Leiden and prothrombin G20210A mutations. **2002**, 22, 239-40		4
272	Heterozygous prothrombin gene mutation: a new risk factor for early renal allograft thrombosis. **1999**, 68, 575-8		30
271	Prothrombotic abnormalities in children with venous thromboembolism. **2000**, 22, 66-72		33
270	Thrombophilia. **1999**, 6, 291-7		17
269	Risk factors for venous thromboembolism in pregnancy. **1999**, 5, 227-32		11
268	Inherited Risk Factors for Thrombophilia Among Children with Legg-Calv□-Perthes Disease. **1999**, 19, 84-87		41
267	Tissue factor pathway inhibitor and the risk of recurrent venous thromboembolism. *Thrombosis and Haemostasis*, **2005**, 94, 787-90	7	44
266	The heterozygous 20210 G/A prothrombin genotype is associated with early venous thrombosis in inherited thrombophilias and is not increased in frequency in artery disease. **1997**, 17, 2418-22		107

265	Congenital Hemorrhagic Disorders: New Insights into the Pathophysiology and Treatment of Hemophilia. **2000**, 2000, 241-265		7
264	Prothrombin G20210A Mutant Genotype Is a Risk Factor for Cerebrovascular Ischemic Disease in Young Patients. *Blood*, **1998**, 91, 3562-3565	2.2	5
263	A Common Genetic Polymorphism (46 C to T Substitution) in the 5?-Untranslated Region of the Coagulation Factor XII Gene Is Associated With Low Translation Efficiency and Decrease in Plasma Factor XII Level. *Blood*, **1998**, 91, 2010-2014	2.2	2
262	The Val34Leu Polymorphism in the A Subunit of Coagulation Factor XIII Contributes to the Large Normal Range in Activity and Demonstrates That the Activation Peptide Plays a Role in Catalytic Activity. *Blood*, **1998**, 92, 2766-2770	2.2	2
261	Genotype/Phenotype Correlations for Coagulation Factor XIII: Specific Normal Polymorphisms Are Associated With High or Low Factor XIII Specific Activity. *Blood*, **1999**, 93, 897-905	2.2	102
260	Genotype/Phenotype Correlations for Coagulation Factor XIII: Specific Normal Polymorphisms Are Associated With High or Low Factor XIII Specific Activity. *Blood*, **1999**, 93, 897-905	2.2	4
259	Association of a Common Polymorphism in the Factor XIII Gene With Venous Thrombosis. *Blood*, **1999**, 93, 906-908	2.2	9
258	Prospective Evaluation of the Thrombotic Risk in Children With Acute Lymphoblastic Leukemia Carrying the MTHFR TT 677 Genotype, the Prothrombin G20210A Variant, and Further Prothrombotic Risk Factors. *Blood*, **1999**, 93, 1595-1599	2.2	6
257	Synergistic Effects of Prothrombotic Polymorphisms and Atherogenic Factors on the Risk of Myocardial Infarction in Young Males. *Blood*, **1999**, 93, 2186-2190	2.2	14
256	Coinheritance of the HR2 Haplotype in the Factor V Gene Confers an Increased Risk of Venous Thromboembolism to Carriers of Factor V R506Q (Factor V Leiden). *Blood*, **1999**, 94, 3062-3066	2.2	4
255	Translational pathophysiology: a novel molecular mechanism of human disease. *Blood*, **2000**, 95, 3280-3288	2.2	6
254	High levels of factor IX increase the risk of venous thrombosis. *Blood*, **2000**, 95, 3678-3682	2.2	101
253	Risk for subsequent venous thromboembolic complications in carriers of the prothrombin or the factor V gene mutation with a first episode of deep-vein thrombosis. *Blood*, **2000**, 96, 3329-3333	2.2	2
252	Fibrinogen Thr312Ala polymorphism and venous thromboembolism. *Blood*, **2000**, 96, 1177-1179	2.2	0
251	Val34Leu polymorphism of plasma factor XIII: biochemistry and epidemiology in familial thrombophilia. *Blood*, **2000**, 96, 2479-2486	2.2	30
250	Life-Threatening Contraceptive-Related Pulmonary Embolism in a 14-Year-Old Girl with Hereditary Thrombophilia. **2015**, 16, 667-9		4
249	Association Between Gene Polymorphisms on Chromosome 1 and Susceptibility to Pre-Eclampsia: An Updated Meta-Analysis. **2016**, 22, 2202-14		15
248	Recent advances in understanding, diagnosing and treating venous thrombosis. **2020**, 9,		2

247	Diagnostic single nucleotide polymorphism analysis of factor V Leiden and prothrombin 20210G > A. A comparison of the Nanogen Eelectronic Microarray with restriction enzyme digestion and the Roche LightCycler. **2003**, 119, 490-6		4
246	Caution in interpreting results from imputation analysis when linkage disequilibrium extends over a large distance: a case study on venous thrombosis. *PLoS ONE*, **2012**, 7, e38538	3.7	16
245	Risk of Budd-Chiari syndrome associated with factor V Leiden and G20210A prothrombin mutation: a meta-analysis. *PLoS ONE*, **2014**, 9, e95719	3.7	13
244	Analysis of Thrombophilia Test Ordering Practices at an Academic Center: A Proposal for Appropriate Testing to Reduce Harm and Cost. *PLoS ONE*, **2016**, 11, e0155326	3.7	21
243	Next-Generation Sequencing and In Vitro Expression Study of ADAMTS13 Single Nucleotide Variants in Deep Vein Thrombosis. *PLoS ONE*, **2016**, 11, e0165665	3.7	4
242	The top 12 advances in vascular medicine. **2004**, 11 Suppl 2, II21-31		1
241	[The association of hemostasis system genes with the development of ischemic stroke in patients under the age of 50 years]. **2018**, 118, 14-21		1
240	Gestational complications of the prothrombin G20210A mutation related to prothrombin activity. **2020**, 14, 192-202		1
239	Incidence of the genetic mutations in patients with coronary artery disease.		1
238	Legg-Calve-Perthes disease and thrombophilia. *Journal of Bone and Joint Surgery - Series A*, **2004**, 86, 2642-7	5.6	78
237	Thrombophilia and Pregnancy. **2017**, 10, 409-422		5
236	Prothrombin gene G20210A mutation in acute deep venous thrombosis patients with poor response to warfarin therapy. **2009**, 3, 147-51		7
235	The frequencies of six important thrombophilic mutations in a population of the Czech Republic. **2014**, 63, 245-53		7
234	Predicting the Risk of Recurrent Venous Thromboembolism: Current Challenges and Future Opportunities. **2020**, 9,		4
233	Risk factors of thrombosis in abdominal veins. **2008**, 14, 4518-22		14
232	Association between thrombotic risk factors and extent of fibrosis in patients with non-alcoholic fatty liver diseases. **2005**, 11, 5834-9		48
231	Prevalence of factor V Leiden and prothrombin G20210A in patients with gastric cancer. **2006**, 12, 4179-80		11
230	Coagulation abnormalities in osteonecrosis and bone marrow edema syndrome. **2013**, 36, 290-300		26

229	Preparing compound heterozygous reference material using gene synthesis technology: a model of thrombophilic mutations. **2014**, 158, 539-43	1
228	Progress in research into the genes associated with venous thromboembolism. **2015**, 6, 100-4	3
227	Polymorphisms in the genes for coagulation factors II, V, and VII in patients with ischemic heart disease. **1999**, 123, 1230-5	18
226	Combined factor V Leiden and prothrombin genotyping in patients presenting with thromboembolic episodes. **2001**, 125, 105-11	15
225	Genetic polymorphisms associated with venous and arterial thrombosis: an overview. **2002**, 126, 295-304	44
224	Prevalence of the 20210 G-->A prothrombin variant and its association with coronary artery disease in a Middle Eastern Arab population. **2002**, 126, 1087-90	12
223	Detection of factor V leiden and prothrombin gene mutations in patients who died with thrombotic events. **2002**, 126, 1193-6	8
222	Laboratory evaluation of hypercoagulability with venous or arterial thrombosis. **2002**, 126, 1281-95	55
221	Clinical and laboratory management of the prothrombin G20210A mutation. **2002**, 126, 1319-25	51
220	Activated protein C resistance and factor V Leiden: a review. **2007**, 131, 866-71	37
219	A Case of Oral-contraceptive Related Ischemic Colitis in Young Woman. **2011**, 44, 129-32	8
218	Ischemic stroke in Ukrainian population: possible involvement of the F2 G20210A, F5 G1691A and MTHFR C677T gene variants. **2010**, 26, 299-305	3
217	Prothrombin 20210 G->A, Prothrombinspiegel und Faktor-V-Leiden bei Thrombosepatienten. **2000**, 320-324	
216	Disorders Predisposing to Venous Thromboembolism. **2000**, 155-163	
215	The risk of recurrent venous thromboembolic disease Implications for treatment. **2000**, 155-160	
214	Genetic control of hemostatic factors in relation to atherosclerosis. **2000**, 179-187	
213	Juvenile ven e Thromboembolie bei einem Geschwisterpaar mit Zusammentreffen von homozygoter Prothrombinmutation (PT20210 A/A) und heterozygoter Faktor-V-Leiden-Mutation (FV 1691 G/A). **2000**, 301-305	
212	Resistenz gegen aktiviertes Protein C, Faktor-V-Leiden und Prothrombin-G-20210-A-Variante bei Kindern mit isch hischen Schlaganf llen. **2000**, 329-335	

211	Clinical implications of the new understanding of thrombophilia. **2000**, 29-41		
210	Infertility, Oral Contraceptive Pills, Hormone Replacement Therapy and the Antiphospholipid Antibody Syndrome. **2000**, 426-446		
209	The molecular mechanisms of inherited thrombophilia. **2000**, 1-20		
208	Risk of Pulmonary Embolism/Venous Thrombosis. **2000**, 607-615		
207	Genetisch bedingte und erworbene Gerinnungsst□□ungen. **2000**, 110-115		
206	Gendefekte als Ursache f□□ Thrombosen in der p□□diatrischen Onkologie. **2000**, 325-328		
205	Molekulare Marker bei Schlaganfallpatienten: Die G 20210 A-Prothrombin-Variante, die Faktor-V-Leiden-Mutation und der C 677 T-MTHFR-Polymorphismus. **2000**, 312-319		
204	Congenital Hemorrhagic Disorders: New Insights into the Pathophysiology and Treatment of Hemophilia. **2000**, 2000, 241-265		1
203	Hereditary and Acquired Causes of a Hypercoagulable State. **2000**, 717-738		
202	Combinations of 4 mutations (FV R506Q, FV H1299R, FV Y1702C, PT 20210G/A) affecting the prothrombinase complex in a thrombophilic family. *Blood*, **2000**, 96, 1443-1448	2.2	
201	Familial thrombophilia associated with fibrinogen Paris V: Dusart syndrome. *Blood*, **2000**, 96, 1191-1193	2.2	1
200	Hyperprothrombinemia may result in acquired activated protein C resistance. *Blood*, **2000**, 96, 3295-3296	2.2	
199	Increased lipoprotein (a) levels as an independent risk factor for venous thromboembolism. *Blood*, **2000**, 96, 3364-3368	2.2	2
198	Fibrinogen Ale s: a homozygous case of dysfibrinogenemia (□Asp330 ->Val) characterized by a defective fibrin polymerization site □□*Blood*, **2000**, 96, 3473-3479	2.2	0
197	Genetic Markers of Hemostatic Factors. **2001**, 71-87		
196	Prevalence of Common Mutations and Polymorphisms of the Genes of FII, FV, FVII, FXII, FXIII, MTHFR and ACE □dentified As Risk Factors for Venous and Arterial Thrombosis □n Germany and Different Ethnic Groups (Indians, Blacks) of Costa Rica. **2001**, 240-260		2
195	Relation Between Prothrombin Mutation 20210 G->A, Prothrombin Time, Factor V Leiden, and Prothrombin Level. **2001**, 266-269		
194	Diseases of Peripheral Arteries and Veins. **2001**, 353-362		

193 Hereditary Thrombophilic Risk Profiles in Children with Spontaneous Venous Thromboembolism. **2001**, 102-109

192 Venous Thromboembolism. **2001**, 363-384 0

191 Role of acquired and inherited Prothrombotic Risk Factors in Pediatric Cerebral Venous Thrombosis Preliminary Results of a Multicenter Case-Control Study. **2002**, 219-224

190 Peripheral Venous Pathomorphology and Pathophysiology. **2002**, 1491-1497

189 Molekulare Grundlagen von Thrombose und Embolie in der Schwangerschaft. **2002**, 119-133

188 Thrombophilic Risk Parameters in Juvenile »Idiopathic« Stroke Patients. **2002**, 244-251

187 Effects of Estrogen Replacement in Women with Coronary Disease. **2002**, 131-138

186 Utilizing genomic DNA purified from clotted blood samples for single nucleotide polymorphism genotyping. **2002**, 126, 266-70 8

185 Increased Resistance to activated Protein C and Protein C Deficiency in the same Family. **2003**, 158-163

184 Factor V Leiden and other thrombotic risk factors in CHD and myocardial Infarction. **2003**, 240-246

183 Prothrombin and Factor VII Genotypes and Phenotypes in healthy Individuals Results from the Lugen Study. **2003**, 233-239

182 First thromboembolic Onset in Children carrying either the heterozygeous Factor V G1691A Mutation or the Prothrombin G20210A Variant. **2003**, 103-110

181 Thrombophile Gerinnungsst ungen. **2004**, 439-446

180 Inherited Disorders. **2004**, 141-184

179 Hematology and Hemostasis During Pregnancy. **2004**, 195-217

178 No effect of the prothrombin G20210A mutation on protein C activation in a large kindred with type I protein C deficiency. **2004**, 15, 573-576 1

177 Risque de thrombose li ' la grossesse chez les femmes porteuses d ne mutation h t rozygote du facteur V Leiden, du facteur II ou de leur association.. **2004**, 188, 1377-1396

176 Thrombotic Vascular Disease. **2005**, 451-471

175	Pathophysiology of acute vascular insufficiency. **2005**, 17-27	1
174	Childhood Pulmonary Arterial Hypertension. **2006**, 910-926	
173	Thromboembolism in Pediatric Critical Care Patients. **2006**, 1156-1172	
172	Coagulation Disorders. **2007**, 135-150	
171	Risk of Pulmonary Embolism/Venous Thrombosis. **2007**, 491-500	
170	Antithrombin plasma levels decrease is associated with pre-eclampsia worsening. **2007**, 071115151007002-???	
169	Understanding hemostasis and thrombosis : The lesson learnt from natural models. *Japanese Journal of Thrombosis and Hemostasis*, **2008**, 19, 85-91	0
168	Pseudohomozygous APC Resistance Report on Two Patients and a Novel Mutation in the Factor V Gene. **2008**, 193-197	
167	Investigaci□□n de la tendencia trombo□□tica. **2008**, 379-398	
166	Venous Thromboembolism (VTE). **2008**, 483-491	
165	An□□lisis molecular y citogen□□tico. **2008**, 477-509	
164	Genetic Polymorphisms in Critical Care and Illness. **2009**, 1-16	
163	Coagulation Disorders. **2009**, 133-148	
162	Prothrombin Gene Mutation Testing. **2009**, 693-694	
161	Hypercoagulable States. **2010**, 588-598	
160	Vitamin-K-abh□□ngige Gerinnungsfaktoren. **2010**, 159-168	1
159	Venous Thromboembolism. **2010**, 255-275	
158	Molekulargenetik. **2010**, 941-950	

157 Thrombophile Gerinnungsst□ □ungen. **2010**, 375-381

156 Acute Deep Venous Thrombosis. **2010**, 736-754

155 Molecular Basis of Disorders of Hemostasis and Thrombosis. **2010**, 511-528

154 Thrombophilias and Pregnancy. 101-117

153 Detection of Factor V Leiden and prothrombin c.20210G>A allele by Roche Diagnostics LightCycler□ . **2011**, 688, 239-55

152 Heritable Thrombophilia. 872-887

151 The blood and hematopoietic system. **2011**, 1303-1374 2

150 Neonatal Thromboembolic Disorders. **2011**, 18, 23 1

149 Full trisomy 5 in a sample of spontaneous abortion and Arias Stella reaction. **2011**, 17, CS116-9

148 Gerinnung. **2011**, 175-205

147 Venous Thromboembolism in Medical-Surgical Critically Ill Patients. **2011**, 1145-1149

146 Molecular Diagnosis of Genetic Diseases. **2011**, 1330-1347

145 Analysis haemostatic system gene polymorphism in pregnant women without complications from Russia and Ukraine. **2011**, 9, 70-80

144 Inherited thrombophilia. **2011**, 207-214

143 Inherited Diseases. **2012**, 1239-1292

142 Molecular and cytogenetic analysis. **2012**, 139-174

141 Inherited and Acquired Thrombophilias. 108-120

140 Inborn Defects of the Coagulative System. **2012**, 73-84

139	Hemostasis in Pregnancy and Obstetric Surgery. **2012**, 133-162		
138	Hemostasis. **2012**, 2083-2128		
137	Investigation of a thrombotic tendency. **2012**, 447-465		
136	Gene Polymorphisms and Signaling Defects. **2013**, 53-102		
135	Acute Myocardial Infarction in a Young Woman With Heterozygous Polymorphism for Methylenetetrahydrofolate Reductase and Prothrombin Gene Mutation. **2013**, 10,		
134	Using Scorpion Primers for Genotyping. **2013**, 75-86		
133	Laboratory Analysis of Coagulation. **2014**, 1-37		
132	Genetic Studies in Osteonecrosis of the Femoral Head. **2014**, 61-69		
131	Biological thrombophilia. **2014**, 90-107		
130	Genetic Polymorphisms in Critical Illness and Injury. **2014**, 177-202		1
129	T. **1990**, 263-321		
128	Individuelle Einsch Etzung des Risikos der ven Sen Thrombose. **1998**, 39-47		
127	Thrombotic Disorders. **1998**, 219-226		
126	The Prothrombin Gene 3?-Untranslated Region Mutation Is Frequently Associated With Factor V Leiden in Thrombophilic Patients and Shows Ethnic-Specific Variation in Allele Frequency. *Blood*, **1998**, 91, 1092-1093	2.2	
125	Rapid Simultaneous Screening of Factor V Leiden and G20210A Prothrombin Variant by Multiplex Polymerase Chain Reaction on Whole Blood. *Blood*, **1998**, 91, 2208-2209	2.2	
124	Changes in Leptin Concentration and Gender Difference during the early Postnatal Period 443. **1998**, 43, 78-78		
123	The Prothrombin G20210A Mutation and Factor V Leiden Mutation in Patients With Cerebrovascular Disease. *Blood*, **1998**, 92, 704-705	2.2	1
122	A Single Genetic Origin for the Common Prothrombotic G20210A Polymorphism in the Prothrombin Gene. *Blood*, **1998**, 92, 1119-1124	2.2	

121	An Association Between the Common Hereditary Hemochromatosis Mutation and the Factor V Leiden Allele in a Population With Thrombosis. *Blood*, **1998**, 92, 1461-1462	2.2	1
120	An Even Easier Method for One-Step Detection of Both FV Leiden and FII G20210A Transition. *Blood*, **1998**, 92, 3478-3479	2.2	
119	Society for Pediatric Research Presidential Address 1998: the SPR and 1-800-NO-CLOTS: a common vision. **1998**, 44, 964-73		
118	Ambulantes Thrombophilie-Screening unter besonderer Berücksichtigung des thromboseassoziierten Polymorphismus im Prothrombingen bei venösen Thromboembolien. **1999**, 350-355		
117	Koexistenz der Prothrombinvariante 20210 GA bei Patienten mit der Faktor-V: R506Q-Mutation und venöser Thrombophilie. **1999**, 61-66		
116	Molekulargenetische Marker bei Patienten mit venösen und arteriellen Thrombosen: Der G20210A-Prothrombin-Polymorphismus, die C677T MTHFR-Mutation und die Faktor-V-Leiden (G1691A) Mutation. **1999**, 67-71		
115	Prothrombinmutation, Prothrombinspiegel und Faktor-V-Leiden in Thrombosekollektiven. **1999**, 72-77		
114	Stellenwert und Prävalenz der Prothrombin-G20210A-Mutation bei Patienten mit hereditärer Thrombophilie. **1999**, 49-54		
113	Zur Prävalenz des G20210A-Prothrombin-Polymorphismus, der C677T-Mutation des MTHFR-Gens und der Faktor-V-Leiden-Mutation in Nordostdeutschland, Argentinien, Venezuela, Costa Rica und Indien. **1999**, 55-60		
112	Multicentre Evaluation of Combined Prothrombotic Defects in Childhood Thromboembolism. **1999**, 105-116	2	
111	Thrombophile Faktoren der Venenthrombose. **1999**, 27-31		
110	Epidemiologie der funktionellen Inhibitormängel und weiterer hereditärer Risikofaktoren für venöse Thromboembolien. **1999**, 304-309		
109	Hormonal Therapy After Stem Cell Transplantation and the Risk of Veno-occlusive Disease. *Blood*, **1999**, 93, 3154-3154	2.2	
108	Lipoprotein (a) and Genetic Polymorphisms of Clotting Factor V, Prothrombin, and Methylenetetrahydrofolate Reductase Are Risk Factors of Spontaneous Ischemic Stroke in Childhood. *Blood*, **1999**, 94, 3678-3682	2.2	3
107	Inhibition of Activated Protein C Anticoagulant Activity by Prothrombin. *Blood*, **1999**, 94, 3839-3846	2.2	1
106	Do We Need More PFO Trials: Hypercoaguable Syndromes, Obstructive Sleep Apnea, and Arrhythmias. **2015**, 211-221		
105	The Neonate. **2015**, 391-409		
104	G20210A mutation and cerebral venous infarct: a rare presentation in a child. **2015**, 14,		

103	Genetics of Pulmonary Vascular Disease. **2016**, 105-121	
102	Detection of Vascular Disease-Related Single Nucleotide Polymorphisms in Clinical Samples Using Ramified Rolling Circle Amplification. **2016**, 67-83	
101	Myeloid Neoplasms with an Erythroid Cell Lineage. **2016**, 1-14	
100	A Better Understanding of Hypercoagulability in the Microsurgical Setting. **2016**, 1437-1446	
99	The contribution of hereditary thrombophilia to increasing the frequency of thrombosis in patients with Ph-negative myeloproliferative neoplasms, including the victims from the Chornobyl accident. **2016**, 21, 291-311	1
98	The role of genetic markers of thrombophilia in the development of thrombosis after coronary artery bypass graft surgery. *Regional Blood Circulation and Microcirculation*, **2016**, 15, 4-10	0.3
97	Alterations in Platelet Activity and Elastic Modulus of Healthy Subjects, Carriers of G20210A Polymorphism in the Prothrombin Gene. *Journal of Biomedical and Clinical Research*, **2016**, 9, 72-79	0
96	Myeloid Neoplasms with an Erythroid Cell Lineage. **2017**, 1413-1426	
95	Ven□se Thromboembolien, Thrombophilie und Thromboseprophylaxe in Gyn□kologie und Geburtshilfe. **2017**, 1-12	
94	Thrombophilia and Thrombocytopenia in the Pregnant Woman. **2017**, 55-76	
93	Bioinformatics Databases: Implications in Human Health. **2017**, 109-132	
92	Thrombotic Disorders. **2017**, 205-221	
91	Cerebral Venous Thrombosis: Genetic Aspects. **2017**, 295-326	
90	Right Iliofemoral Venous Thrombosis in a Prothrombin 20210GA carrier with Duplicated Inferior Vena Cava. An Unusual Case Report. *International Journal of Vascular Surgery and Medicine*, **2017**, 3, 043-045	0
89	High-Risk Pregnancy: Management Options. **2018**,	1
88	Exploration des facteurs de risque biologiques de maladie thromboembolique. **2018**, 163-183	
87	Investigation of congenital thrombophilic conditions: when, in whom, focusing on what or not at all?. *Vnitrni Lekarstvi*, **2018**, 64, 559-563	0.3
86	F11 gene polymorphism in patients with vein thrombosis in the population of Latvia. *Acta Phlebologica*, **2019**, 19,	0.9

85	Vitamin K-dependent protein S: Function and etiological significance. *Japanese Journal of Thrombosis and Hemostasis*, **2019**, 30, 642-651	0	
84	Phenotypic Manifestations of Prothrombin Gene Mutation, Genotype, in Women of Reproductive Age. *Flebologiya*, **2019**, 13, 285	0.4	
83	Blood coagulation in venous thrombosis, complicating treatment of children, adolescents and young adults with lymphomas. *Oncogematologiya*, **2019**, 13, 37-45	0.3	
82	Venous thrombosis in children, adolescents and young adults with acute lymphoblastic leukemia receiving chemotherapy in the Republic of Belarus. *Oncogematologiya*, **2019**, 14, 13-23	0.3	
81	A Study on the Role of Thrombophilic Genetic Disorders as a Risk Factor for Thrombotic Complications in Patients with Myeloproliferative Disorders. *Journal of Biomedical and Clinical Research*, **2019**, 12, 19-26	0	
80	PREVALENCE OF FACTOR V LEIDEN AND PROTHROMBIN G20210A IN WOMEN WITH VON WILLEBRAND DISEASE TYPE 1. *Gematologiya I Transfuziologiya*, **2019**, 64, 60-65	0.4	0
79	Study of hereditary thrombophilia (factor V leiden and protrombine 20210) in a population of women in fertile age who suffered a thromboembolic event studied in the tucum□ß public health laboratory. *Journal of Cardiology & Current Research*, **2020**, 13, 35-39	0.1	
78	Thromboembolism. **2021**, 269-294		
77	Factors predisposing to thrombosis after major joint arthroplasty. *World Journal of Orthopedics*, **2020**, 11, 400-410	2.2	0
76	Simultaneous and sensitive detection of two pathogenic genes of thrombotic diseases using SPRi sensor with one-step fixation probe by a poly-adenine oligonucleotide approach. *Colloids and Surfaces B: Biointerfaces*, **2022**, 209, 112184	6	0
75	Prediction of primary venous thromboembolism based on clinical and genetic factors within the U.K. Biobank. *Scientific Reports*, **2021**, 11, 21340	4.9	0
74	Association of G20210A Prothrombin Gene Mutation and Cerebral Ischemic Stroke in Young Patients. *Cureus*, **2020**, 12, e11984	1.2	2
73	Venous Thromboembolism in the Context of Reproduction: The Royal College of Obstetricians and Gynecologists Recommendations.		
72	Coagulation, Vascular Morphology, and Vasculogenesis in Spinal Ligament Ossification Model Mice. *Spine*, **2021**, 46, E802-E809	3.3	1
71	Coagulopathies. **2020**, 579-593		
70	Hypercoagulable States. **2020**, 215-232		
69	Comparison between thrombophilic gene polymorphisms among high risk patients. *Romanian Journal of Internal Medicine = Revue Roumaine De Medecine Interne*, **2020**, 58, 20-26	1.5	1
68	Coagulation assay discrepancies in Japanese patients with non-severe hemophilia A. *International Journal of Hematology*, **2021**, 1	2.3	0

67	Gerinnung. **2006**, 171-200		
66	Effects of the Factor V G1691 A Mutation and the Factor II G20210A Variant on the Clinical Expression of Severe Hemophilia A (2006, 87-94		
65	Pathogenesis of Hepatic Veno-Occlusive Disease in Patients Undergoing Hematopoietic Stem Cell Transplantation. **2006**, 247-258		
64	Angeborene und erworbene Thrombophilien. **2006**, 402-418		
63	Platelets and Prothrombin. **2005**, 283-300		
62	Hereditary and Acquired Thrombophilia. **2007**, 187-198		0
61	Algorithms for Hypercoagulation Testing. *Laboratory Medicine*, **2003**, 34, 216-222	1.6	
60	Clotting Disorders: What Should the Vascular Surgeon Know About Hypercoagulation States in Venous Diseases?. **2007**, 41-49		
59	Congenital and Acquired Hypercoagulable States. **2021**, 547-565		
58	MTHFR C677T, Prothrombin G20210A, and Factor V Leiden (G1691A) Polymorphism and Beta-Thalassemia Risk: A Meta-Analysis. *Cureus*, **2020**, 12, e10743	1.2	
57	Yenido□an yo□un bak□m □□itesinde izlenen ge□ preterm bebeklerin maternal risk fakt□rlerine ba□l□ morbiditelerinin de□erlendirilmesi.		
56	Cryptogenic Stroke in the Young: Role of Candidate Gene Polymorphisms in Indian Patients with Ischemic Etiology.. *Neurology India*, **2021**, 69, 1655-1662	0.7	0
55	Le bilan biologique de thrombose veineuse. *Bio Tribune Magazine*, **2001**, 1, 10-15		
54	Clinical and Molecular Study of Common Thrombophilia Mutation Prothrombin G20210A.. *Advances in Experimental Medicine and Biology*, **2021**, 1339, 331-336	3.6	
53	Atipik Yerle□imli Trombozlar ile 40 Ya□Alt□ Eri□kin Hastalardaki Tipik Yerle□imli Trombozlarda Etyolojik Fakt□rler.. *A□□zet Baysal Tp Fak□ltesi Dergisi*, **2021**, 10, 231-240		
52	Reference values of coagulation assays performed for thrombophilia screening after a first venous thrombosis and their intra-patient associations.. *Thrombosis Research*, **2022**, 210, 94-103	8.2	0
51	Inherited Thrombophilia in the Era of Direct Oral Anticoagulants.. *International Journal of Molecular Sciences*, **2022**, 23,	6.3	2
50	The influence of corn trypsin inhibitor on the contribution of coagulation determinants to the Technoclone Thrombin Generation Assay (TGA) and the Calibrated Automated Thrombogram (CAT).. *PLoS ONE*, **2022**, 17, e0263960	3.7	

49	Association between cardiovascular risk factors and venous thromboembolism in the elderly.. *Research and Practice in Thrombosis and Haemostasis*, **2022**, 6, e12671	5.1	0
48	High Prevalence of Plasminogen Activator Inhibitor-1 4G/5G Polymorphism among Patients with Venous Thromboembolism in Kerala, India.. *Hamostaseologie*, **2022**,	1.9	
47	The Impact of Direct Oral Anticoagulant Prophylaxis for Thromboembolism in Thrombophilic Patients Undergoing Abdominoplastic Surgery.. *Healthcare (Switzerland)*, **2022**, 10,	3.4	1
46	Association of MTHFR rs1801133 and homocysteine with Legg-Calv□¦Perthes disease in Mexican patients.. *Orphanet Journal of Rare Diseases*, **2022**, 17, 123	4.2	1
45	Recommendations from the ICM-VTE: General.. *Journal of Bone and Joint Surgery - Series A*, **2022**, 104, 4-162	5.6	0
44	Clinical and genetic characteristics of Legg-Calve-Perthes disease. *Journal of Musculoskeletal Surgery and Research*, 6, 1-8	0.4	
43	Prothrombin G20210A Gene Mutation-Induced Recurrent Deep Vein Thrombosis and Pulmonary Embolism: Case Report and Literature Review.. *Journal of Investigative Medicine High Impact Case Reports*, **2022**, 10, 23247096211058486	1.2	1
42	Update on pregnancy-associated venous thromboembolism. *Thrombosis Update*, **2022**, 100107	0.9	
41	Data_Sheet_1.XLSX. **2020**,		
40	Data_Sheet_2.XLSX. **2020**,		
39	Efficient recovery of DNA from peripheral blood for diagnostic analysis with a vacuum manifold. *Molecular Diagnosis and Therapy*, **2000**, 5, 151-4		
38	Thrombosis-Related DNA Polymorphisms.		
37	Hereditary Thrombophilia Testing Among Hospitalized Patients: Is It Warranted?. *Cureus*, **2022**,	1.2	
36	Central retinal artery occlusion and subsequent amaurosis fugax in the contralateral eye associated with the G20210A prothrombin gene (F2) variant: a case report.. *Ophthalmic Genetics*, **2022**, 1-7	1.2	
35	Prevalence, Genetic Background, and Clinical Phenotype of Congenital Thrombophilia in Chronic Thromboembolic Pulmonary Hypertension. *JACC Asia*, **2022**, 2, 247-255		0
34	Nursing Care of Deep Vein Thrombosis. *Advances in Clinical Medicine*, **2022**, 12, 4461-4465	0	
33	Joint effect of multiple prothrombotic genotypes and mean platelet volume on the risk of incident venous thromboembolism. *Thrombosis and Haemostasis*,	7	
32	Trombofilias constitucionales y s□ndrome de los antifosfol□pidos. *EMC - Tratado De Medicina*, **2022**, 26, 1-7	0	

31	High Altitude Induced Thrombosis: Challenges and Recent Advancements in Pathogenesis and Management. **2022**, 85-101		
30	Relationships between coagulation factors and thrombin generation in a general population with arterial and venous disease background. *Thrombosis Journal*, **2022**, 20,	5.6	
29	A System-Wide Investigation and Stratification of the Hemostatic Proteome in Premature Myocardial Infarction. *Frontiers in Cardiovascular Medicine*, 9,	5.4	
28	Large-scale screening for factor V Leiden (G1691A), prothrombin (G20210A), and MTHFR (C677T) mutations in Greek population. *Health Science Reports*, **2022**, 5,	2.2	0
27	Cerebral venous sinus thrombosis after COVID-19 vaccination and congenital deficiency of coagulation factors: Is there a correlation?. *Human Vaccines and Immunotherapeutics*,	4.4	0
26	Whole Blood Samples for Faster Real-Time PCR Analysis of Thrombophilic Mutations in SARS-CoV-2 Virus Positive Patients. 439-445		
25	Impact of hereditary thrombophilia on cancer-associated thrombosis, tumour susceptibility and progression: A review of existing evidence. **2022**, 1877, 188778		0
24	To clot, or not to clot: The dilemma of hormone treatment options for menopause. **2022**, 218, 99-111		0
23	Disorders of Hemostasis and Thrombosis. **2023**, 173-211		
22	Evolving Knowledge on Primary and Secondary Prevention of Venous Thromboembolism in Carriers of Hereditary Thrombophilia: A Narrative Review.		0
21	Evolving Knowledge on Primary and Secondary Prevention of Venous Thromboembolism in Carriers of Hereditary Thrombophilia: A Narrative Review.		0
20	Hematological Profile Changes Among Oral Contraceptive Users: A Narrative Review. Volume 13, 525-536		1
19	A review of laboratory considerations in thrombophilia testing. **2022**,		0
18	Biomarkers to predict risk of venous thromboembolism in patients with rheumatoid arthritis receiving tofacitinib or tumour necrosis factor inhibitors. **2022**, 8, e002571		0
17	The PORtromb Project: Prothrombin G20210A Mutation and Venous Thromboembolism in Young People. **2002**, 10, 45-48		0
16	Thrombosis and hemostasis at the University of Padua: a reappraisal on the occasion of its 800th year of history. **2022**, 1,		0
15	Molecular basis of rare congenital bleeding disorders. **2022**, 101029		0
14	Maternal Inherited Thrombophilia in Monochorionic Twin Pregnancy with Twin-Twin Transfusion Syndrome. **2022**, 11, 7054		0

13	Today's view of hereditary thrombophilia. **2022**, 68, 488-492	0
12	Factor V Leiden but not the factor II 20210G>A mutation is a risk factor for premature coronary artery disease: a case-control study in Iran.. **2023**, 100048	0
11	Hypercoagulable states associated with chronic venous insufficiency. **2023**, 139-157	0
10	The Tissue Factor Pathway in Cancer: Overview and Role of Heparan Sulfate Proteoglycans. **2023**, 15, 1524	2
9	Identifying individuals at extreme risk of venous thromboembolism using polygenic risk scores. **2023**, 55, 358-360	0
8	A Comprehensive Review of Risk Factors for Venous Thromboembolism: From Epidemiology to Pathophysiology. **2023**, 24, 3169	0
7	TROMBOSE VENOSA CEREBRAL SECUND□RIA A MUTA□□□O DO FATOR V DE LEIDEN: UM RELATO DE CASO. **2023**, 16, e1166	0
6	Internal Carotid Artery Dissection With Thrombosis in a Child With Prothrombin Gene Mutation. **2023**,	0
5	The Impact of Thrombophilic Factors on Disease Progression in Children with Biliary Atresia□A Single-Centre Cohort Study. **2023**, 12, 2108	0
4	Four cases of venous thrombosis in athletes with silent hereditary defects of the protein C system. **2005**, 94, 463-464	0
3	Superior sagittal sinus thrombosis after lumbar puncture in a patient with T-cell lymphoblastic lymphoma: role of the prothrombin G20210A mutation and 4G/4G genotype. **2005**, 94, 881-882	0
2	Hematology and Coagulation. **2013**, 131-147.e6	0
1	Homozygous Carriers of F2 c.20210G>A Variant: A Report of Two Cases and Literature Review. **2023**,	0